0001564590-19-019256.txt : 20190515 0001564590-19-019256.hdr.sgml : 20190515 20190515070133 ACCESSION NUMBER: 0001564590-19-019256 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190515 DATE AS OF CHANGE: 20190515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VACCINEX, INC. CENTRAL INDEX KEY: 0001205922 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 161603202 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38624 FILM NUMBER: 19825030 BUSINESS ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 BUSINESS PHONE: 585-271-2700 MAIL ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 FORMER COMPANY: FORMER CONFORMED NAME: VACCINEX INC DATE OF NAME CHANGE: 20021114 10-Q 1 vcnx-10q_20190331.htm 10-Q vcnx-10q_20190331.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                        to    

Commission File Number: 001-38624

 

Vaccinex, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

16-1603202

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

1895 Mount Hope Avenue

Rochester, New York

14620

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (585) 271-2700

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes   No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

 

 

 

Non-accelerated filer

 

  

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value

VCNX

Nasdaq Global Market

 

As of May 10, 2019, the registrant had 11,478,843 shares of common stock, $0.0001 par value per share, outstanding.

 

 

 


 

 

 


VACCINEX, INC.

FORM 10-Q

TABLE OF CONTENTS

 

 

 

 

Page

 

 

 

 

 

PART I – FINANCIAL INFORMATION

 

 

 

 

 

 

 

 

 

 

Item 1.

Unaudited Condensed Consolidated Financial Statements

 

3

 

 

 

 

 

Condensed Consolidated Balance Sheets (Unaudited)

 

3

 

 

 

 

 

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

 

4

 

 

 

 

 

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Unaudited)

 

5

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows (Unaudited)

 

6

 

 

 

 

 

Notes to Condensed Consolidated Financial Statements (Unaudited)

 

7

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

18

 

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

26

 

 

 

 

Item 4.

Controls and Procedures

 

26

 

 

 

 

 

PART II – OTHER INFORMATION

 

 

 

 

 

 

Item 1.

Legal Proceedings

 

27

 

 

 

 

Item 1A.

Risk Factors

 

27

 

 

 

 

Item 6.

Exhibits

 

28

 

 

 

 

 

Signatures

 

29

 

 

2


PART I - FINANCIAL INFORMATION

Item 1. Unaudited Condensed Consolidated Financial Statements

VACCINEX, INC.

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share and per share data)

 

 

 

As of

March 31, 2019

 

 

As of

December 31, 2018

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

8,942

 

 

$

5,618

 

Marketable securities

 

 

2,348

 

 

 

14,106

 

Accounts receivable, net

 

 

628

 

 

 

639

 

Prepaid expenses and other current assets

 

 

832

 

 

 

1,061

 

Total current assets

 

 

12,750

 

 

 

21,424

 

Property and equipment, net

 

 

544

 

 

 

604

 

TOTAL ASSETS

 

$

13,294

 

 

$

22,028

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

2,439

 

 

$

2,322

 

Accrued expenses

 

 

4,520

 

 

 

4,364

 

TOTAL LIABILITIES

 

 

6,959

 

 

 

6,686

 

Commitments and contingencies (Note 9)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of

   March 31, 2019 and December 31, 2018; 11,476,601 shares issued

   as of March 31, 2019 and December 31, 2018; 11,475,749 shares

   outstanding as of March 31, 2019 and December 31, 2018

 

 

1

 

 

 

1

 

Additional paid-in capital

 

 

208,216

 

 

 

208,156

 

Treasury stock, at cost; 852 shares

   of common stock as of March 31, 2019 and December 31, 2018

 

 

(11

)

 

 

(11

)

Accumulated deficit

 

 

(225,834

)

 

 

(216,767

)

Total Vaccinex, Inc. stockholders’ deficit

 

 

(17,628

)

 

 

(8,621

)

Noncontrolling interests

 

 

23,963

 

 

 

23,963

 

TOTAL STOCKHOLDERS’ EQUITY

 

 

6,335

 

 

 

15,342

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$

13,294

 

 

$

22,028

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3


VACCINEX, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(in thousands, except share and per share data)

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

Revenue

 

$

94

 

 

$

206

 

Costs and expenses:

 

 

 

 

 

 

 

 

Cost of revenue

 

 

175

 

 

 

240

 

Research and development

 

 

7,412

 

 

 

4,454

 

General and administrative

 

 

1,647

 

 

 

1,221

 

Total costs and expenses

 

 

9,234

 

 

 

5,915

 

Loss from operations

 

 

(9,140

)

 

 

(5,709

)

Change in fair value of derivative liabilities

 

 

-

 

 

 

308

 

Interest expense

 

 

-

 

 

 

(267

)

Loss on extinguishment of related party convertible promissory note

 

 

-

 

 

 

(2,180

)

Other income (expense), net

 

 

73

 

 

 

(14

)

Loss before provision for income taxes

 

 

(9,067

)

 

 

(7,862

)

Provision for income taxes

 

 

-

 

 

 

-

 

Net loss

 

 

(9,067

)

 

 

(7,862

)

Net loss attributable to noncontrolling interests

 

 

-

 

 

 

-

 

Net loss attributable to Vaccinex, Inc. common stockholders, basic and diluted

 

$

(9,067

)

 

$

(7,862

)

Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted

 

$

(0.79

)

 

$

(7.13

)

Weighted-average shares used in computing net loss per share attributable to Vaccinex,

   Inc. common stockholders, basic and diluted

 

 

11,475,749

 

 

 

1,102,571

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4


 

VACCINEX, INC.

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Unaudited)

(in thousands, except share data)

 

 

 

 

Redeemable Convertible

Preferred Stock

 

 

 

Convertible

Preferred Stock

 

 

Common Stock

 

 

 

 

 

 

Treasury Stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Additional

Paid-in

Capital

 

 

Redeemable

Convertible

Preferred

Stock Shares

 

 

Common

Stock

Shares

 

 

Amount

 

 

Accumulated

Deficit

 

 

Total

Vaccinex, Inc.

Stockholders’

Deficit

 

 

Noncontrolling

Interests

 

 

Total

Stockholders’

Equity

(Deficit)

 

Balance as of January 1, 2018

 

 

53,089,959

 

 

$

111,718

 

 

 

 

5,702,450

 

 

$

7,684

 

 

 

1,103,396

 

 

$

-

 

 

$

54,123

 

 

 

163

 

 

 

836

 

 

$

(11

)

 

$

(187,249

)

 

$

(125,453

)

 

$

11,963

 

 

$

(113,490

)

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

36

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

36

 

 

 

-

 

 

 

36

 

Capital contribution

 

 

-

 

 

 

-

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

8,000

 

 

 

8,000

 

Net loss

 

 

-

 

 

 

-

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(7,862

)

 

 

(7,862

)

 

 

-

 

 

 

(7,862

)

Balance as of March 31, 2018

 

 

53,089,959

 

 

$

111,718

 

 

 

 

5,702,450

 

 

$

7,684

 

 

 

1,103,396

 

 

$

-

 

 

$

54,159

 

 

 

163

 

 

 

836

 

 

$

(11

)

 

$

(195,111

)

 

$

(133,279

)

 

$

19,963

 

 

$

(113,316

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable Convertible

Preferred Stock

 

 

 

Convertible

Preferred Stock

 

 

Common Stock

 

 

 

 

 

 

Treasury Stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Additional

Paid-in

Capital

 

 

Redeemable

Convertible

Preferred

Stock Shares

 

 

Common

Stock

Shares

 

 

Amount

 

 

Accumulated

Deficit

 

 

Total

Vaccinex, Inc.

Stockholders’

Deficit

 

 

Noncontrolling

Interests

 

 

Total

Stockholders’

Equity

 

Balance as of January 1, 2019

 

 

-

 

 

$

-

 

 

 

 

-

 

 

$

-

 

 

 

11,476,601

 

 

$

1

 

 

$

208,156

 

 

 

-

 

 

 

852

 

 

$

(11

)

 

$

(216,767

)

 

$

(8,621

)

 

$

23,963

 

 

$

15,342

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

60

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

60

 

 

 

-

 

 

 

60

 

Net loss

 

 

-

 

 

 

-

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(9,067

)

 

 

(9,067

)

 

 

-

 

 

 

(9,067

)

Balance as of March 31, 2019

 

 

-

 

 

$

-

 

 

 

 

-

 

 

$

-

 

 

 

11,476,601

 

 

$

1

 

 

$

208,216

 

 

 

-

 

 

 

852

 

 

$

(11

)

 

$

(225,834

)

 

$

(17,628

)

 

$

23,963

 

 

$

6,335

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

 

5


VACCINEX, INC.

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(9,067

)

 

$

(7,862

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

60

 

 

 

56

 

Amortization of debt discount

 

 

-

 

 

 

235

 

Net amortization of premiums and discounts on marketable securities

 

 

(42

)

 

 

-

 

Stock-based compensation

 

 

60

 

 

 

36

 

Change in fair value of derivative liabilities

 

 

-

 

 

 

(308

)

Loss on extinguishment of related party convertible promissory note

 

 

-

 

 

 

2,180

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

11

 

 

 

37

 

Prepaid expenses and other current assets

 

 

229

 

 

 

(65

)

Accounts payable

 

 

117

 

 

 

348

 

Accrued expenses

 

 

156

 

 

 

309

 

Deferred revenue

 

 

-

 

 

 

(131

)

Net cash used in operating activities

 

 

(8,476

)

 

 

(5,165

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Sales and maturities of marketable securities

 

 

11,800

 

 

 

-

 

Purchase of property and equipment

 

 

-

 

 

 

(47

)

Net cash provided by (used in) investing activities

 

 

11,800

 

 

 

(47

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Payments of initial public offering costs

 

 

-

 

 

 

(44

)

Repayment of convertible promissory note, related party

 

 

-

 

 

 

(4,000

)

Proceeds from capital contribution

 

 

-

 

 

 

8,000

 

Net cash provided by financing activities

 

 

-

 

 

 

3,956

 

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

 

 

3,324

 

 

 

(1,256

)

CASH AND CASH EQUIVALENTS–Beginning of period

 

 

5,618

 

 

 

4,180

 

CASH AND CASH EQUIVALENTS–End of period

 

$

8,942

 

 

$

2,924

 

SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND

   FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

-

 

 

$

13

 

Purchase of property and equipment in accounts payable

 

$

-

 

 

$

9

 

Deferred offering costs in accounts payable and accrued expenses

 

$

-

 

 

$

573

 

Deferred offering costs reclassed from prepaid expenses and other current assets

 

$

-

 

 

$

38

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6


VACCINEX, INC.

Notes to Condensed Consolidated Financial Statements (Unaudited)

1.

COMPANY AND NATURE OF BUSINESS

Description of Business

Vaccinex, Inc. (together with its subsidiaries, the “Company”) was incorporated in Delaware in April 2001 and is headquartered in Rochester, New York. The Company is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Since its inception, the Company has devoted substantially all of its efforts toward product research, manufacturing and clinical development.

The Company is subject to a number of risks common to other early-stage biotechnology companies including, but not limited to, the successful development and commercialization of its product candidates, rapid technological change and competition, dependence on key personnel and collaborative partners, uncertainty of protection of proprietary technology and patents, clinical trial uncertainty, fluctuation in operating results and financial performance, the need to obtain additional funding, potential product liability, compliance with governmental regulations, technological and medical risks, customer demand, management of growth and effectiveness of marketing by the Company. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.

Going Concern

These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flow from operations of $8.5 million and $25.3 million for the three months ended March 31, 2019 and year ended December 31, 2018, respectively, and an accumulated deficit of $225.8 million and $216.8 million as of March 31, 2019 and December 31, 2018, respectively. The Company’s ability to continue as a going concern is at issue due to its historical net losses and negative cash flows from operations, and its need for additional financing to fund future operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

To date, the Company has relied on equity and debt financing to fund its operations. In addition, the Company received $12.0 million in capital contributions from noncontrolling interests during each of the years ended December 31, 2018 and 2017. As the Company’s product candidates are still in the early stages of development, substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. Given our projected operating requirements and our existing cash and cash equivalents and marketable securities, we plan to complete an additional financing transaction prior to the commencement of the 2019 fourth quarter in order for us to continue operations.  Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors, refinancing of existing debt obligations or obtaining additional debt financing. There can be no assurances that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms.

7


Initial Public Offering

In August 2018, the Company completed its initial public offering (the “IPO”) in which it issued and sold 3,333,334 shares of its common stock, $0.0001 par value, at a public offering price of $12.00 per share. The Company received net proceeds of $37.2 million after deducting underwriting discounts and commissions of $2.8 million, but before deducting offering expenses of $2.7 million. In addition, in connection with the IPO:

 

all shares of the Company’s then-outstanding convertible preferred stock were automatically converted and reclassified into 7,039,155 shares of its common stock, $0.0001 par value;

 

a 1-for-10 reverse stock split of the Company’s common stock was effected; and

 

the Company repaid a $1.5 million convertible promissory note issued in June 2016 (the “June 2016 Note”), held by a related party, Vaccinex (Rochester), L.L.C. (“Vaccinex LLC”), which is majority owned and controlled by Dr. Maurice Zauderer, the Company’s President, Chief Executive Officer and a member of its board of directors.

 

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Consolidation

These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. All intercompany transactions and balances have been eliminated.

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and following the requirements of the Securities and Exchange Commission ("SEC"), for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the entire year ending December 31, 2019. The year-end balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. Certain information and note disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted under the rules and regulations of the SEC.

These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 13, 2019.

 

Use of Estimates

These condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, the valuation of derivative instruments, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.

8


Concentration of Credit Risk, Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Cash equivalents are deposited in interest-bearing money market accounts and short-term investments consist of highly liquid U.S. government treasury bills and notes. The Company deposits its cash with multiple financial institutions and cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.

The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company’s product candidates and adversely impact its results of operations.

Comprehensive Loss

The Company did not have any other comprehensive income or loss for any of the periods presented and therefore comprehensive loss did not differ from net loss.

Recent Accounting Pronouncements Not Yet Adopted

In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) No. 2016-02, Leases, which supersedes the Accounting Standards Codification (“ASC”) No. 840, Leases. ASU No. 2016-02 requires lessees to recognize all leases, with exception of short-term leases, as lease liabilities on the balance sheet. Under ASU No. 2016-02, a lease is defined as a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset during the lease term. ASU No. 2016-02 also requires additional disclosure about the amount, timing and uncertainty of cash flow from leases. The new standard is effective for the Company at the earlier of losing the emerging growth company status or the Company’s fiscal year beginning January 1, 2020. Early adoption is permitted. This new standard will require the present value of these leases to be recorded in the condensed consolidated balance sheets as a right-of-use asset and lease liability. The Company will adopt the new standard effective January 1, 2020 and is continuing to evaluate the impact of this guidance on its condensed consolidated financial statements and related disclosures.

Recently Adopted Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which supersedes the revenue recognition requirements in ASC No. 605, Revenue Recognition. ASU No. 2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU No. 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenues and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, the FASB issued ASU No. 2015-14 to defer the effective date by one year with early adoption permitted as of the original effective date. In addition, the FASB issued ASU Nos. 2016-08, 2016-10 and 2016-12 in March 2016, April 2016 and May 2016, respectively, to help provide interpretive clarification on the new guidance in ASC No. 606. ASU Nos. 2016-08, 2016-10 and 2016-12 are all effective beginning the same period as ASU No. 2014-09. The Company adopted the new revenue standards using the modified retrospective method as of January 1, 2019; however, it is not required to reflect the effects of adoption in its consolidated financial statements until it files its annual report for the fiscal year ending December 31, 2019. The Company is in the process of evaluating the effect that the new revenue standards will have on its consolidated financial statements and related disclosures.

9


3.

BALANCE SHEET COMPONENTS

Property and Equipment

Property and equipment consist of the following (in thousands):

 

 

 

As of

March 31,

2019

 

 

As of

December 31,

2018

 

Leasehold improvements

 

$

3,145

 

 

$

3,145

 

Research equipment

 

 

3,219

 

 

 

3,219

 

Furniture and fixtures

 

 

350

 

 

 

350

 

Computer equipment

 

 

214

 

 

 

214

 

Property and equipment, gross

 

 

6,928

 

 

 

6,928

 

Less: accumulated depreciation and amortization

 

 

(6,384

)

 

 

(6,324

)

Property and equipment, net

 

$

544

 

 

$

604

 

 

Depreciation and amortization expense related to property and equipment was $60,000 and $56,000 for the three months ended March 31, 2019 and 2018, respectively.

Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

 

As of

March 31,

2019

 

 

As of

December 31,

2018

 

Accrued clinical trial cost

 

$

4,084

 

 

$

3,796

 

Accrued payroll and related benefits

 

 

247

 

 

 

236

 

Accrued consulting and legal

 

 

117

 

 

 

296

 

Accrued other

 

 

72

 

 

 

36

 

Accrued expenses

 

$

4,520

 

 

$

4,364

 

 

4.

MARKETABLE SECURITIES

As of March 31, 2019, the fair value of available-for-sale marketable securities was as follows (in thousands):

 

 

 

As of March 31, 2019

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains

 

 

Gross

Unrealized

Losses

 

 

Fair Value

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

2,348

 

 

$

-

 

 

$

-

 

 

$

2,348

 

 

 

$

2,348

 

 

$

-

 

 

$

-

 

 

$

2,348

 

 

 

 

As of December 31, 2018

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains

 

 

Gross

Unrealized

Losses

 

 

Fair Value

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

14,106

 

 

$

-

 

 

$

-

 

 

$

14,106

 

 

 

$

14,106

 

 

$

-

 

 

$

-

 

 

$

14,106

 

 

All of the Company’s available-for-sale marketable securities at March 31, 2019 are maturing in one year or less.

10


 

5.

FAIR VALUE OF FINANCIAL MEASUREMENTS

Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on the following three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The assets’ or liabilities’ fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The following table sets forth the fair value of the Company’s financial assets by level within the fair value hierarchy (in thousands):

 

 

 

As of March 31, 2019

 

 

 

Fair Value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

8,233

 

 

$

8,233

 

 

$

-

 

 

$

-

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U. S. Treasury securities

 

 

2,348

 

 

 

-

 

 

 

2,348

 

 

 

-

 

Total Financial Assets

 

$

10,581

 

 

$

8,233

 

 

$

2,348

 

 

$

-

 

 

 

 

As of December 31, 2018

 

 

 

Fair Value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

4,881

 

 

$

4,881

 

 

$

-

 

 

$

-

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U. S. Treasury securities

 

 

14,106

 

 

 

-

 

 

 

14,106

 

 

 

-

 

Total Financial Assets

 

$

18,987

 

 

$

4,881

 

 

$

14,106

 

 

$

-

 

 

The Company did not transfer any assets measured at fair value on a recurring basis to or from Level 1 and Level 2 during either of the three months ended March 31, 2019 and 2018.

6.

LICENSE AND SERVICES AGREEMENT

In November 2017, the Company entered into a license agreement (the “VX3 License Agreement”) with VX3 (DE) LLP (“VX3”), which was formed by a group of Canadian investors including the Company’s majority stockholder, FCMI Parent Co. (“FCMI Parent”). VX3 was created for the purpose of funding the Company’s research and development activities for VX15, our most advanced product candidate. In June 2018, the U.S. Adopted Name Council approved the use of pepinemab as the adopted name for VX15. Under the VX3 License Agreement, the Company granted VX3 the license to use, make, have made, sell, offer and import pepinemab for the

11


treatment of Huntington’s disease in the U.S. and Canada and, in return, VX3 agreed to fund research and development activities with up to an aggregate of $32.0 million in milestone payments to the Company and to share any pepinemab profits and sublicensing revenue under the agreement in an amount based on a calculation set forth in the agreement. The Company also entered into a services agreement with VX3 (the Services Agreement), pursuant to which the Company will carry out development activities for pepinemab for the treatment of Huntington’s disease in the U.S. and Canada in exchange for services payments from VX3, including a payment of $11.9 million in 2017. The VX3 License Agreement expires upon the last to expire licensed patent and may be terminated by either party upon uncured material breach, the occurrence of certain transactions or financings including the consummation of an initial public offering by the Company, uncured failure of VX3 to make any payment due under the Services Agreement, or upon written notice after November 6, 2020. The Services Agreement may be terminated by either party upon an uncured material breach and is automatically terminated upon termination of the VX3 License Agreement. The VX3 License Agreement provides that upon termination, the Company will issue to VX3 or its designees the number of shares of the Company’s common stock equal to the lesser of (1) the aggregate of all payments made to VX3 by the Canadian investors divided by $18.20 and (2) the then fair market value of VX3 divided by the then fair market value of one share of the Company’s common stock.

The Company has a variable interest in VX3 through FCMI Parent, which is majority owned and controlled by the Company’s chairman, and it controlled 90% of VX3’s voting interest at each of March 31, 2019 and December 31, 2018. VX3 does not have any business operations or generate any income or expenses and is primarily a funding mechanism specifically for the benefit of the Company, as its only activities consist of the receipt of funding and the contribution of such funding to the Company. Therefore, the Company determined that it is the primary beneficiary of VX3 and that the operating results of VX3 should be incorporated into the Company’s condensed consolidated financial statements accordingly.

In February, May and June 2018, the Services Agreement was amended to allow VX3 to provide additional funding for future research and development activities to take place in the year ending December 31, 2018 and to repay an outstanding convertible note in the amount of $4.0 million (Note 8). No other terms of the Services Agreement were amended; therefore, the above assessment resulting in the Company being the primary beneficiary of the VX3 entity remained unchanged as of March 31, 2019.

For the three months ended March 31, 2018, the Company recorded the gross proceeds of $8.0 million, received from VX3 as capital contributions from noncontrolling interests on the condensed consolidated financial statements.

7.

COLLABORATION AGREEMENTS

Merck Sharp & Dohme Corp.

In September 2017, the Company entered into a research agreement with Merck Sharp & Dohme Corp. (“Merck”) to test vaccinia strain Modified Vaccinia Ankara. Under the research agreement, the Company designed genetic sequence for all constructs listed in the agreement and conducted research in accordance with the research protocol and a mutually agreed scope of work outlined in the agreement. Merck supplied the Company sufficient samples of the antibodies to carry out the research and has sole ownership of all right, title, interest and copy rights of the research results. Under the research agreement, the Company recognized service revenue of $69,000 for the three months ended March 31, 2018. The research agreement expired in June 2018. In the fourth quarter of 2018, the Company entered into a second research agreement with Merck to test these antigen particles in an antibody discovery campaign.

Surface Oncology, Inc.

In November 2017, the Company entered into a research collaboration and license option agreement with Surface Oncology, Inc. (“Surface”) to identify and select antibodies against two target antigens, using the Company’s proprietary technology as described in the agreement. The term for each research program is nine to twelve months (not exceeding twelve months unless extended by written agreement) including time necessary for any functional assessment conducted by Surface following the commencement of the research program. Surface will provide the Company material to carry out the research activities. During the research program term, the Company

12


also grants Surface non-exclusive, worldwide, limited-purpose license for each target to use the Company’s research program materials for conducting the research work pursuant to the agreement.

Under the agreement, Surface has been granted exclusive options, exercisable by providing a written notice to the Company, to obtain (i) an exclusive product license to make, use, sell and import products incorporating the antibody targeting the first antigen and (ii) an exclusive research tool license to use the antibody targeting the second antigen to perform research.

Under the agreement, Surface will pay an upfront technology access fee of $250,000 and milestone payments upon completion of each of four designated milestones for the first target antigen specified in the agreement. For the second target antigen, Surface will make payments to the Company based on time incurred by the Company in the conduct of the work plan described in the agreement. Surface will reimburse the Company for expenses incurred (i) in the conduct of the work plan as detailed in the research funding budget and (ii) for patent filings and prosecution of the Company’s program intellectual property as described in the agreement. The exercise of each option would also entail a license fee and annual maintenance fees, and in the case of the product license, royalties and additional milestone payments. During the year ended December 31, 2017, the Company received the upfront technology access fee of $250,000, of which $63,000 was recognized as revenue from the amortization of this upfront fee for the three months ended March 31, 2018. The Company also received $93,877 and $69,172 service fee payments for work conducted under the agreement for the three months ended March 31, 2019 and 2018, respectively. This agreement will expire upon the expiration of both research programs and all evaluation and testing periods.

8.

CONVERTIBLE PROMISSORY NOTES  

 

As of March 31, 2019, the Company did not have any convertible promissory notes outstanding. See “Repayment of Convertible Promissory Notes” below.

 

June 2016 Note

In June 2016, the Company issued a $1.5 million convertible promissory note to a related party. The June 2016 Note accrued interest at a compounded annual rate of 8% and had a maturity date three years from issuance, if not converted before then. Upon the occurrence of a default event, such as payment or performance defaults, bankruptcy, change in control (if elected to be treated as such by the lenders), or other violation, the interest rate would increase to a compounded annual rate of 12% until such time the default is cured. Upon maturity, the holder of these convertible promissory notes was to be repaid the outstanding principal plus all accrued interest. The Company also had the ability to prepay the convertible promissory notes, plus accrued interest, without penalty. The debt issuance costs for these convertible promissory notes were not material. The June 2016 Note was paid in full on August 17, 2018. See “Repayment of Convertible Promissory Notes” below.

January 2017 Notes

In January 2017, the Company entered into a convertible promissory note agreement whereby it agreed to issue, in the aggregate, $10.0 million of convertible promissory notes to a related party (the “January 2017 Notes”). The $4.0 million of the January 2017 Notes issued in January 2017 did not accrue interest, but the other $6.0 million of the January 2017 Notes issued in April, August and October 2017 accrued interest at an annual rate of 2%. The January 2017 Notes had a maturity date three years from issuance. Upon maturity, the holder of these convertible promissory notes was to be repaid the outstanding principal plus all accrued interest. The Company was also authorized to prepay the January 2017 Notes, plus accrued interest, without penalty. The debt issuance costs for these convertible promissory notes were not material. Of the January 2017 Notes, $6.0 million were paid in 2017 and the balance was paid in full on March 8, 2018. See “Repayment of Convertible Promissory Notes” below.

Derivative Liabilities

From the proceeds of the convertible promissory notes, the portion equal to the fair value of the embedded derivative liabilities and the option derivative at the time of each respective issuance was recognized as a debt

13


discount to be amortized to interest expense over the term of the related convertible promissory notes. The Company recognized interest expense of $235,000 for the amortization of the debt discounts during the three months ended March 31, 2018.

Repayment of Convertible Promissory Notes

Of the January 2017 Notes, $2.0 million issued in April 2017 was repaid along with accrued interest in May 2017, $4.0 million issued in August and October 2017 was repaid along with accrued interest in November 2017 and $4.0 million issued in January 2017 was repaid in March 2018. The option arrangement associated with the January 2017 Notes was also waived upon the repayment of the January 2017 Notes. As a result of this repayment, the related $0.3 million derivative liabilities associated with the conversion feature and the option arrangement were written off and the $2.2 million unamortized debt discount was recognized as a loss on extinguishment of related party convertible promissory note in the condensed consolidated statement of operations for the three months ended March 31, 2018.

The June 2016 Note was repaid along with accrued interest in August 2018. As a result of this repayment, the related $31,000 derivative liability associated with the conversion feature and the option arrangement were written off and the $199,000 unamortized debt discount was recognized as a loss on extinguishment of related party convertible promissory note in the condensed consolidated statements of operations in the three months ended September 30, 2018.

 

 

9.

COMMITMENTS AND CONTINGENCIES

Sublicense Termination Payments

In 2006, the Company licensed certain technology to EUSA Pharma SAS (“EUSA”) and in 2008, this technology was sublicensed by EUSA to Glaxo Group Limited (“GSK”) for development. GSK terminated its sub-license with EUSA in March 2010 and ownership of the technology reverted back to the Company. The Company may be required to pay EUSA up to $25.5 million plus ongoing royalty payments of 1% of net sales upon the occurrence of certain events involving the previously licensed technology, including a Phase 3 clinical trial, FDA acceptance and approval and product sales. The Company is not planning any further commercialization efforts related to the previously licensed technology, and therefore does not anticipate any of the above described amounts will be paid.

Operating Lease

The Company leases its facilities from 1895 Management, Ltd., a New York corporation controlled by an entity affiliated with a director of the Company, under non-cancellable operating leases. Following entry into a lease extension agreement in July 2018, the lease agreement requires monthly rental payments of $14,000 through October 31, 2020. The Company is responsible for all maintenance, utilities, insurance and taxes related to the facility.

As of March 31, 2019, the future minimum payments for the operating lease are $266,000.

Rent expense incurred under the operating lease was $42,000 for each of the three months ended March 31, 2019 and 2018.

Contingencies

The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount.

In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be

14


reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. As of March 31, 2019 and December 31, 2018, the Company was not involved in any material legal proceedings.

10.

COMMON STOCK RESERVED FOR ISSUANCE

Common stock has been reserved for the following potential future issuances:

 

 

 

As of

March 31, 2019

 

 

As of

December 31, 2018

 

Shares underlying outstanding stock options

 

 

538,702

 

 

 

405,683

 

Shares available for future stock option grants

 

 

289,981

 

 

 

423,000

 

Exchange of Vaccinex Products, LP units

 

 

1,202,566

 

 

 

1,202,566

 

Conversion of VX3 units

 

 

1,318,797

 

 

 

1,318,797

 

Total shares of common stock reserved

 

 

3,350,046

 

 

 

3,350,046

 

 

11.

STOCK-BASED COMPENSATION

2011 Employee Equity Plan

The Company’s 2011 Employee Equity Plan (the “2011 Plan”) was terminated in connection with the adoption of the Company’s 2018 Omnibus Incentive Plan (the “2018 Plan”) in August 2018, and the Company will not grant any additional stock options under the 2011 Plan. However, the 2011 Plan will continue to govern the terms and conditions of the outstanding stock options previously granted thereunder. Stock options granted under the 2011 Plan expire in five or ten years from the date of grant.

2018 Omnibus Incentive Plan

In August 2018, the Company’s Board of Directors adopted, and its stockholders approved, the 2018 Plan, which allows for the granting of stock, stock option, and stock appreciation rights awards to employees, advisors and consultants. Stock options granted under the 2018 Plan may be either incentive stock options or non-statutory stock options. Incentive stock options may be granted to employees, advisors and consultants at exercise prices of no less than the fair value of the common stock on the grant date. If at the time of grant, the optionee owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price must be at least 110% of the fair value of the common stock on the grant date as determined by the board of directors. Non-statutory stock options may be granted to employees, advisors and consultants at exercise prices of less than the fair market value of a share of common stock on the date the non-statutory stock option is granted but shall under no circumstances be less than adequate consideration as determined by the board of directors for such a share. Vesting period of stock option grants is determined by the board of directors, ranging from zero to eight years. Stock options granted under the 2018 Plan expire in five or ten years from the date of grant.

The Company reserved 425,000 shares of common stock for issuance, subject to certain adjustments, pursuant to awards under the 2018 Plan. Any shares of common stock related to awards outstanding under the 2011 Plan as of the effective date of the 2018 Plan, which thereafter terminate by expiration, forfeiture, cancellation or otherwise without the issuance of such shares, will be added to, and included in, the number of shares of common stock available for grant under the 2018 Plan. In addition, effective January 1, 2020 and continuing until the expiration of the 2018 Plan, the number of shares of common stock available for issuance under the 2018 Plan will automatically increase annually by 2% of the total number of issued and outstanding shares of our common stock as of December 31st of the immediately preceding year or such lesser number as our board of directors may decide, which may be zero.

15


A summary of the Company’s stock option activity and related information is as follows:

 

 

 

Options Outstanding

 

 

 

Stock Options

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Life (Years)

 

 

Aggregate

Intrinsic

Value (000's)

 

Balance as of December 31, 2018

 

 

405,683

 

 

$

9.69

 

 

 

6.5

 

 

$

-

 

Granted

 

 

135,972

 

 

 

3.97

 

 

 

 

 

 

 

 

 

Exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

Canceled

 

 

(2,953

)

 

 

12.60

 

 

 

 

 

 

 

 

 

Balance as of March 31, 2019

 

 

538,702

 

 

$

8.23

 

 

 

7.2

 

 

$

175

 

Exercisable as of March 31, 2019

 

 

373,777

 

 

$

9.43

 

 

 

6.1

 

 

$

-

 

 

 

The weighted-average grant date fair value of stock options granted to employees for the three months ended March 31, 2019 and 2018 was $2.65 and $15.63 per share, respectively. The aggregate grant date fair value of stock options that vested during the three months ended March 31, 2019 and 2018 was $53,716 and $79,000, respectively.

The intrinsic value of stock options vested and expected to vest and exercisable is calculated based on the difference between the exercise price and the fair value of the Company’s common stock as of March 31, 2019 and December 31, 2018. The intrinsic value of exercised stock options is the difference between the fair value of the underlying common stock and the exercise price as of the exercise date.

As of March 31, 2019 and December 31, 2018, total unrecognized compensation cost related to stock options granted to employees was $710,285 and $435,639, respectively, which is expected to be recognized over a weighted-average period of 3.3 and 2.8 years, respectively.

The grant date fair value of employee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:  

 

 

Three Months Ended

March 31,

 

 

2019

 

 

2018

 

Expected term (in years)

 

6.0

 

 

 

6.0

 

Expected volatility

 

75

%

 

 

75

%

Risk-free interest rate

 

2.5

%

 

 

2.6

%

Expected dividend yield

 

-

%

 

 

-

%

 

Total stock-based compensation expense recognized in the condensed consolidated statements of operations is as follows (in thousands):

 

 

 

Three Months Ended

March 31,

 

 

 

2019

 

 

2018

 

Research and development

 

$

15

 

 

$

21

 

General and administrative

 

 

45

 

 

 

15

 

Total stock-based compensation expense

 

$

60

 

 

$

36

 

 

12.

INCOME TAXES

No provision for income taxes was recorded in either of the three months ended March 31, 2019 and 2018. The Company remains in a cumulative loss position with a full valuation allowance recorded against its net deferred income tax assets as of March 31, 2019.

 

 

16


The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of March 31, 2019 and December 31, 2018, the Company had no unrecognized income tax benefits that would affect the Company’s effective tax rate if recognized.

 

13.

NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS

 

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

 

 

 

Three Months Ended

March 31,

 

 

 

2019

 

 

2018

 

Preferred stock (if converted)

 

 

-

 

 

 

7,039,155

 

Options to purchase common stock

 

 

432,051

 

 

 

424,843

 

Contingently issuable common stock upon exchange of

   Vaccinex Products, LP units

 

 

1,202,566

 

 

 

1,202,566

 

Contingently issuable common stock upon exchange of

   VX3 units

 

 

1,318,797

 

 

 

800,880

 

 

14.

SEGMENT AND GEOGRAPHIC INFORMATION

The Company’s chief operating decision maker, its Chief Executive Officer, reviews its operating results on an aggregate basis for purposes of allocating resources and evaluating financial performance. The Company has one business activity, the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, and there are no segment managers who are held accountable for operations or operating results. Accordingly, the Company operates in one segment. As of March 31, 2019 and December 31, 2018, all long-lived assets are located in the United States.

15.

EMPLOYEE BENEFIT PLAN

The Company sponsors a 401(k) plan that stipulates that eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100% of eligible compensation on a pre-tax basis. Through March 31, 2019, the Company has not elected to match employee contributions as permitted by the plan. The Company pays the administrative costs for the plan.

16.

RELATED PARTY TRANSACTIONS

As discussed in Note 9, the Company leases its facility from 1895 Management, Ltd., a New York corporation controlled by an entity affiliated with the Company’s chairman and major stockholder of the Company. Rent expense incurred under this operating lease was $42,000 for each of the three months ended March 31, 2019 and 2018.

As discussed in Note 7, in November 2017, we entered into a research collaboration and license option agreement with Surface to identify and select antibodies against two target antigens, using our proprietary technology as described in the agreement. J. Jeffrey Goater, a member of our board of directors, served as the Chief Business Officer of Surface at that time, and currently serves as the Chief Executive Officer and a director of Surface. The Company received $93,877 and $69,172 service fee payments for work conducted under the agreement for the three months ended March 31, 2019 and 2018, respectively.

 

17


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of financial condition and results of operations together with our condensed consolidated financial statements and related notes included elsewhere in this report. References in this report to the “Company,” “we,” “our,” or “us” mean Vaccinex, Inc. and its subsidiaries except where the context otherwise requires. This discussion and other parts of this Quarterly Report on Form 10-Q (the “Report”) contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the risk factors identified in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018 and in the cautionary statement below.

Cautionary Note Regarding Forward-Looking Statements

Some of the statements made in this Report constitute forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends” or “continue,” or the negative of these terms or other comparable terminology.

Forward-looking statements include, but are not limited to, statements about:

 

our estimates regarding our expenses, future revenues, anticipated capital requirements and our needs for additional financing;

 

the implementation of our business model and strategic plans for our business and technology;

 

the timing and success of the commencement, progress and receipt of data from any of our preclinical and clinical trials;

 

our expectations regarding the potential safety, efficacy or clinical utility of our product candidates;

 

the expected results of any clinical trial and the impact on the likelihood or timing of any regulatory approval;

 

the difficulties in obtaining and maintaining regulatory approval of our product candidates;

 

the rate and degree of market acceptance of any of our product candidates;

 

the success of competing therapies and products that are or become available;

 

regulatory developments in the United States and foreign countries;

 

current and future legislation regarding the healthcare system;

 

the scope of protection we establish and maintain for intellectual property rights covering our technology;

 

developments relating to our competitors and our industry;

 

our failure to recruit or retain key scientific or management personnel or to retain our executive officers;

 

the performance of third parties, including collaborators, contract research organizations and third-party manufacturers;

 

the development of our commercialization capabilities, including the need to develop or obtain additional capabilities; and

 

our use of the proceeds from our recent initial public offering.

18


These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in greater detail in the risk factors in Item 1A of our 2018 Annual Report on Form 10-K. You should not rely upon forward-looking statements as predictions of future events.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, after the date of this Report, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Company Overview

We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. We believe we are the leader in the field of SEMA4D biology and that we are the only company targeting SEMA4D as a potential treatment for cancer, neurodegenerative diseases, or autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the migration of immune and inflammatory cells to sites of injury, cancer or infection. We are leveraging our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, VX15, which we believe utilizes novel mechanisms of action. In June 2018, the U.S. Adopted Name Council approved the use of pepinemab as the adopted name for VX15.  We are focused on the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington’s disease. We have developed multiple proprietary platform technologies and are developing product candidates to address serious diseases or conditions that have a substantial impact on day-to-day functioning and for which treatment is not addressed adequately by available therapies. We employ our proprietary platform technologies, including through our work with our academic collaborators, to identify potential product candidates for sustained expansion of our internal product pipeline and to facilitate strategic development and commercial partnerships.

Our lead platform technologies include our SEMA4D antibody platform and our ActivMAb antibody discovery platform.

Our SEMA4D antibody platform is the application of our extensive knowledge of SEMA4D biology to develop our lead product candidate pepinemab for the treatment of various indications, including cancer and neuroinflammatory and neurodegenerative diseases.  We believe pepinemab’s mechanisms of action block the SEMA4D signal and activate innate physiological mechanisms to respond to tumors or tissue injury. We have demonstrated in animal models in preclinical studies that the biological activities associated with an antibody blockade of SEMA4D can promote immune cell infiltration into tumors and the repair or prevention of neurological damage in neuroinflammatory and neurodegenerative diseases.

Our ActivMAb® antibody discovery platform is a proprietary human antibody discovery platform based on a novel method for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. We believe our ActivMAb technology offers (i) rapid generation of high affinity, full-length, human monoclonal antibodies synthesized and naturally modified in mammalian cells, (ii) expression and selection of antibodies that easily and predictably transition to manufacturing in mammalian lines, and (iii) an innovative and efficient method for selecting antibodies against multi-pass membrane proteins, an important class of pharmacological targets. Our product candidate VX5 was generated by our ActivMAb platform and is currently in preclinical development for the treatment of MS and potentially for other autoimmune disorders. We intend to continue to utilize our ActivMAb platform to identify additional product candidates for our own pipeline development and for strategic collaborations.

In addition, we and our academic collaborators are using our Natural Killer T, or NKT, vaccine platform to discover product candidates that target and extend the activity of NKT cells. NKT cells work directly to kill certain types of parasites and cells, including tumor cells and virus-infected cells. We are applying our agonists to direct NKT cells to the site of tumors, potentially enhancing tumor-specific immunity through recruitment and activation of cytotoxic T cells, or CTL, and antibody-armed natural killer, or NK, cells that will work to eradicate the tumor.

19


We have generated a limited amount of service revenue from collaboration agreements but have not generated any revenue from product sales to date. We continue to incur significant development and other expenses related to our ongoing operations. As a result, we are not and have never been profitable and have incurred losses in each period since our inception. For the three months ended March 31, 2019 and 2018, we reported a net loss of $9.1 million and $7.9 million, respectively. As of March 31, 2019 and December 31, 2018, we had cash and cash equivalents and marketable securities of $11.3 million and $19.7 million, respectively. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates. Our recurring net losses and negative cash flows from operations have raised substantial doubt regarding our ability to continue as a going concern, and as a result, our independent registered public accounting firm has noted this in the opinion they issued on our consolidated financial statements for the year ended December 31, 2018. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues, if any. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders’ equity and working capital.

Financial Overview

Revenue

To date, we have not generated any revenue from product sales. During the three months ended March 31, 2019 and 2018, we generated a limited amount of service revenue from our collaboration agreements, including with Surface Oncology, Inc. (“Surface”) and Merck Sharp & Dohme Corp. (“Merck”).

Our ability to generate revenue and become profitable depends on our ability to successfully obtain marketing approval of and commercialize our product candidates. We do not expect to generate product revenue in the foreseeable future as we continue our development of, and seek regulatory approvals for, our product candidates, and potentially commercialize approved products, if any.

Operating Expenses

Research and Development. Research and development expenses consist primarily of costs for our clinical trials and activities related to regulatory filings, employee compensation-related costs, supply expenses, equipment depreciation and amortization, consulting and other miscellaneous costs. The following table sets forth the components of our research and development expenses and the amount as a percentage of total research and development expenses for the periods indicated.

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

 

 

(in thousands)

 

 

%

 

 

(in thousands)

 

 

%

 

Clinical trial costs

 

$

5,776

 

 

 

78

%

 

$

3,050

 

 

 

68

%

Wages, benefits, and related costs

 

 

885

 

 

 

12

%

 

 

753

 

 

 

17

%

Preclinical supplies and equipment depreciation

 

 

471

 

 

 

6

%

 

 

493

 

 

 

11

%

Consulting, non-clinical trial services, and other

 

 

280

 

 

 

4

%

 

 

158

 

 

 

4

%

Total research and development expenses

 

$

7,412

 

 

 

 

 

 

$

4,454

 

 

 

 

 

 

Our current research and development activities primarily relate to the clinical development of the following programs:

 

Non-Small Cell Lung Cancer (NSCLC). In the CLASSICAL–Lung clinical trial, in which we are evaluating pepinemab in combination with avelumab in NSCLC, the dose escalation phase of the trial consisting of 12 subjects is complete, and we have identified the intended Phase 2 dose for the dose expansion phase. We plan to enroll a total of 50 subjects in two cohorts: because of changes in the regulatory environment following initiation of this study that have made it increasingly difficult to enroll immunotherapy naïve subjects, we have changed the allocation of subjects from 22 to 17 subjects in one cohort in which patients are immunotherapy naïve and 28 to 33 subjects in a second cohort whose

20


 

tumors have progressed during or following an initial treatment with anti-PD1/PD-L1. Primary completion for this trial is expected in the second half of 2019.

 

Huntington’s Disease. Enrollment in Cohort B of our SIGNAL trial evaluating pepinemab for the treatment of Huntington’s disease, consisting of 265 subjects, was completed in December 2018. We expect data from this study in the second half of 2020.

 

In addition, pepinemab is being evaluated in multiple investigator-sponsored trials (ISTs) in additional indications:

 

o

Melanoma - The UCLA School of Medicine, in collaboration with Bristol-Myers Squibb, is evaluating pepinemab in combination with the checkpoint inhibitors nivolumab and ipilimumab in two cohorts of patients with advanced melanoma whose tumors progressed during or following initial treatment with immunotherapy.

 

o

Osteosarcoma - The National Cancer Institute’s Children’s Oncology Group is evaluating pepinemab for the treatment of osteosarcoma.

 

o

Other Cancers - Multiple “window of opportunity” trials are being conducted by the Winship Cancer Institute of Emory University to evaluate pepinemab in combination with immunotherapies in colorectal, pancreatic, head and neck cancer and melanoma.

As a result of our current research and development activities, the following milestones are anticipated:

 

Second quarter of 2019 – Presentation of additional data from the Classical-Lung study of pepinemab in combination with avelumab in NSCLC

 

Second half of 2019 – Anticipated publication of SIGNAL Cohort A data in Huntington’s disease

 

Second half of 2019 – Estimated primary completion date of combination study in NSCLC

 

Second half of 2020 – Expected topline data from Cohort B of SIGNAL trial of pepinemab in Huntington’s disease

 

Second half of 2020 – Estimated primary completion date of melanoma combination study being conducted at the UCLA School of Medicine with Bristol-Myers Squibb

We expense research and development costs as incurred. We record costs for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment. We do not allocate employee related costs, depreciation, rental and other indirect costs to specific research and development programs because these costs are deployed across multiple of our product programs under research and development.

21


Results of Operations

The following table set forth our results of operations for the periods presented (in thousands):

 

 

 

Three Months Ended

March 31,

 

 

 

2019

 

 

2018

 

Revenue

 

$

94

 

 

$

206

 

Costs and expenses:

 

 

 

 

 

 

 

 

Cost of revenue

 

 

175

 

 

 

240

 

Research and development

 

 

7,412

 

 

 

4,454

 

General and administrative

 

 

1,647

 

 

 

1,221

 

Total costs and expenses

 

 

9,234

 

 

 

5,915

 

Loss from operations

 

 

(9,140

)

 

 

(5,709

)

Change in fair value of derivative liabilities

 

 

-

 

 

 

308

 

Interest expense

 

 

-

 

 

 

(267

)

Loss on extinguishment of related party convertible promissory note

 

 

-

 

 

 

(2,180

)

Other income (expense), net

 

 

73

 

 

 

(14

)

Loss before provision for income taxes

 

 

(9,067

)

 

 

(7,862

)

Provision for income taxes

 

 

-

 

 

 

-

 

Net loss

 

 

(9,067

)

 

 

(7,862

)

Net loss attributable to noncontrolling interests

 

 

-

 

 

 

-

 

Net loss attributable to Vaccinex, Inc.

 

$

(9,067

)

 

$

(7,862

)

 

Comparison of the Three Months Ended March 31, 2019 and 2018

Operating Expenses

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

 

$ Change

 

 

% Change

 

 

 

(in thousands)

 

 

 

 

 

Research and development

 

$

7,412

 

 

$

4,454

 

 

$

2,958

 

 

 

66

%

General and administrative

 

 

1,647

 

 

 

1,221

 

 

 

426

 

 

 

35

%

Total operating expenses

 

$

9,059

 

 

$

5,675

 

 

$

3,384

 

 

 

60

%

 

Research and Development. Research and development expenses in the three months ended March 31, 2019 increased by $3.0 million, or 66%, compared to the three months ended March 31, 2018. This increase was attributable to the increase in patients enrolled in active clinical trials.

 

General and Administrative. General and administrative expenses in the three months ended March 31, 2019 increased by $426,000, or 35%, compared to the three months ended March 31, 2018. This increase was attributable to costs associated with directors compensation and liability insurance as a result of being a public company.

Change in fair value of derivative liabilities

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

 

$ Change

 

 

% Change

 

 

 

(in thousands)

 

 

 

 

 

Change in fair value of derivative liabilities

 

$

-

 

 

$

308

 

 

$

(308

)

 

 

(100

)%

 

Change in fair value of derivative liabilities in the three months ended March 31, 2018 was due to the repayment of $10.0 million of convertible promissory notes to a related party (the “January 2017 Notes”) and the waiving of the associated option arrangement in March 2018.

22


Interest Expense

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

 

$ Change

 

 

% Change

 

 

 

(in thousands)

 

 

 

 

 

Interest expense

 

$

-

 

 

$

(267

)

 

$

(267

)

 

 

(100

)%

 

Interest expense in the three months ended March 31, 2019 decreased by $267,000, compared to the three months ended March 31, 2018, as a result of the repayment of the January 2017 Notes in March 2018 and the $1.5 million convertible promissory note issued in June 2016 to a related party (the “June 2016 Note”) in August 2018.

Liquidity and Capital Resources

To date, we have not generated any revenue from product sales. Since our inception in 2001, we have financed our operations principally through private placements of our preferred stock, issuances of convertible promissory notes and other promissory notes and funding from collaboration agreements with our variable interest entities. Through March 31, 2019, we have received net proceeds of $87.1 million from the issuance of shares of our preferred stock, $39.0 million from issuance of convertible promissory notes and $72.1 million from our variable interest entities.

In August 2018, we completed an initial public offering (“IPO”) of our common stock. We received net proceeds of $37.2 million after deducting underwriting discounts and commissions of $2.8 million but before deducting offering costs of $2.7 million.

Operating Capital Requirements

Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party research services and amounts due to vendors for research supplies. As of March 31, 2019 and December 31, 2018, our principal source of liquidity was cash and cash equivalents and marketable securities in the amount of $11.3 million and $19.7 million, respectively. Given our projected operating requirements, our existing cash and cash equivalents and marketable securities, we plan to complete an additional financing transaction prior to the commencement of the fourth quarter of the year ended December 31, 2019 in order for us to continue operations.

Since our inception in 2001, we have incurred significant net losses and negative cash flows from operations. For the three months ended March 31, 2019 and 2018, we reported a net loss of $9.1 million and $7.9 million, respectively. As of March 31, 2019 and December 31, 2018, we had an accumulated deficit of $225.8 million and $216.8 million, respectively. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates. We are subject to all of the risks associated with the development of new biopharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.

Until we can generate a sufficient amount of revenue from our products, we expect to finance future cash needs through public or private equity, debt offerings, or capital contributions from our noncontrolling interests. In 2018, VX3 (DE) LLP (“VX3”), received a commitment of $8.0 million of additional funding from FCMI Parent Co. (“FCMI Parent”), which was received in the first quarter of 2018, and commitments of $4.0 million of additional funding in the aggregate from FCMI Parent and another investor, which were received in the second quarter of 2018. In August 2018, we completed our IPO and received net proceeds of $37.2 million. Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us we may have to significantly delay, scale back or discontinue the development of one or more of our product candidates. If we raise additional funds through the issuance of additional debt or equity securities it could result in dilution to our existing stockholders, increased fixed payment obligations and these securities may have rights senior to those of our common stock and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license our intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial condition and prospects.

23


Cash Flows

The following table summarizes our cash flows for the periods presented:

 

 

 

Three Months Ended March 30,

 

 

 

2019

 

 

2018

 

 

 

(in thousands)

 

Cash used in operating activities

 

$

(8,476

)

 

$

(5,165

)

Cash provided by (used in) investing activities

 

 

11,800

 

 

 

(47

)

Cash provided by financing activities

 

 

-

 

 

 

3,956

 

 

Operating Activities. We have historically experienced negative cash flows as we developed our product candidates and continued to expand our business. Our net cash used in operating activities primarily results from our net loss adjusted for non-cash expenses and changes in working capital components as we have continued our research and development and is influenced by the timing of cash payments for research related expenses. Our primary uses of cash from operating activities are compensation and related-expenses, employee-related expenditures, third-party research services and amounts due to vendors for research supplies. Our cash flows from operating activities will continue to be affected principally by the extent to which we increase spending on personnel, research and development and other operating activities as our business grows.

During the three months ended March 31, 2019, operating activities used $8.5 million in cash, primarily as a result of our net loss of $9.1 million.

During the three months ended March 31, 2018, operating activities used $5.2 million in cash, primarily as a result of our net loss of $7.9 million, aggregate non-cash items of $2.2 million, and $0.5 million net outflow change in our operating assets and liabilities. Non-cash items included a $2.2 million loss from unamortized debt issuance cost upon the repayment of the $4.0 million January 2017 Note in March 2018, $0.2 million amortization of debt discount related to certain convertible promissory notes, a $0.3 million gain in fair value of derivative liabilities, $56,000 depreciation expense and $36,000 of stock-based compensation expense.

Investing Activities. Cash provided by investing activities during the three months ended March 31, 2019 resulted from sales and maturities of marketable securities.

Financing Activities. During the three months ended March 31, 2018, financing activities provided $4.0 million primarily attributable to the capital contribution from noncontrolling interests of $8.0 million partially offset by a $4.0 million repayment of a convertible promissory note.

Convertible Promissory Notes

During the year ended December 31, 2017, we raised funds through the issuance of $10.0 million of convertible promissory notes, of which $6.0 million were repaid in the same year. On March 8, 2018, we repaid the $4.0 million January 2017 Note and on August 17, 2018, the $1.5 million June 2016 Note was repaid.

The June 2016 Note, together with accrued interest, was convertible: (i) automatically upon a future qualifying financing event, which includes the sale of shares in a future preferred stock financing with gross proceeds of at least $5.0 million or the issuance of shares of common stock in an initial public offering; (ii) upon a change of control (unless the lenders elected to treat such event as a default); or (iii) upon a future non-qualifying financing event at the election of the lenders. Upon a future qualifying financing event, the outstanding principal, together with accrued interest, would convert into shares of the newly issued securities at 85% of the price paid in the financing. Upon the election to convert the June 2016 Note in the event of a change of control, the outstanding principal, together with accrued interest, would convert based on the conversion price of the Series C redeemable convertible preferred stock, which was $18.20 per share as of December 31, 2017, at the time of conversion. Upon the election to convert the June 2016 Note in the event of a non-qualifying financing event, the outstanding principal, together with accrued interest, would convert based on the lowest price per share paid for in the financing.

24


All of the convertible promissory notes were allowed to be prepaid, plus accrued interest if applicable, without penalty.

Capital Contributions from Noncontrolling Interests

In November 2017, we entered into a license agreement (the “VX3 License Agreement”), with VX3, which was formed in October 2017 by a group of Canadian investors including our majority stockholder FCMI Parent. Under the VX3 License Agreement, we granted VX3 the license to use, make, have made, sell, offer and import pepinemab for the treatment of Huntington’s disease in the U.S. and Canada. Pursuant to the VX3 License Agreement, VX3 agreed to pay us up to an aggregate of $32.0 million in milestone payments and to share any pepinemab profits and sublicensing revenue under the agreement in an amount based on a calculation set forth in the agreement. In connection with the VX3 License Agreement, we also entered into a services agreement with VX3 (the “Services Agreement”), effective as of January 1, 2017, pursuant to which we will carry out development activities for pepinemab for the treatment of Huntington’s disease in the U.S. and Canada in exchange for services payments from VX3, including a payment of $11.9 million for 2017 net of certain related expenses. On February 28, 2018, May 15, 2018 and June 12, 2018, the Services Agreement was amended to provide for additional payments of $8.0 million, $2.0 million and $2.0 million, respectively, from VX3 for services performed in 2018. The VX3 License Agreement expires upon the last to expire licensed patent and may be terminated by either party upon uncured material breach, the occurrence of certain transactions or financings including the consummation of an initial public offering by us, uncured failure of VX3 to make any payment due under the services agreement, or upon written notice after November 6, 2020. The Services Agreement may be terminated by either party upon uncured material breach and is automatically terminated upon termination of the VX3 License Agreement. The VX3 License Agreement provides that upon termination, we will issue to VX3 or its designees the number of shares of our common stock equal to the lesser of (1) the aggregate of all capital contributions made to VX3 by its partners (i.e. the Canadian investors) divided by $18.20 and (2) the then fair market value of VX3 divided by the then fair market value of one share of our common stock.

We have determined VX3 to be a variable interest entity in which we are the primary beneficiary. As such, we recorded the gross proceeds of $12.0 million received from VX3 as a capital contribution from noncontrolling interests on our consolidated financial statements for the year ended December 31, 2018.

Contractual Obligations

There were no significant changes to our contractual obligations described in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 13, 2019.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.

JOBS Act Accounting Election

We are an “emerging growth company” within the meaning of the Jumpstart Our Business Startups Act (the “JOBS Act”). Section 107(b) of the JOBS Act provides that an emerging growth company can leverage the extended transition period, provided in Section 102(b) of the JOBS Act, for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. We have elected to use this extended transition period and, as a result, our condensed consolidated financial statements may not be comparable to companies that comply with public company effective dates of such accounting standards.

Critical Accounting Policies and Estimates

Our unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures. We evaluate our estimates and assumptions on an ongoing basis. Our

25


estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Our actual results could differ from these estimates.

There have been no material changes to our critical accounting policies and significant judgments as compared to the critical accounting policies and estimates disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.

Recent Accounting Pronouncements Not Yet Adopted

For a discussion of recent accounting pronouncements that we have not yet adopted, see Note 2 to our unaudited condensed consolidated financial statements.

Recently Adopted Accounting Pronouncements

For a discussion of accounting pronouncements that we have recently adopted, see Note 2 to our unaudited condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

As a smaller reporting company, we are not required to provide the information required by this item.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of March 31, 2019, the end of the period covered by this Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2019, our disclosure controls and procedures were effective.

Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2019 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

26


Part II - OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently subject to any material legal proceedings.

Item 1A. Risk Factors

There have been no material changes from the risk factors as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 13, 2019.

27


Item 6. Exhibits

INDEX TO EXHIBITS

 

Exhibit

No.

 

Description

  31.1*

 

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

  31.2*

 

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

  32.1*

 

Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

 

 

 

101*

 

The following items from this Quarterly Report on Form 10-Q formatted in Extensible Business Reporting Language: (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Operations (unaudited), (iii) Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit (unaudited), (iv) Condensed Consolidated Statements of Cash Flows (unaudited), and (v) Notes to Condensed Consolidated Financial Statements

 

*

Filed herewith.

28


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

 

Vaccinex, Inc.

 

 

(Registrant)

 

 

 

May 15, 2019

By:

/s/ Maurice Zauderer

 

 

Maurice Zauderer, Ph.D.

 

 

President & Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

May 15, 2019

By:

/s/ Scott E. Royer

 

 

Scott E. Royer, CFA, MBA

 

 

Chief Financial Officer

 

 

(Principal Financial Officer)

 

 

 

29

EX-31.1 2 vcnx-ex311_150.htm EX-31.1 vcnx-ex311_150.htm

 

Exhibit 31.1

 

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Maurice Zauderer, certify that:

1.

I have reviewed this quarterly report on Form 10-Q for the three months ended March 31, 2019 of Vaccinex, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

 

 

Dated: May 15, 2019

By:

/s/ Maurice Zauderer

 

 

Maurice Zauderer, Ph.D.

 

 

President and Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

EX-31.2 3 vcnx-ex312_151.htm EX-31.2 vcnx-ex312_151.htm

 

Exhibit 31.2

 

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Scott E. Royer, certify that:

1.

I have reviewed this quarterly report on Form 10-Q for the three months ended March 31, 2019 of Vaccinex, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

 

 

Dated: May 15, 2019

By:

/s/ Scott E. Royer

 

 

Scott E. Royer

 

 

Chief Financial Officer

 

 

(Principal Financial Officer)

 

 

EX-32.1 4 vcnx-ex321_149.htm EX-32.1 vcnx-ex321_149.htm

 

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report of Vaccinex, Inc., (the "Company") on Form 10-Q for the three months ended March 31, 2019 (the "Report"), I, Maurice Zauderer, Ph.D., President and Chief Executive Officer of the Company and Scott E. Royer, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

Dated: May 15, 2019

By:

/s/ Maurice Zauderer

 

 

Maurice Zauderer, Ph.D.

 

 

President and Chief Executive Officer

 

 

 

 

Dated: May 15, 2019

By:

/s/ Scott E. Royer

 

 

Scott E. Royer

 

 

Chief Financial Officer

 

 

EX-101.INS 5 vcnx-20190331.xml XBRL INSTANCE DOCUMENT xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure vcnx:TargetAntigen vcnx:Milestone vcnx:BusinessActivity vcnx:SegmentManager vcnx:Segment 0001205922 2019-01-01 2019-03-31 0001205922 2019-05-10 0001205922 2019-03-31 0001205922 2018-12-31 0001205922 2018-01-01 2018-03-31 0001205922 us-gaap:RedeemableConvertiblePreferredStockMember 2017-12-31 0001205922 us-gaap:ConvertiblePreferredStockMember 2017-12-31 0001205922 us-gaap:CommonStockMember 2017-12-31 0001205922 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001205922 us-gaap:TreasuryStockMember us-gaap:RedeemableConvertiblePreferredStockMember 2017-12-31 0001205922 us-gaap:TreasuryStockMember 2017-12-31 0001205922 us-gaap:RetainedEarningsMember 2017-12-31 0001205922 us-gaap:ParentMember 2017-12-31 0001205922 us-gaap:NoncontrollingInterestMember 2017-12-31 0001205922 2017-12-31 0001205922 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001205922 us-gaap:ParentMember 2018-01-01 2018-03-31 0001205922 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-03-31 0001205922 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001205922 us-gaap:RedeemableConvertiblePreferredStockMember 2018-03-31 0001205922 us-gaap:ConvertiblePreferredStockMember 2018-03-31 0001205922 us-gaap:CommonStockMember 2018-03-31 0001205922 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001205922 us-gaap:TreasuryStockMember us-gaap:RedeemableConvertiblePreferredStockMember 2018-03-31 0001205922 us-gaap:TreasuryStockMember 2018-03-31 0001205922 us-gaap:RetainedEarningsMember 2018-03-31 0001205922 us-gaap:ParentMember 2018-03-31 0001205922 us-gaap:NoncontrollingInterestMember 2018-03-31 0001205922 2018-03-31 0001205922 us-gaap:CommonStockMember 2018-12-31 0001205922 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001205922 us-gaap:TreasuryStockMember 2018-12-31 0001205922 us-gaap:RetainedEarningsMember 2018-12-31 0001205922 us-gaap:ParentMember 2018-12-31 0001205922 us-gaap:NoncontrollingInterestMember 2018-12-31 0001205922 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001205922 us-gaap:ParentMember 2019-01-01 2019-03-31 0001205922 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001205922 us-gaap:CommonStockMember 2019-03-31 0001205922 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001205922 us-gaap:TreasuryStockMember 2019-03-31 0001205922 us-gaap:RetainedEarningsMember 2019-03-31 0001205922 us-gaap:ParentMember 2019-03-31 0001205922 us-gaap:NoncontrollingInterestMember 2019-03-31 0001205922 2018-01-01 2018-12-31 0001205922 2017-01-01 2017-12-31 0001205922 us-gaap:IPOMember us-gaap:CommonStockMember 2018-08-09 2018-08-09 0001205922 us-gaap:IPOMember 2018-08-09 0001205922 us-gaap:IPOMember 2018-08-09 2018-08-09 0001205922 vcnx:VaccinexRochesterLimitedLiabilityCompanyMember us-gaap:IPOMember vcnx:ConvertiblePromissoryNotesMember 2018-08-09 2018-08-09 0001205922 us-gaap:LeaseholdImprovementsMember 2019-03-31 0001205922 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001205922 vcnx:ResearchEquipmentMember 2019-03-31 0001205922 vcnx:ResearchEquipmentMember 2018-12-31 0001205922 us-gaap:FurnitureAndFixturesMember 2019-03-31 0001205922 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001205922 us-gaap:ComputerEquipmentMember 2019-03-31 0001205922 us-gaap:ComputerEquipmentMember 2018-12-31 0001205922 us-gaap:USTreasurySecuritiesMember 2019-03-31 0001205922 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001205922 srt:MaximumMember 2019-01-01 2019-03-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-03-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-03-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2019-03-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-03-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-03-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2018-12-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2018-12-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001205922 us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0001205922 vcnx:VXThreeLicenseAgreementMember 2017-11-01 2017-11-30 0001205922 vcnx:ServicesAgreementMember 2017-01-01 2017-12-31 0001205922 vcnx:VXThreeLicenseAgreementMember 2019-01-01 2019-03-31 0001205922 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2019-01-01 2019-03-31 0001205922 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2018-01-01 2018-12-31 0001205922 vcnx:JanuaryTwoThousandSeventeenNotesMember 2018-03-01 2018-03-31 0001205922 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2018-01-01 2018-03-31 0001205922 vcnx:MerckSharpDohmeCorpMember 2018-01-01 2018-03-31 0001205922 vcnx:SurfaceOncologyIncMember 2017-11-01 2017-11-30 0001205922 vcnx:SurfaceOncologyIncMember srt:MinimumMember 2017-11-01 2017-11-30 0001205922 vcnx:SurfaceOncologyIncMember srt:MaximumMember 2017-11-01 2017-11-30 0001205922 vcnx:SurfaceOncologyIncMember 2017-11-30 0001205922 vcnx:SurfaceOncologyIncMember 2017-01-01 2017-12-31 0001205922 vcnx:SurfaceOncologyIncMember 2018-01-01 2018-03-31 0001205922 vcnx:SurfaceOncologyIncMember 2019-01-01 2019-03-31 0001205922 vcnx:JuneTwoThousandSixteenNoteMember 2016-06-01 2016-06-30 0001205922 vcnx:JuneTwoThousandSixteenNoteMember 2016-06-30 0001205922 2017-01-31 0001205922 2017-01-01 2017-01-31 0001205922 2017-04-01 2017-04-30 0001205922 2017-08-01 2017-08-31 0001205922 2017-10-01 2017-10-31 0001205922 2017-04-30 0001205922 2017-08-31 0001205922 2017-10-31 0001205922 vcnx:ConvertiblePromissoryNotesMember vcnx:JanuaryTwoThousandSeventeenNotesMember 2017-04-30 0001205922 vcnx:ConvertiblePromissoryNotesMember vcnx:JanuaryTwoThousandSeventeenNotesMember 2017-10-31 0001205922 vcnx:ConvertiblePromissoryNotesMember vcnx:JanuaryTwoThousandSeventeenNotesMember 2017-01-31 0001205922 vcnx:ConvertiblePromissoryNotesMember vcnx:JanuaryTwoThousandSeventeenNotesMember 2017-04-01 2017-04-30 0001205922 vcnx:ConvertiblePromissoryNotesMember vcnx:JanuaryTwoThousandSeventeenNotesMember 2017-11-01 2017-11-30 0001205922 vcnx:ConvertiblePromissoryNotesMember vcnx:JanuaryTwoThousandSeventeenNotesMember 2018-03-01 2018-03-31 0001205922 vcnx:ConvertiblePromissoryNotesMember vcnx:JanuaryTwoThousandSeventeenNotesMember 2018-01-01 2018-03-31 0001205922 2016-06-30 0001205922 vcnx:ConvertiblePromissoryNotesMember vcnx:JuneTwoThousandSixteenNoteMember 2018-07-01 2018-09-30 0001205922 us-gaap:ContractTerminationMember 2019-01-01 2019-03-31 0001205922 vcnx:SharesUnderlyingOutstandingStockOptionsMember 2019-03-31 0001205922 vcnx:SharesUnderlyingOutstandingStockOptionsMember 2018-12-31 0001205922 vcnx:SharesAvailableForFutureStockOptionGrantsMember 2019-03-31 0001205922 vcnx:SharesAvailableForFutureStockOptionGrantsMember 2018-12-31 0001205922 vcnx:ExchangeOfVaccinexProductsLPUnitsMember 2019-03-31 0001205922 vcnx:ExchangeOfVaccinexProductsLPUnitsMember 2018-12-31 0001205922 vcnx:ConversionOfVX3UnitsMember 2019-03-31 0001205922 vcnx:ConversionOfVX3UnitsMember 2018-12-31 0001205922 srt:MinimumMember vcnx:TwoThousandEighteenEmployeeEquityPlanMember 2019-01-01 2019-03-31 0001205922 srt:MinimumMember us-gaap:EmployeeStockOptionMember vcnx:TwoThousandElevenEmployeeEquityPlanMember 2019-01-01 2019-03-31 0001205922 srt:MinimumMember us-gaap:EmployeeStockOptionMember vcnx:TwoThousandEighteenEmployeeEquityPlanMember 2019-01-01 2019-03-31 0001205922 srt:MaximumMember us-gaap:EmployeeStockOptionMember vcnx:TwoThousandElevenEmployeeEquityPlanMember 2019-01-01 2019-03-31 0001205922 srt:MaximumMember us-gaap:EmployeeStockOptionMember vcnx:TwoThousandEighteenEmployeeEquityPlanMember 2019-01-01 2019-03-31 0001205922 vcnx:TwoThousandEighteenEmployeeEquityPlanMember 2019-03-31 0001205922 vcnx:TwoThousandEighteenEmployeeEquityPlanMember 2019-01-01 2019-03-31 0001205922 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001205922 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001205922 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001205922 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001205922 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0001205922 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001205922 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0001205922 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-03-31 0001205922 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001205922 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0001205922 vcnx:VaccinexProductsLPUnitsMember 2019-01-01 2019-03-31 0001205922 vcnx:VaccinexProductsLPUnitsMember 2018-01-01 2018-03-31 0001205922 vcnx:VX3DELPUnitsMember 2019-01-01 2019-03-31 0001205922 vcnx:VX3DELPUnitsMember 2018-01-01 2018-03-31 0001205922 country:US 2019-01-01 2019-03-31 0001205922 country:US 2018-01-01 2018-12-31 10-Q false 2019-03-31 2019 Q1 VCNX Vaccinex, Inc. 0001205922 --12-31 Non-accelerated Filer true true false 11478843 8942000 5618000 2348000 14106000 628000 639000 832000 1061000 12750000 21424000 544000 604000 13294000 22028000 2439000 2322000 4520000 4364000 6959000 6686000 1000 1000 208216000 208156000 11000 11000 -225834000 -216767000 -17628000 -8621000 23963000 23963000 6335000 15342000 13294000 22028000 0.0001 0.0001 100000000 100000000 11476601 11476601 11475749 11475749 852 852 94000 206000 175000 240000 7412000 4454000 1647000 1221000 9234000 5915000 -9140000 -5709000 308000 267000 -2180000 73000 -14000 -9067000 -7862000 0 0 -9067000 -7862000 0 0 -9067000 -7862000 -0.79 -7.13 11475749 1102571 53089959 111718000 5702450 7684000 1103396 54123000 163 836 -11000 -187249000 -125453000 11963000 -113490000 36000 36000 36000 8000000 8000000 -7862000 -7862000 53089959 111718000 5702450 7684000 1103396 54159000 163 836 -11000 -195111000 -133279000 19963000 -113316000 11476601 1000 208156000 852 -11000 -216767000 -8621000 23963000 60000 60000 60000 -9067000 -9067000 11476601 1000 208216000 852 -11000 -225834000 -17628000 23963000 60000 56000 235000 42000 60000 36000 -11000 -37000 -229000 65000 117000 348000 156000 309000 -131000 -8476000 -5165000 11800000 47000 11800000 -47000 44000 4000000 8000000 3956000 3324000 -1256000 4180000 2924000 13000 9000 573000 38000 <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">COMPANY AND NATURE OF BUSINESS </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vaccinex, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) was incorporated in Delaware in April 2001 and is headquartered in Rochester, New York. The Company is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Since its inception, the Company has devoted substantially all of its efforts toward product research, manufacturing and clinical development. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks common to other early-stage biotechnology companies including, but not limited to, the successful development and commercialization of its product candidates, rapid technological change and competition, dependence on key personnel and collaborative partners, uncertainty of protection of proprietary technology and patents, clinical trial uncertainty, fluctuation in operating results and financial performance, the need to obtain additional funding, potential product liability, compliance with governmental regulations, technological and medical risks, customer demand, management of growth and effectiveness of marketing by the Company. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Going Concern</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flow from operations of $8.5 million and $25.3&#160;million for the three months ended March 31, 2019 and year ended December&#160;31, 2018, respectively, and an accumulated deficit of $225.8&#160;million and $216.8&#160;million as of March 31, 2019 and December&#160;31, 2018, respectively. The Company&#8217;s ability to continue as a going concern is at issue due to its historical net losses and negative cash flows from operations, and its need for additional financing to fund future operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the Company has relied on equity and debt financing to fund its operations. In addition, the Company received $12.0&#160;million in capital contributions from noncontrolling interests during each of the years ended December&#160;31, 2018 and 2017. As the Company&#8217;s product candidates are still in the early stages of development, substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. Given our projected operating requirements and our existing cash and cash equivalents and marketable securities, we plan to complete an additional financing transaction prior to the commencement of the 2019 fourth quarter in order for us to continue operations. &#160;Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors, refinancing of existing debt obligations or obtaining additional debt financing. There can be no assurances that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial Public Offering</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company completed its initial public offering (the &#8220;IPO&#8221;) in which it issued and sold 3,333,334 shares of its common stock, $0.0001 par value, at a public offering price of $12.00 per share. The Company received net proceeds of $37.2 million after deducting underwriting discounts and commissions of $2.8 million, but before deducting offering expenses of $2.7 million. <font style="Background-color:#FFFFFF;">In addition, in connection with the IPO:</font></p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all shares of the Company&#8217;s then-outstanding convertible preferred stock were automatically converted and reclassified into 7,039,155 shares of its common stock, $0.0001 par value; </p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a 1-for-10 reverse stock split of the Company&#8217;s common stock was effected; and</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company repaid a $1.5 million convertible promissory note issued in June 2016 (the &#8220;June 2016 Note&#8221;), held by a related party, Vaccinex (Rochester), L.L.C. (&#8220;Vaccinex LLC&#8221;), which is majority owned and controlled by Dr. Maurice Zauderer, the Company&#8217;s President, Chief Executive Officer and a member of its board of directors.</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation and Consolidation </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. All intercompany transactions and balances have been eliminated. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and following the requirements of the Securities and Exchange Commission ("SEC"), for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company&#8217;s financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the entire year ending December 31, 2019. The year-end balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. Certain information and note disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted under the rules and regulations of the SEC.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and related notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 13, 2019.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, the valuation of derivative instruments, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Other Risks and Uncertainties </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Cash equivalents are deposited in interest-bearing money market accounts and short-term investments consist of highly liquid U.S. government treasury bills and notes. The Company deposits its cash with multiple financial institutions and cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company&#8217;s product candidates and adversely impact its results of operations. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have any other comprehensive income or loss for any of the periods presented and therefore comprehensive loss did not differ from net loss.<font style="font-weight:bold;font-style:italic;"> </font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements Not Yet Adopted </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-02,<font style="font-style:italic;">&#160;Leases</font>, which supersedes the Accounting Standards Codification (&#8220;ASC&#8221;) No.&#160;840, <font style="font-style:italic;">Leases</font>. ASU No.&#160;2016-02 requires lessees to recognize all leases, with exception of short-term leases, as lease liabilities on the balance sheet. Under ASU No.&#160;2016-02, a lease is defined as a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis, and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset during the lease term. ASU No.&#160;2016-02 also requires additional disclosure about the amount, timing and uncertainty of cash flow from leases. The new standard is effective for the Company at the earlier of losing the emerging growth company status or the Company&#8217;s fiscal year beginning January&#160;1, 2020. Early adoption is permitted. This new standard will require the present value of these leases to be recorded in the condensed consolidated balance sheets as a right-of-use asset and lease liability. The Company will adopt the new standard effective January&#160;1, 2020 and is continuing to evaluate the impact of this guidance on its condensed consolidated financial statements and related disclosures.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No.&#160;2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers</font>, which supersedes the revenue recognition requirements in ASC No.&#160;605, <font style="font-style:italic;">Revenue Recognition</font>. ASU No.&#160;2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU No.&#160;2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenues and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, the FASB issued ASU No.&#160;2015-14 to defer the effective date by one year with early adoption permitted as of the original effective date. In addition, the FASB issued ASU Nos.&#160;2016-08, 2016-10 and 2016-12 in March 2016, April 2016 and May 2016, respectively, to help provide interpretive clarification on the new guidance in ASC No.&#160;606. ASU Nos.&#160;2016-08, 2016-10 and 2016-12 are all effective beginning the same period as ASU No.&#160;2014-09. The Company adopted the new revenue standards using the modified retrospective method as of January&#160;1, 2019; however, it is not required to reflect the effects of adoption in its consolidated financial statements until it files its annual report for the fiscal year ending December 31, 2019. The Company is in the process of evaluating the effect that the new revenue standards will have on its consolidated financial statements and related disclosures. </p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">BALANCE SHEET COMPONENTS </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,145</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,145</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,219</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,219</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,928</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,928</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,384</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,324</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense related to property and equipment was<font style="font-size:12pt;">&#160;</font>$60,000 and $56,000 for the three months ended March 31, 2019 and 2018, respectively. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Expenses </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial cost</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,084</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,796</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related benefits</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">247</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued consulting and legal</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">296</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,520</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,364</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">MARKETABLE SECURITIES</p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2019, the fair value of available-for-sale marketable securities was as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.02%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.02%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div></div> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the Company&#8217;s available-for-sale marketable securities at March 31, 2019 are maturing in one year or less.</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FAIR VALUE OF FINANCIAL MEASUREMENTS </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value<font style="font-size:12pt;"> </font>hierarchy based on the following three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities. </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assets&#8217; or liabilities&#8217; fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the fair value of the Company&#8217;s financial assets by level within the fair value hierarchy (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,233</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,233</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U. S. Treasury securities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Financial Assets</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,581</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,233</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,881</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,881</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U. S. Treasury securities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr style="height:15.65pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Financial Assets</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,987</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,881</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not transfer any assets measured at fair value on a recurring basis to or from Level&#160;1 and Level&#160;2 during either of the three months ended March 31, 2019 and 2018.</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">LICENSE AND SERVICES AGREEMENT </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2017, the Company entered into a license agreement (the &#8220;VX3 License Agreement&#8221;) with VX3 (DE) LLP (&#8220;VX3&#8221;), which was formed by a group of Canadian investors including the Company&#8217;s majority stockholder, FCMI Parent Co. (&#8220;FCMI Parent&#8221;). VX3 was created for the purpose of funding the Company&#8217;s research and development activities for VX15, our most advanced product candidate. In June 2018, the U.S. Adopted Name Council approved the use of pepinemab as the adopted name for VX15. Under the VX3 License Agreement, the Company granted VX3 the license to use, make, have made, sell, offer and import pepinemab for the treatment of Huntington&#8217;s disease in the U.S. and Canada and, in return, VX3 agreed to fund research and development activities with up to an aggregate of $32.0 million in milestone payments to the Company and to share any pepinemab profits and sublicensing revenue under the agreement in an amount based on a calculation set forth in the agreement. The Company also entered into a services agreement with VX3 (the &#8220;Services Agreement&#8221;), pursuant to which the Company will carry out development activities for pepinemab for the treatment of Huntington&#8217;s disease in the U.S. and Canada in exchange for services payments from VX3, including a payment of $11.9&#160;million in 2017. The VX3 License Agreement expires upon the last to expire licensed patent and may be terminated by either party upon uncured material breach, the occurrence of certain transactions or financings including the consummation of an initial public offering by the Company, uncured failure of VX3 to make any payment due under the Services Agreement, or upon written notice after November&#160;6, 2020. The Services Agreement may be terminated by either party upon an uncured material breach and is automatically terminated upon termination of the VX3 License Agreement. The VX3 License Agreement provides that upon termination, the Company will issue to VX3 or its designees the number of shares of the Company&#8217;s common stock equal to the lesser of (1)&#160;the aggregate of all payments made to VX3 by the Canadian investors divided by $18.20 and (2)&#160;the then fair market value of VX3 divided by the then fair market value of one share of the Company&#8217;s common stock. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a variable interest in VX3 through FCMI Parent, which is majority owned and controlled by the Company&#8217;s chairman, and it controlled 90% of VX3&#8217;s voting interest at each of March 31, 2019 and December 31, 2018. VX3 does not have any business operations or generate any income or expenses and is primarily a funding mechanism specifically for the benefit of the Company, as its only activities consist of the receipt of funding and the contribution of such funding to the Company. Therefore, the Company determined that it is the primary beneficiary of VX3 and that the operating results of VX3 should be incorporated into the Company&#8217;s condensed consolidated financial statements accordingly. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February, May and June 2018, the Services Agreement was amended to allow VX3 to provide additional funding for future research and development activities to take place in the year ending December 31, 2018 and to repay an outstanding convertible note in the amount of $4.0 million (Note 8). No other terms of the Services Agreement were amended; therefore, the above assessment resulting in the Company being the primary beneficiary of the VX3 entity remained unchanged as of March 31, 2019. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended March 31, 2018, the Company recorded the gross proceeds of $8.0 million, received from VX3 as capital contributions from noncontrolling interests on the condensed consolidated financial statements. </p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">COLLABORATION AGREEMENTS </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Merck Sharp&#160;&amp; Dohme Corp. </p> <p style="margin-bottom:6pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2017, the Company entered into a research agreement with Merck Sharp&#160;&amp; Dohme Corp. (&#8220;Merck&#8221;) to test vaccinia strain Modified Vaccinia Ankara. Under the research agreement, the Company designed genetic sequence for all constructs listed in the agreement and conducted research in accordance with the research protocol and a mutually agreed scope of work outlined in the agreement. Merck supplied the Company sufficient samples of the antibodies to carry out the research and has sole ownership of all right, title, interest and copy rights of the research results. Under the research agreement, the Company recognized service revenue of $69,000 for the three months ended March 31, 2018. The research agreement expired in June 2018. In the fourth quarter of 2018, the Company entered into a second research agreement with Merck to test these antigen particles in an antibody discovery campaign.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Surface Oncology, Inc. </p> <p style="margin-bottom:6pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2017, the Company entered into a research collaboration and license option agreement with Surface Oncology, Inc. (&#8220;Surface&#8221;) to identify and select antibodies against two target antigens, using the Company&#8217;s proprietary technology as described in the agreement. The term for each research program is nine to twelve months (not exceeding twelve months unless extended by written agreement) including time necessary for any functional assessment conducted by Surface following the commencement of the research program. Surface will provide the Company material to carry out the research activities. During the research program term, the Company also grants Surface non-exclusive, worldwide, limited-purpose license for each target to use the Company&#8217;s research program materials for conducting the research work pursuant to the agreement. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement, Surface has been granted exclusive options, exercisable by providing a written notice to the Company, to obtain (i)&#160;an exclusive product license to make, use, sell and import products incorporating the antibody targeting the first antigen and (ii)&#160;an exclusive research tool license to use the antibody targeting the second antigen to perform research. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement, Surface will pay an upfront technology access fee of $250,000 and milestone payments upon completion of each of four designated milestones for the first target antigen specified in the agreement. For the second target antigen, Surface will make payments to the Company based on time incurred by the Company in the conduct of the work plan described in the agreement. Surface will reimburse the Company for expenses incurred (i)&#160;in the conduct of the work plan as detailed in the research funding budget and (ii)&#160;for patent filings and prosecution of the Company&#8217;s program intellectual property as described in the agreement. The exercise of each option would also entail a license fee and annual maintenance fees, and in the case of the product license, royalties and additional milestone payments. During the year ended December&#160;31, 2017, the Company received the upfront technology access fee of $250,000, of which $63,000 was recognized as revenue from the amortization of this upfront fee for the three months ended March 31, 2018. The Company also received $93,877 and $69,172 service fee payments for work conducted under the agreement for the three months ended March 31, 2019 and 2018, respectively. This agreement will expire upon the expiration of both research programs and all evaluation and testing periods. </p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CONVERTIBLE PROMISSORY NOTES <font style="font-size:12pt;font-weight:normal;">&#160;</font></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2019, the Company did not have any convertible promissory notes outstanding. See &#8220;Repayment of Convertible Promissory Notes&#8221; below.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">June 2016 Note </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Company issued a $1.5&#160;million convertible promissory note to a related party.<font style="font-size:12pt;"> </font>The June 2016 Note accrued interest at a compounded annual rate of 8% and had a maturity date three years from issuance, if not converted before then. Upon the occurrence of a default event, such as payment or performance defaults, bankruptcy, change in control (if elected to be treated as such by the lenders), or other violation, the interest rate would increase to a compounded annual rate of 12% until such time the default is cured. Upon maturity, the holder of these convertible promissory notes was to be repaid the outstanding principal plus all accrued interest. The Company also had the ability to prepay the convertible promissory notes, plus accrued interest, without penalty. The debt issuance costs for these convertible promissory notes were not material. The June 2016 Note was paid in full on August 17, 2018. See &#8220;Repayment of Convertible Promissory Notes&#8221; below.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">January 2017 Notes </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, the Company entered into a convertible promissory note agreement whereby it agreed to issue, in the aggregate, $10.0 million of convertible promissory notes to a related party (the &#8220;January 2017 Notes&#8221;). The $4.0&#160;million of the January 2017 Notes issued in January 2017 did not accrue interest, but the other $6.0&#160;million of the January 2017 Notes issued in April, August and October 2017 accrued interest at an annual rate of 2%. The January 2017 Notes had a maturity date three years from issuance. Upon maturity, the holder of these convertible promissory notes was to be repaid the outstanding principal plus all accrued interest. The Company was also authorized to prepay the January 2017 Notes, plus accrued interest, without penalty. The debt issuance costs for these convertible promissory notes were not material. Of the January 2017 Notes, $6.0 million were paid in 2017 and the balance was paid in full on March 8, 2018. See &#8220;Repayment of Convertible Promissory Notes&#8221; below. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Derivative Liabilities </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From the proceeds of the convertible promissory notes, the portion equal to the fair value of the embedded derivative liabilities and the option derivative at the time of each respective issuance was recognized as a debt discount to be amortized to interest expense over the term of the related convertible promissory notes. The Company recognized interest expense of $235,000 for the amortization of the debt discounts during the three months ended March 31, 2018.<font style="font-weight:bold;font-style:italic;"> </font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Repayment of Convertible Promissory Notes </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the January 2017 Notes, $2.0 million issued in April 2017 was repaid along with accrued interest in May 2017, $4.0 million issued in August and October 2017 was repaid along with accrued interest in November 2017 and $4.0 million issued in January 2017 was repaid in March 2018. The option arrangement associated with the January 2017 Notes was also waived upon the repayment of the January 2017 Notes. As a result of this repayment, the related $0.3 million derivative liabilities associated with the conversion feature and the option arrangement were written off and the $2.2 million unamortized debt discount was recognized as a loss on extinguishment of related party convertible promissory note in the condensed consolidated statement of operations for the three months ended March 31, 2018. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The June 2016 Note was repaid along with accrued interest in August 2018. As a result of this repayment, the related $31,000 derivative liability associated with the conversion feature and the option arrangement were written off and the $199,000 unamortized debt discount was recognized as a loss on extinguishment of related party convertible promissory note in the condensed consolidated statements of operations in the three months ended September 30, 2018.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">COMMITMENTS AND CONTINGENCIES </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sublicense Termination Payments </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2006, the Company licensed certain technology to EUSA Pharma SAS (&#8220;EUSA&#8221;) and in 2008, this technology was sublicensed by EUSA to Glaxo Group Limited (&#8220;GSK&#8221;) for development. GSK terminated its sub-license with EUSA in March 2010 and ownership of the technology reverted back to the Company. The Company may be required to pay EUSA up to $25.5&#160;million plus ongoing royalty payments of 1% of net sales upon the occurrence of certain events involving the previously licensed technology, including a Phase&#160;3 clinical trial, FDA acceptance and approval and product sales. The Company is not planning any further commercialization efforts related to the previously licensed technology, and therefore does not anticipate any of the above described amounts will be paid. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Lease </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases its facilities from 1895 Management, Ltd., a New York corporation controlled by an entity affiliated with a director of the Company, under non-cancellable operating leases. Following entry into a lease extension agreement in July 2018, the lease agreement requires monthly rental payments of $14,000 through October&#160;31, 2020. The Company is responsible for all maintenance, utilities, insurance and taxes related to the facility. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2019, the future minimum payments for the operating lease are $266,000. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense incurred under the operating lease was $42,000 for each of the three months ended March 31, 2019 and 2018. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingencies </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. As of March 31, 2019 and December&#160;31, 2018, the Company was not involved in any material legal proceedings. </p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">COMMON STOCK RESERVED FOR ISSUANCE </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock has been reserved for the following potential future issuances: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares underlying outstanding stock options</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">538,702</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405,683</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future stock option grants</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289,981</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">423,000</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange of Vaccinex Products, LP units</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202,566</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202,566</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of VX3 units</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,350,046</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,350,046</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">STOCK-BASED COMPENSATION </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2011 Employee Equity Plan</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2011 Employee Equity Plan (the &#8220;2011 Plan&#8221;) was terminated in connection with the adoption of the Company&#8217;s 2018 Omnibus Incentive Plan (the &#8220;2018 Plan&#8221;) in August 2018, and the Company will not grant any additional stock options under the 2011 Plan. However, the 2011 Plan will continue to govern the terms and conditions of the outstanding stock options previously granted thereunder. <font style="color:#000000;">Stock options granted under the 2011 Plan expire in five or ten years from the date of grant.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2018 Omnibus Incentive Plan</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2018 Plan, which allows for the granting of stock, stock option, and stock appreciation rights awards to employees, advisors and consultants. Stock options granted under the 2018 Plan may be either incentive stock options or non-statutory stock options. Incentive stock options may be granted to employees, advisors and consultants at exercise prices of no less than the fair value of the common stock on the grant date. If at the time of grant, the optionee owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price must be at least 110% of the fair value of the common stock on the grant date as determined by the board of directors. Non-statutory stock options may be granted to employees, advisors and consultants at exercise prices of less than the fair market value of a share of common stock on the date the non-statutory stock option is granted but shall under no circumstances be less than adequate consideration as determined by the board of directors for such a share. Vesting period of stock option grants is determined by the board of directors, ranging from zero to eight years. Stock options granted under the 2018 Plan expire in five or ten years from the date of grant.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reserved 425,000 shares of common stock for issuance, subject to certain adjustments, pursuant to awards under the 2018 Plan. Any shares of common stock related to awards outstanding under the 2011 Plan as of the effective date of the 2018 Plan, which thereafter terminate by expiration, forfeiture, cancellation or otherwise without the issuance of such shares, will be added to, and included in, the number of shares of common stock available for grant under the 2018 Plan. In addition, effective January 1, 2020 and continuing until the expiration of the 2018 Plan, the number of shares of common stock available for issuance under the 2018 Plan will automatically increase annually by 2% of the total number of issued and outstanding shares of our common stock as of December 31<sup style="font-size:85%; vertical-align:top">st</sup> of the immediately preceding year or such lesser number as our board of directors may decide, which may be zero.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s stock option activity and related information is as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Options</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (Years)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value (000's)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405,683</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.69</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,972</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.97</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,953</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.60</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2019</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">538,702</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.23</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of March 31, 2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373,777</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.43</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of stock options granted to employees for the three months ended March 31, 2019 and 2018 was $2.65 and $15.63 per share, respectively. The aggregate grant date fair value of stock options that vested during the three months ended March 31, 2019 and 2018 was $53,716 and $79,000, respectively. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intrinsic value of stock options vested and expected to vest and exercisable is calculated based on the difference between the exercise price and the fair value of the Company&#8217;s common stock as of March 31, 2019 and December&#160;31, 2018. The intrinsic value of exercised stock options is the difference between the fair value of the underlying common stock and the exercise price as of the exercise date. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2019 and December&#160;31, 2018, total unrecognized compensation cost related to stock options granted to employees was $710,285 and $435,639, respectively, which is expected to be recognized over a weighted-average period of 3.3 and 2.8 years, respectively. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant date fair value of employee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions: <font style="font-size:12pt;">&#160;</font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense recognized in the condensed consolidated statements of operations is as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">INCOME TAXES </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No provision for income taxes was recorded in either of the three months ended March 31, 2019 and 2018. The Company remains in a cumulative loss position with a full valuation allowance recorded against its net deferred income tax assets as of March 31, 2019. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of March 31, 2019 and December&#160;31, 2018, the Company had no unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock (if converted)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,039,155</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">432,051</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424,843</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingently issuable common stock upon exchange of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Vaccinex Products, LP units</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202,566</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202,566</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingently issuable common stock upon exchange of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; VX3 units</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,880</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SEGMENT AND GEOGRAPHIC INFORMATION </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s chief operating decision maker, its Chief Executive Officer, reviews its operating results on an aggregate basis for purposes of allocating resources and evaluating financial performance. The Company has one business activity, the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, and there are no segment managers who are held accountable for operations or operating results. Accordingly, the Company operates in one segment. As of March 31, 2019 and December&#160;31, 2018, all long-lived assets are located in the United States. </p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">EMPLOYEE BENEFIT PLAN </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sponsors a 401(k) plan that stipulates that eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100% of eligible compensation on a pre-tax basis. Through March 31, 2019, the Company has not elected to match employee contributions as permitted by the plan. The Company pays the administrative costs for the plan. </p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">RELATED PARTY TRANSACTIONS </p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 9, the Company leases its facility from 1895 Management, Ltd., a New York corporation controlled by an entity affiliated with the Company&#8217;s chairman and major stockholder of the Company. Rent expense incurred under this operating lease was $42,000 for each of the three months ended March 31, 2019 and 2018. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 7, in November 2017, we entered into a research collaboration and license option agreement with Surface to identify and select antibodies against two target antigens, using our proprietary technology as described in the agreement. J. Jeffrey Goater, a member of our board of directors, served as the Chief Business Officer of Surface at that time, and currently serves as the Chief Executive Officer and a director of Surface.<font style="font-size:12pt;"> </font>The Company received $93,877 and $69,172 service fee payments for work conducted under the agreement for the three months ended March 31, 2019 and 2018, respectively.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation and Consolidation </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. All intercompany transactions and balances have been eliminated. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and following the requirements of the Securities and Exchange Commission ("SEC"), for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company&#8217;s financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the entire year ending December 31, 2019. The year-end balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. Certain information and note disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted under the rules and regulations of the SEC.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and related notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 13, 2019.</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, the valuation of derivative instruments, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Other Risks and Uncertainties </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Cash equivalents are deposited in interest-bearing money market accounts and short-term investments consist of highly liquid U.S. government treasury bills and notes. The Company deposits its cash with multiple financial institutions and cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company&#8217;s product candidates and adversely impact its results of operations. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not have any other comprehensive income or loss for any of the periods presented and therefore comprehensive loss did not differ from net loss.<font style="font-weight:bold;font-style:italic;"> </font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements Not Yet Adopted </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-02,<font style="font-style:italic;">&#160;Leases</font>, which supersedes the Accounting Standards Codification (&#8220;ASC&#8221;) No.&#160;840, <font style="font-style:italic;">Leases</font>. ASU No.&#160;2016-02 requires lessees to recognize all leases, with exception of short-term leases, as lease liabilities on the balance sheet. Under ASU No.&#160;2016-02, a lease is defined as a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis, and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset during the lease term. ASU No.&#160;2016-02 also requires additional disclosure about the amount, timing and uncertainty of cash flow from leases. The new standard is effective for the Company at the earlier of losing the emerging growth company status or the Company&#8217;s fiscal year beginning January&#160;1, 2020. Early adoption is permitted. This new standard will require the present value of these leases to be recorded in the condensed consolidated balance sheets as a right-of-use asset and lease liability. The Company will adopt the new standard effective January&#160;1, 2020 and is continuing to evaluate the impact of this guidance on its condensed consolidated financial statements and related disclosures.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No.&#160;2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers</font>, which supersedes the revenue recognition requirements in ASC No.&#160;605, <font style="font-style:italic;">Revenue Recognition</font>. ASU No.&#160;2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU No.&#160;2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenues and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, the FASB issued ASU No.&#160;2015-14 to defer the effective date by one year with early adoption permitted as of the original effective date. In addition, the FASB issued ASU Nos.&#160;2016-08, 2016-10 and 2016-12 in March 2016, April 2016 and May 2016, respectively, to help provide interpretive clarification on the new guidance in ASC No.&#160;606. ASU Nos.&#160;2016-08, 2016-10 and 2016-12 are all effective beginning the same period as ASU No.&#160;2014-09. The Company adopted the new revenue standards using the modified retrospective method as of January&#160;1, 2019; however, it is not required to reflect the effects of adoption in its consolidated financial statements until it files its annual report for the fiscal year ending December 31, 2019. The Company is in the process of evaluating the effect that the new revenue standards will have on its consolidated financial statements and related disclosures. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,145</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,145</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,219</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,219</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,928</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,928</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,384</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,324</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">604</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial cost</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,084</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,796</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and related benefits</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">247</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued consulting and legal</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">296</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,520</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,364</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2019, the fair value of available-for-sale marketable securities was as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.02%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.02%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the fair value of the Company&#8217;s financial assets by level within the fair value hierarchy (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,233</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,233</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U. S. Treasury securities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Financial Assets</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,581</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,233</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,348</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Assets:</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,881</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,881</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U. S. Treasury securities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr style="height:15.65pt;"> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Financial Assets</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,987</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,881</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,106</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock has been reserved for the following potential future issuances: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares underlying outstanding stock options</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">538,702</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405,683</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future stock option grants</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">289,981</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">423,000</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange of Vaccinex Products, LP units</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202,566</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202,566</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of VX3 units</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,350,046</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,350,046</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s stock option activity and related information is as follows: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Options</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (Years)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value (000's)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405,683</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.69</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.5</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,972</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.97</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,953</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.60</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2019</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">538,702</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.23</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable as of March 31, 2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373,777</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.43</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td> </tr> </table></div> The grant date fair value of employee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions: <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense recognized in the condensed consolidated statements of operations is as follows (in thousands): </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock (if converted)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,039,155</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">432,051</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424,843</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingently issuable common stock upon exchange of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Vaccinex Products, LP units</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202,566</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202,566</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingently issuable common stock upon exchange of</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; VX3 units</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318,797</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,880</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> -25300000 12000000 12000000 3333334 0.0001 12.00 37200000 2800000 2700000 7039155 1-for-10 10 1500000 3145000 3145000 3219000 3219000 350000 350000 214000 214000 6928000 6928000 6384000 6324000 4084000 3796000 247000 236000 117000 296000 72000 36000 2348000 2348000 0 0 0 0 2348000 2348000 14106000 14106000 0 0 0 0 14106000 14106000 P1Y 8233000 8233000 2348000 2348000 10581000 8233000 2348000 4881000 4881000 14106000 14106000 18987000 4881000 14106000 0 0 0 0 32000000 11900000 the Company will issue to VX3 or its designees the number of shares of the Company’s common stock equal to the lesser of (1) the aggregate of all payments made to VX3 by the Canadian investors divided by $18.20 and (2) the then fair market value of VX3 divided by the then fair market value of one share of the Company’s common stock. 18.20 0.90 0.90 4000000 8000000 69000 2 P9M P12M 250000 4 250000 63000 93877 69172 0.08 P3Y 0.12 1500000 10000000 4000000 0.00 0.02 0.02 0.02 P3Y 6000000 6000000 6000000 6000000 235000000 2000000 4000000 4000000 2000000 4000000 4000000 300000 -2200000 31000 -199000 25500 0.01 14000 266000 42000 42000 538702 405683 289981 423000 1202566 1202566 1318797 1318797 3350046 3350046 0.10 1.10 P5Y P5Y P10Y P10Y 425000 0.02 405683 135972 2953 538702 373777 9.69 3.97 12.60 8.23 9.43 P6Y6M0D P7Y2M12D P6Y1M6D 175000 2.65 15.63 53716 79000 710285 435639 P3Y3M19D P2Y9M18D P6Y P6Y 0.75 0.75 0.025 0.026 15000 21000 45000 15000 60000 36000 0 0 7039155 432051 424843 1202566 1202566 1318797 800880 1 0 1 1 1.00 1.00 EX-101.SCH 6 vcnx-20190331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document And Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Company and Nature of Business link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Balance Sheet Components link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Marketable Securities link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Fair Value of Financial Measurements link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - License and Services Agreement link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Collaboration Agreements link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Convertible Promissory Notes link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Commitment and Contingencies link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Common Stock Reserved For Issuance link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Net Loss Per Share Attributable to Common Stockholders link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Segment and Geographical Information link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Employee Benefit Plan link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Balance Sheet Components (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Marketable Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Fair Value of Financial Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Common Stock Reserved For Issuance (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Company and Nature of Business - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Balance Sheet Components - Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Balance Sheet Components - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Marketable Securities - Summary of the Fair Value of Available-for-sale Marketable Securities (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Marketable Securities - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Fair Value of Financial Measurements - Summary of Fair Value of Financial Assets by Level within Fair Value Hierarchy (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Fair Value of Financial Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - License and Services Agreement - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Collaboration Agreements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Convertible Promissory Notes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Common Stock Reserved For Issuance - Common Stock Reserved For Potential Future Issuances (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Stock-Based Compensation - Grant Date Fair Value of Employee Stock Options Estimated Using Black-Scholes Option-Pricing Model with Weighted-Average Assumptions (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Segment and Geographic Information - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Employee Benefit Plan - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Related Party Transactions - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 vcnx-20190331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 vcnx-20190331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 vcnx-20190331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and Entity Information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Statement Of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Marketable securities Marketable Securities Current Accounts receivable, net Accounts Receivable Net Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net TOTAL ASSETS Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current TOTAL LIABILITIES Liabilities Commitments and contingencies (Note 9) Commitments And Contingencies Stockholders’ equity: Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract] Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 11,476,601 shares issued as of March 31, 2019 and December 31, 2018; 11,475,749 shares outstanding as of March 31, 2019 and December 31, 2018 Common Stock Value Additional paid-in capital Additional Paid In Capital Treasury stock, at cost; 852 shares of common stock as of March 31, 2019 and December 31, 2018 Treasury Stock Value Accumulated deficit Retained Earnings Accumulated Deficit Total Vaccinex, Inc. stockholders’ deficit Stockholders Equity Noncontrolling interests Minority Interest TOTAL STOCKHOLDERS’ EQUITY Stockholders Equity Including Portion Attributable To Noncontrolling Interest TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Treasury stock, common shares Treasury Stock Common Shares Net income (loss) available to common stockholders basic and diluted. Income Statement [Abstract] Revenue Revenue From Contract With Customer Excluding Assessed Tax Costs and expenses: Costs And Expenses [Abstract] Cost of revenue Cost Of Revenue Research and development Research And Development Expense General and administrative General And Administrative Expense Total costs and expenses Costs And Expenses Loss from operations Operating Income Loss Change in fair value of derivative liabilities Derivative Gain Loss On Derivative Net Interest expense Interest Expense Loss on extinguishment of related party convertible promissory note Gains Losses On Extinguishment Of Debt Other income (expense), net Other Nonoperating Income Expense Loss before provision for income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Provision for income taxes Income Tax Expense Benefit Net loss Profit Loss Net loss attributable to noncontrolling interests Net Income Loss Attributable To Noncontrolling Interest Net loss attributable to Vaccinex, Inc. common stockholders, basic and diluted Net Income Loss Available To Common Stockholders Basic And Diluted Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted Earnings Per Share Basic And Diluted Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Treasury Stock Treasury Stock [Member] Accumulated Deficit Retained Earnings [Member] Total Vaccinex,Inc. Stockholders' Deficit Parent [Member] Noncontrolling Interests Noncontrolling Interest [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Redeemable Convertible Preferred Stock Redeemable Convertible Preferred Stock [Member] Convertible Preferred Stock Convertible Preferred Stock [Member] Statement [Line Items] Statement [Line Items] Balance Balance, Shares Temporary Equity Shares Issued Balance Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests Balance, Shares Shares Outstanding Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Capital contribution Noncontrolling Interest Increase From Sale Of Parent Equity Interest Net loss Balance Balance, Shares Balance Balance, Shares Deferred offering costs in accounts payable and accrued expenses. Deferred offering costs reclassed from prepaid expenses and other current assets. Statement Of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Amortization of debt discount Amortization Of Debt Discount Premium Net amortization of premiums and discounts on marketable securities Accretion Amortization Of Discounts And Premiums Investments Stock-based compensation Share Based Compensation Change in fair value of derivative liabilities Loss on extinguishment of related party convertible promissory note Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued expenses Increase Decrease In Accrued Liabilities Deferred revenue Increase Decrease In Contract With Customer Liability Net cash used in operating activities Net Cash Provided By Used In Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided By Used In Investing Activities [Abstract] Sales and maturities of marketable securities Proceeds From Sale And Maturity Of Marketable Securities Purchase of property and equipment Payments To Acquire Property Plant And Equipment Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided By Used In Financing Activities [Abstract] Payments of initial public offering costs Payments Of Stock Issuance Costs Repayment of convertible promissory note, related party Repayments Of Related Party Debt Proceeds from capital contribution Proceeds From Contributed Capital Net cash provided by financing activities Net Cash Provided By Used In Financing Activities NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash And Cash Equivalents Period Increase Decrease CASH AND CASH EQUIVALENTS–Beginning of period CASH AND CASH EQUIVALENTS–End of period SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES: Noncash Investing And Financing Items [Abstract] Cash paid for interest Interest Paid Net Purchase of property and equipment in accounts payable Capital Expenditures Incurred But Not Yet Paid Deferred offering costs in accounts payable and accrued expenses Deferred Offering Costs In Accounts Payable And Accrued Expenses Deferred offering costs reclassed from prepaid expenses and other current assets Deferred Offering Costs Reclassed From Prepaid Expenses And Other Current Assets Organization Consolidation And Presentation Of Financial Statements [Abstract] Company and Nature of Business Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Balance Sheet Related Disclosures [Abstract] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Investments Debt And Equity Securities [Abstract] Marketable Securities Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value of Financial Measurements Fair Value Disclosures [Text Block] License and services agreement. Research And Development [Abstract] License and Services Agreement License And Services Agreement [Text Block] Collaboration agreements. Collaboration Agreements [Abstract] Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Convertible promissory note. Debt Disclosure [Abstract] Convertible Promissory Notes Convertible Promissory Note [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Common stock reserved for issuance. Equity [Abstract] Common Stock Reserved For Issuance Common Stock Reserved For Issuance [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss Per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Segment Reporting [Abstract] Segment and Geographic Information Segment Reporting Disclosure [Text Block] Compensation And Retirement Disclosure [Abstract] Employee Benefit Plan Compensation And Employee Benefit Plans [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Basis of presentation and consolidation. Basis of Presentation and Consolidation Basis Of Presentation And Consolidation Policy [Text Block] Use of Estimates Use Of Estimates Concentration of Credit Risk, Other Risks and Uncertainties Concentration Risk Credit Risk Comprehensive Loss Comprehensive Income Policy Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Property and Equipment Property Plant And Equipment [Text Block] Accrued Expenses Schedule Of Accrued Liabilities Table [Text Block] Summary of the Fair Value of Available-for-sale Marketable Securities Marketable Securities [Text Block] Summary of Fair Value of Financial Assets by Level within Fair Value Hierarchy Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block] Common stock reserved for future issuance. Common Stock Reserved for Potential Future Issuances Common Stock Reserved For Future Issuance Table [Text Block] Summary of Stock Option Activity and Related Information Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Grant Date Fair Value of Employee Stock Options Estimated Using Black-Scholes Option-Pricing Model with Weighted-Average Assumptions Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Total Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Organization consolidation and presentation of financial statements. Organization consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] IPO I P O [Member] Related Party Transaction Related Party Transaction [Axis] Related Party Transaction Related Party Transaction [Domain] Vaccinex (Rochester) Limited Liability Company. Vaccinex LLC Vaccinex Rochester Limited Liability Company [Member] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Convertible promissory note. Convertible Promissory Notes Convertible Promissory Notes [Member] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Cash flow from operations Accumulated deficit Number of shares issued and sold Stock Issued During Period Shares New Issues Public offering price, per share Shares Issued Price Per Share Net proceeds from initial public offering Proceeds From Issuance Initial Public Offering Underwriting discounts and commissions Payments For Underwriting Expense Offering expenses Convertible preferred stock converted and reclassified into common stock Convertible Preferred Stock Shares Issued Upon Conversion Reverse stock split of common stock description Stockholders Equity Reverse Stock Split Reverse stock split of common stock Stockholders Equity Note Stock Split Conversion Ratio1 Repayment of convertible promissory note, related party Property Plant And Equipment [Abstract] Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Leasehold Improvements Leasehold Improvements [Member] Research equipment. Research Equipment Research Equipment [Member] Furniture and Fixtures Furniture And Fixtures [Member] Computer Equipment Computer Equipment [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment, gross Property Plant And Equipment Gross Less: accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Depreciation and amortization expense Accrued clinical trial cost current. Payables And Accruals [Abstract] Accrued clinical trial cost Accrued Clinical Trial Cost Current Accrued payroll and related benefits Employee Related Liabilities Current Accrued consulting and legal Accrued Professional Fees Current Accrued other Other Accrued Liabilities Current Accrued expenses Marketable Securities [Table] Marketable Securities [Table] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] U.S. Treasury Securities U S Treasury Securities [Member] Marketable Securities [Line Items] Marketable Securities [Line Items] Securities Available for Sale, Amortized Cost Available For Sale Debt Securities Amortized Cost Basis Securities Available for Sale, Gross Unrealized Gains Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Securities Available for Sale, Gross Unrealized Losses Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Securities Available for Sale, Fair Value Available For Sale Securities Debt Securities Available for sale marketable securities maturity period. Range Range [Axis] Range Range [Member] Maximum Maximum [Member] Minimum Minimum [Member] Available for sale marketable securities maturity period Available For Sale Marketable Securities Maturity Period Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Fair Value, Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value Measurements Recurring Fair Value Measurements Recurring [Member] Level 1 Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Level 3 Fair Value Inputs Level3 [Member] Money Market Funds Money Market Funds [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Financial Assets: Assets Fair Value Disclosure [Abstract] Cash equivalents, Fair value disclosure Cash And Cash Equivalents Fair Value Disclosure Securities Available for Sale, Fair Value Total Financial Assets Assets Fair Value Disclosure Financial assets, level 1 to level 2 transfers, amount Fair Value Assets Level1 To Level2 Transfers Amount Financial assets, level 2 to level 1 transfers, amount Fair Value Assets Level2 To Level1 Transfers Amount Research and development milestone payments. Base amount to determine issuance of common stock upon termination. Services payments received for development activities. Terms of license agreement upon termination. License and services agreement. License and services agreement. License And Services Agreement [Table] License And Services Agreement [Table] Variable Interest Entities Variable Interest Entities By Classification Of Entity [Axis] Variable Interest Entity, Classification Classification Of Variable Interest Entity [Domain] V X Three license agreement. VX3 License Agreement V X Three License Agreement [Member] Services agreement. Services Agreement Services Agreement [Member] VX3 Variable Interest Entity Primary Beneficiary [Member] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] January two thousand seventeen notes. January 2017 Notes January Two Thousand Seventeen Notes [Member] License And Services Agreement [Line Items] License And Services Agreement [Line Items] Research and development, milestone payments to company Research And Development Milestone Payments Services payments received Services Payments Received For Development Activities Terms of license agreement upon termination Terms Of License Agreement Upon Termination Base amount to determine issuance of common stock upon termination Base Amount To Determine Issuance Of Common Stock Upon Termination Percentage of voting interest Variable Interest Entity Ownership Percentage Repay an outstanding convertible note Repayments Of Convertible Debt Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp. Merck Sharp Dohme Corp [Member] Surface Oncology, Inc. Surface Oncology, Inc. Surface Oncology Inc [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Service revenue recognized Contract With Customer Liability Revenue Recognized Number of target antigens against which antibodies are to be identified and selected. Term of research program. Number of target antigens against which antibodies are to be identified and selected Number Of Target Antigens Against Which Antibodies Are To Be Identified And Selected Term of research program Term Of Research Program Number of designated milestones. Upfront fee to be received Contract With Customer Asset Net Number of designated milestones Number Of Designated Milestones Upfront payments fee received Proceeds From Collaborators Debt Instrument [Table] Debt Instrument [Table] June two thousand sixteen note. June 2016 Note June Two Thousand Sixteen Note [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Annual interest rate Debt Instrument Basis Spread On Variable Rate1 Debt instrument maturity term Debt Instrument Term Increase of interest rate Debt Instrument Interest Rate Increase Decrease Debt Instrument Face Amount Debt Instrument Face Amount Debt Instrument Carrying Amount Debt Instrument Carrying Amount Debt Instrument Periodic Payment Principal Debt Instrument Periodic Payment Principal Interest expense Interest Expense Debt Derivative liabilities written off with repayment of convertible notes. Repayments of convertible debt Derivative liabilities written off with conversion of repayment Derivative Liabilities Written Off With Repayment Of Convertible Notes Embedded derivative, Derivative liability Embedded Derivative Fair Value Of Embedded Derivative Liability Royalty payments, percent of net sales. Commitments and contingencies. Commitments and contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Restructuring Type Restructuring Cost And Reserve [Axis] Type of Restructuring Type Of Restructuring [Domain] Contract Termination Contract Termination [Member] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Termination payment Business Exit Costs1 Royalty payments, percent of net sales Royalty Payments Percent Of Net Sales Operating lease monthly rental payments. Monthly rental payments Operating Lease Monthly Rental Payments Future minimum operating leases Operating Leases Future Minimum Payments Due Rent expense incurred under operating lease Operating Leases Rent Expense Net Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Exchange of Vaccinex Products, LP units. Exchange of Vaccinex Products, LP Units Exchange Of Vaccinex Products L P Units [Member] Conversion of VX3 units. Conversion of VX3 Units Conversion Of V X3 Units [Member] Shares underlying outstanding stock options. Shares Underlying Outstanding Stock Options Shares Underlying Outstanding Stock Options [Member] Shares available for future stock option grants. Shares Available For Future Stock Option Grants Shares Available For Future Stock Option Grants [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Total shares of common stock reserved Common Stock Capital Shares Reserved For Future Issuance Percentage of voting power of all classes of stock to be owned by optionee to determine exercise price. Exercise price as percentage of fair value of common stock on grant date if optionee owns stock representing more than 10 percent of voting power of all classes of stock. Percentage of increase in common stock capital shares reserved for future issuance. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Employee Stock Options Employee Stock Option [Member] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand eleven employee equity plan. 2011 Employee Equity Plan Two Thousand Eleven Employee Equity Plan [Member] Two Thousand Eighteen Employee Equity Plan. 2018 Omnibus Incentive Plan Two Thousand Eighteen Employee Equity Plan [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Percentage of voting power of all classes of stock to be owned by optionee to determine the exercise price Percentage Of Voting Power Of All Classes Of Stock To Be Owned By Optionee To Determine Exercise Price Exercise price as a percentage of fair value of common stock on grant date if optionee owns stock representing more than 10 percent of voting power of all classes of stock Exercise Price As Percentage Of Fair Value Of Common Stock On Grant Date If Optionee Owns Stock Representing More Than10 Percent Of Voting Power Of All Classes Of Stock Stock options granted, expiration year Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Percentage of total shares of common stock reserved Percentage Of Increase In Common Stock Capital Shares Reserved For Future Issuance Share based compensation arrangement by share based payment award options available for grant outstanding number. Share based compensation arrangement by share based payment award number of shares available for grant, shares granted. Share based compensation arrangement by share based payment award number of shares available for grant shares exercised. Share based compensation arrangement by share based payment award number of shares available for grant, shares canceled. Options Outstanding, Shares Available for Grant, Balance Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant Outstanding Number Options Outstanding, Shares Available for Grant, Granted Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Granted Options Outstanding, Shares Available for Grant, Exercised Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Exercised Options Outstanding, Shares Available for Grant, Canceled Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Canceled Options Outstanding, Options, Balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Options Outstanding, Options, Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Options Outstanding, Options, Exercised Stock Issued During Period Shares Stock Options Exercised Options Outstanding, Options, Cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Options Outstanding, Options, Balance Options Outstanding, Options, Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Options Outstanding, Weighted-Average Exercise Price, Balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Options Outstanding, Weighted-Average Exercise Price, Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Options Outstanding, Weighted-Average Exercise Price, Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Options Outstanding, Weighted-Average Exercise Price, Canceled Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Options Outstanding, Weighted-Average Exercise Price, Balance Options Outstanding, Weighted-Average Exercise Price, Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Options Outstanding Weighted-Average Remaining Contractual Life (Years), Balance Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Options Outstanding Weighted-Average Remaining Contractual Life (Years), Exercisable Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Options Outstanding, Aggregate Intrinsic Value, Balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Options Outstanding, Aggregate Intrinsic Value, Balance Options Outstanding, Aggregate Intrinsic Value, Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value Weighted-average grant date fair value of stock options granted to employees Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Options granted Aggregate grant date fair value of stock options vested Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 Total unrecognized compensation cost related to stock options granted to employees Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Total unrecognized compensation cost related to stock options granted to employees, weighted-average recognition period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Expected term of stock option Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Expected dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Research And Development Expense [Member] General and Administrative General And Administrative Expense [Member] Total stock-based compensation expense Allocated Share Based Compensation Expense Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits That Would Impact Effective Tax Rate Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Vaccinex Products, LP units. Vaccinex Products, LP Units Vaccinex Products L P Units [Member] VX3 DE LP units. VX3 Units V X3 D E L P Units [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Weighted-average common stock equivalents excluded from calculation of diluted net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Number of business activity. Number of segment managers for operations or operating results. Schedule Of Segment Reporting Information By Segment [Table] Schedule Of Segment Reporting Information By Segment [Table] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] United States UNITED STATES Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Number of business activity Number Of Business Activity Number of segment managers held accountable for operations or operating results Number Of Segment Managers For Operations Or Operating Results Number of operating segments Number Of Operating Segments Maximum employee contribution to plan Defined Contribution Plan Maximum Annual Contributions Per Employee Percent Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Line Items] Related Party Transaction [Line Items] EX-101.PRE 10 vcnx-20190331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.19.1
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2019
May 10, 2019
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2019  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q1  
Trading Symbol VCNX  
Entity Registrant Name Vaccinex, Inc.  
Entity Central Index Key 0001205922  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Common Stock, Shares Outstanding   11,478,843
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 8,942 $ 5,618
Marketable securities 2,348 14,106
Accounts receivable, net 628 639
Prepaid expenses and other current assets 832 1,061
Total current assets 12,750 21,424
Property and equipment, net 544 604
TOTAL ASSETS 13,294 22,028
Current liabilities:    
Accounts payable 2,439 2,322
Accrued expenses 4,520 4,364
TOTAL LIABILITIES 6,959 6,686
Commitments and contingencies (Note 9)
Stockholders’ equity:    
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of March 31, 2019 and December 31, 2018; 11,476,601 shares issued as of March 31, 2019 and December 31, 2018; 11,475,749 shares outstanding as of March 31, 2019 and December 31, 2018 1 1
Additional paid-in capital 208,216 208,156
Treasury stock, at cost; 852 shares of common stock as of March 31, 2019 and December 31, 2018 (11) (11)
Accumulated deficit (225,834) (216,767)
Total Vaccinex, Inc. stockholders’ deficit (17,628) (8,621)
Noncontrolling interests 23,963 23,963
TOTAL STOCKHOLDERS’ EQUITY 6,335 15,342
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 13,294 $ 22,028
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2019
Dec. 31, 2018
Statement Of Financial Position [Abstract]    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 11,476,601 11,476,601
Common stock, shares outstanding 11,475,749 11,475,749
Treasury stock, common shares 852 852
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Income Statement [Abstract]    
Revenue $ 94,000 $ 206,000
Costs and expenses:    
Cost of revenue 175,000 240,000
Research and development 7,412,000 4,454,000
General and administrative 1,647,000 1,221,000
Total costs and expenses 9,234,000 5,915,000
Loss from operations (9,140,000) (5,709,000)
Change in fair value of derivative liabilities   308,000
Interest expense   (267,000)
Loss on extinguishment of related party convertible promissory note   (2,180,000)
Other income (expense), net 73,000 (14,000)
Loss before provision for income taxes (9,067,000) (7,862,000)
Provision for income taxes 0 0
Net loss (9,067,000) (7,862,000)
Net loss attributable to noncontrolling interests 0 0
Net loss attributable to Vaccinex, Inc. common stockholders, basic and diluted $ (9,067,000) $ (7,862,000)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted $ (0.79) $ (7.13)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted 11,475,749 1,102,571
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.19.1
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Total
Redeemable Convertible Preferred Stock
Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Treasury Stock
Treasury Stock
Redeemable Convertible Preferred Stock
Accumulated Deficit
Total Vaccinex,Inc. Stockholders' Deficit
Noncontrolling Interests
Balance at Dec. 31, 2017 $ (113,490)   $ 7,684   $ 54,123 $ (11)   $ (187,249) $ (125,453) $ 11,963
Balance, Shares at Dec. 31, 2017   53,089,959                
Balance at Dec. 31, 2017   $ 111,718                
Balance, Shares at Dec. 31, 2017     5,702,450 1,103,396   836 163      
Stock-based compensation 36       36       36  
Capital contribution 8,000                 8,000
Net loss (7,862)             (7,862) (7,862)  
Balance at Mar. 31, 2018 (113,316)   $ 7,684   54,159 $ (11)   (195,111) (133,279) 19,963
Balance, Shares at Mar. 31, 2018   53,089,959                
Balance at Mar. 31, 2018   $ 111,718                
Balance, Shares at Mar. 31, 2018     5,702,450 1,103,396   836 163      
Balance at Dec. 31, 2018 15,342     $ 1 208,156 $ (11)   (216,767) (8,621) 23,963
Balance, Shares at Dec. 31, 2018       11,476,601   852        
Stock-based compensation 60       60       60  
Net loss (9,067)             (9,067) (9,067)  
Balance at Mar. 31, 2019 $ 6,335     $ 1 $ 208,216 $ (11)   $ (225,834) $ (17,628) $ 23,963
Balance, Shares at Mar. 31, 2019       11,476,601   852        
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (9,067) $ (7,862)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 60 56
Amortization of debt discount   235
Net amortization of premiums and discounts on marketable securities (42)  
Stock-based compensation 60 36
Change in fair value of derivative liabilities   (308)
Loss on extinguishment of related party convertible promissory note   2,180
Changes in operating assets and liabilities:    
Accounts receivable 11 37
Prepaid expenses and other current assets 229 (65)
Accounts payable 117 348
Accrued expenses 156 309
Deferred revenue   (131)
Net cash used in operating activities (8,476) (5,165)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Sales and maturities of marketable securities 11,800  
Purchase of property and equipment   (47)
Net cash provided by (used in) investing activities 11,800 (47)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments of initial public offering costs   (44)
Repayment of convertible promissory note, related party   (4,000)
Proceeds from capital contribution   8,000
Net cash provided by financing activities   3,956
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 3,324 (1,256)
CASH AND CASH EQUIVALENTS–Beginning of period 5,618 4,180
CASH AND CASH EQUIVALENTS–End of period $ 8,942 2,924
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:    
Cash paid for interest   13
Purchase of property and equipment in accounts payable   9
Deferred offering costs in accounts payable and accrued expenses   573
Deferred offering costs reclassed from prepaid expenses and other current assets   $ 38
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.19.1
Company and Nature of Business
3 Months Ended
Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Company and Nature of Business

1.

COMPANY AND NATURE OF BUSINESS

Description of Business

Vaccinex, Inc. (together with its subsidiaries, the “Company”) was incorporated in Delaware in April 2001 and is headquartered in Rochester, New York. The Company is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Since its inception, the Company has devoted substantially all of its efforts toward product research, manufacturing and clinical development.

The Company is subject to a number of risks common to other early-stage biotechnology companies including, but not limited to, the successful development and commercialization of its product candidates, rapid technological change and competition, dependence on key personnel and collaborative partners, uncertainty of protection of proprietary technology and patents, clinical trial uncertainty, fluctuation in operating results and financial performance, the need to obtain additional funding, potential product liability, compliance with governmental regulations, technological and medical risks, customer demand, management of growth and effectiveness of marketing by the Company. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.

Going Concern

These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flow from operations of $8.5 million and $25.3 million for the three months ended March 31, 2019 and year ended December 31, 2018, respectively, and an accumulated deficit of $225.8 million and $216.8 million as of March 31, 2019 and December 31, 2018, respectively. The Company’s ability to continue as a going concern is at issue due to its historical net losses and negative cash flows from operations, and its need for additional financing to fund future operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

To date, the Company has relied on equity and debt financing to fund its operations. In addition, the Company received $12.0 million in capital contributions from noncontrolling interests during each of the years ended December 31, 2018 and 2017. As the Company’s product candidates are still in the early stages of development, substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. Given our projected operating requirements and our existing cash and cash equivalents and marketable securities, we plan to complete an additional financing transaction prior to the commencement of the 2019 fourth quarter in order for us to continue operations.  Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors, refinancing of existing debt obligations or obtaining additional debt financing. There can be no assurances that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms.

Initial Public Offering

In August 2018, the Company completed its initial public offering (the “IPO”) in which it issued and sold 3,333,334 shares of its common stock, $0.0001 par value, at a public offering price of $12.00 per share. The Company received net proceeds of $37.2 million after deducting underwriting discounts and commissions of $2.8 million, but before deducting offering expenses of $2.7 million. In addition, in connection with the IPO:

 

all shares of the Company’s then-outstanding convertible preferred stock were automatically converted and reclassified into 7,039,155 shares of its common stock, $0.0001 par value;

 

a 1-for-10 reverse stock split of the Company’s common stock was effected; and

 

the Company repaid a $1.5 million convertible promissory note issued in June 2016 (the “June 2016 Note”), held by a related party, Vaccinex (Rochester), L.L.C. (“Vaccinex LLC”), which is majority owned and controlled by Dr. Maurice Zauderer, the Company’s President, Chief Executive Officer and a member of its board of directors.

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Consolidation

These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. All intercompany transactions and balances have been eliminated.

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and following the requirements of the Securities and Exchange Commission ("SEC"), for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the entire year ending December 31, 2019. The year-end balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. Certain information and note disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted under the rules and regulations of the SEC.

These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 13, 2019.

 

Use of Estimates

These condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, the valuation of derivative instruments, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.

Concentration of Credit Risk, Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Cash equivalents are deposited in interest-bearing money market accounts and short-term investments consist of highly liquid U.S. government treasury bills and notes. The Company deposits its cash with multiple financial institutions and cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.

The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company’s product candidates and adversely impact its results of operations.

Comprehensive Loss

The Company did not have any other comprehensive income or loss for any of the periods presented and therefore comprehensive loss did not differ from net loss.

Recent Accounting Pronouncements Not Yet Adopted

In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) No. 2016-02, Leases, which supersedes the Accounting Standards Codification (“ASC”) No. 840, Leases. ASU No. 2016-02 requires lessees to recognize all leases, with exception of short-term leases, as lease liabilities on the balance sheet. Under ASU No. 2016-02, a lease is defined as a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset during the lease term. ASU No. 2016-02 also requires additional disclosure about the amount, timing and uncertainty of cash flow from leases. The new standard is effective for the Company at the earlier of losing the emerging growth company status or the Company’s fiscal year beginning January 1, 2020. Early adoption is permitted. This new standard will require the present value of these leases to be recorded in the condensed consolidated balance sheets as a right-of-use asset and lease liability. The Company will adopt the new standard effective January 1, 2020 and is continuing to evaluate the impact of this guidance on its condensed consolidated financial statements and related disclosures.

Recently Adopted Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which supersedes the revenue recognition requirements in ASC No. 605, Revenue Recognition. ASU No. 2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU No. 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenues and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, the FASB issued ASU No. 2015-14 to defer the effective date by one year with early adoption permitted as of the original effective date. In addition, the FASB issued ASU Nos. 2016-08, 2016-10 and 2016-12 in March 2016, April 2016 and May 2016, respectively, to help provide interpretive clarification on the new guidance in ASC No. 606. ASU Nos. 2016-08, 2016-10 and 2016-12 are all effective beginning the same period as ASU No. 2014-09. The Company adopted the new revenue standards using the modified retrospective method as of January 1, 2019; however, it is not required to reflect the effects of adoption in its consolidated financial statements until it files its annual report for the fiscal year ending December 31, 2019. The Company is in the process of evaluating the effect that the new revenue standards will have on its consolidated financial statements and related disclosures.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.19.1
Balance Sheet Components
3 Months Ended
Mar. 31, 2019
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Components

3.

BALANCE SHEET COMPONENTS

Property and Equipment

Property and equipment consist of the following (in thousands):

 

 

 

As of

March 31,

2019

 

 

As of

December 31,

2018

 

Leasehold improvements

 

$

3,145

 

 

$

3,145

 

Research equipment

 

 

3,219

 

 

 

3,219

 

Furniture and fixtures

 

 

350

 

 

 

350

 

Computer equipment

 

 

214

 

 

 

214

 

Property and equipment, gross

 

 

6,928

 

 

 

6,928

 

Less: accumulated depreciation and amortization

 

 

(6,384

)

 

 

(6,324

)

Property and equipment, net

 

$

544

 

 

$

604

 

 

Depreciation and amortization expense related to property and equipment was $60,000 and $56,000 for the three months ended March 31, 2019 and 2018, respectively.

Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

 

As of

March 31,

2019

 

 

As of

December 31,

2018

 

Accrued clinical trial cost

 

$

4,084

 

 

$

3,796

 

Accrued payroll and related benefits

 

 

247

 

 

 

236

 

Accrued consulting and legal

 

 

117

 

 

 

296

 

Accrued other

 

 

72

 

 

 

36

 

Accrued expenses

 

$

4,520

 

 

$

4,364

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.19.1
Marketable Securities
3 Months Ended
Mar. 31, 2019
Investments Debt And Equity Securities [Abstract]  
Marketable Securities

4.

MARKETABLE SECURITIES

As of March 31, 2019, the fair value of available-for-sale marketable securities was as follows (in thousands):

 

 

 

As of March 31, 2019

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains

 

 

Gross

Unrealized

Losses

 

 

Fair Value

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

2,348

 

 

$

-

 

 

$

-

 

 

$

2,348

 

 

 

$

2,348

 

 

$

-

 

 

$

-

 

 

$

2,348

 

 

 

 

As of December 31, 2018

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains

 

 

Gross

Unrealized

Losses

 

 

Fair Value

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

14,106

 

 

$

-

 

 

$

-

 

 

$

14,106

 

 

 

$

14,106

 

 

$

-

 

 

$

-

 

 

$

14,106

 

 

All of the Company’s available-for-sale marketable securities at March 31, 2019 are maturing in one year or less.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value of Financial Measurements
3 Months Ended
Mar. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value of Financial Measurements

5.

FAIR VALUE OF FINANCIAL MEASUREMENTS

Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on the following three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The assets’ or liabilities’ fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The following table sets forth the fair value of the Company’s financial assets by level within the fair value hierarchy (in thousands):

 

 

 

As of March 31, 2019

 

 

 

Fair Value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

8,233

 

 

$

8,233

 

 

$

-

 

 

$

-

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U. S. Treasury securities

 

 

2,348

 

 

 

-

 

 

 

2,348

 

 

 

-

 

Total Financial Assets

 

$

10,581

 

 

$

8,233

 

 

$

2,348

 

 

$

-

 

 

 

 

As of December 31, 2018

 

 

 

Fair Value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

4,881

 

 

$

4,881

 

 

$

-

 

 

$

-

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U. S. Treasury securities

 

 

14,106

 

 

 

-

 

 

 

14,106

 

 

 

-

 

Total Financial Assets

 

$

18,987

 

 

$

4,881

 

 

$

14,106

 

 

$

-

 

 

The Company did not transfer any assets measured at fair value on a recurring basis to or from Level 1 and Level 2 during either of the three months ended March 31, 2019 and 2018.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.19.1
License and Services Agreement
3 Months Ended
Mar. 31, 2019
Research And Development [Abstract]  
License and Services Agreement

6.

LICENSE AND SERVICES AGREEMENT

In November 2017, the Company entered into a license agreement (the “VX3 License Agreement”) with VX3 (DE) LLP (“VX3”), which was formed by a group of Canadian investors including the Company’s majority stockholder, FCMI Parent Co. (“FCMI Parent”). VX3 was created for the purpose of funding the Company’s research and development activities for VX15, our most advanced product candidate. In June 2018, the U.S. Adopted Name Council approved the use of pepinemab as the adopted name for VX15. Under the VX3 License Agreement, the Company granted VX3 the license to use, make, have made, sell, offer and import pepinemab for the treatment of Huntington’s disease in the U.S. and Canada and, in return, VX3 agreed to fund research and development activities with up to an aggregate of $32.0 million in milestone payments to the Company and to share any pepinemab profits and sublicensing revenue under the agreement in an amount based on a calculation set forth in the agreement. The Company also entered into a services agreement with VX3 (the “Services Agreement”), pursuant to which the Company will carry out development activities for pepinemab for the treatment of Huntington’s disease in the U.S. and Canada in exchange for services payments from VX3, including a payment of $11.9 million in 2017. The VX3 License Agreement expires upon the last to expire licensed patent and may be terminated by either party upon uncured material breach, the occurrence of certain transactions or financings including the consummation of an initial public offering by the Company, uncured failure of VX3 to make any payment due under the Services Agreement, or upon written notice after November 6, 2020. The Services Agreement may be terminated by either party upon an uncured material breach and is automatically terminated upon termination of the VX3 License Agreement. The VX3 License Agreement provides that upon termination, the Company will issue to VX3 or its designees the number of shares of the Company’s common stock equal to the lesser of (1) the aggregate of all payments made to VX3 by the Canadian investors divided by $18.20 and (2) the then fair market value of VX3 divided by the then fair market value of one share of the Company’s common stock.

The Company has a variable interest in VX3 through FCMI Parent, which is majority owned and controlled by the Company’s chairman, and it controlled 90% of VX3’s voting interest at each of March 31, 2019 and December 31, 2018. VX3 does not have any business operations or generate any income or expenses and is primarily a funding mechanism specifically for the benefit of the Company, as its only activities consist of the receipt of funding and the contribution of such funding to the Company. Therefore, the Company determined that it is the primary beneficiary of VX3 and that the operating results of VX3 should be incorporated into the Company’s condensed consolidated financial statements accordingly.

In February, May and June 2018, the Services Agreement was amended to allow VX3 to provide additional funding for future research and development activities to take place in the year ending December 31, 2018 and to repay an outstanding convertible note in the amount of $4.0 million (Note 8). No other terms of the Services Agreement were amended; therefore, the above assessment resulting in the Company being the primary beneficiary of the VX3 entity remained unchanged as of March 31, 2019.

For the three months ended March 31, 2018, the Company recorded the gross proceeds of $8.0 million, received from VX3 as capital contributions from noncontrolling interests on the condensed consolidated financial statements.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.19.1
Collaboration Agreements
3 Months Ended
Mar. 31, 2019
Collaboration Agreements [Abstract]  
Collaboration Agreements

7.

COLLABORATION AGREEMENTS

Merck Sharp & Dohme Corp.

In September 2017, the Company entered into a research agreement with Merck Sharp & Dohme Corp. (“Merck”) to test vaccinia strain Modified Vaccinia Ankara. Under the research agreement, the Company designed genetic sequence for all constructs listed in the agreement and conducted research in accordance with the research protocol and a mutually agreed scope of work outlined in the agreement. Merck supplied the Company sufficient samples of the antibodies to carry out the research and has sole ownership of all right, title, interest and copy rights of the research results. Under the research agreement, the Company recognized service revenue of $69,000 for the three months ended March 31, 2018. The research agreement expired in June 2018. In the fourth quarter of 2018, the Company entered into a second research agreement with Merck to test these antigen particles in an antibody discovery campaign.

Surface Oncology, Inc.

In November 2017, the Company entered into a research collaboration and license option agreement with Surface Oncology, Inc. (“Surface”) to identify and select antibodies against two target antigens, using the Company’s proprietary technology as described in the agreement. The term for each research program is nine to twelve months (not exceeding twelve months unless extended by written agreement) including time necessary for any functional assessment conducted by Surface following the commencement of the research program. Surface will provide the Company material to carry out the research activities. During the research program term, the Company also grants Surface non-exclusive, worldwide, limited-purpose license for each target to use the Company’s research program materials for conducting the research work pursuant to the agreement.

Under the agreement, Surface has been granted exclusive options, exercisable by providing a written notice to the Company, to obtain (i) an exclusive product license to make, use, sell and import products incorporating the antibody targeting the first antigen and (ii) an exclusive research tool license to use the antibody targeting the second antigen to perform research.

Under the agreement, Surface will pay an upfront technology access fee of $250,000 and milestone payments upon completion of each of four designated milestones for the first target antigen specified in the agreement. For the second target antigen, Surface will make payments to the Company based on time incurred by the Company in the conduct of the work plan described in the agreement. Surface will reimburse the Company for expenses incurred (i) in the conduct of the work plan as detailed in the research funding budget and (ii) for patent filings and prosecution of the Company’s program intellectual property as described in the agreement. The exercise of each option would also entail a license fee and annual maintenance fees, and in the case of the product license, royalties and additional milestone payments. During the year ended December 31, 2017, the Company received the upfront technology access fee of $250,000, of which $63,000 was recognized as revenue from the amortization of this upfront fee for the three months ended March 31, 2018. The Company also received $93,877 and $69,172 service fee payments for work conducted under the agreement for the three months ended March 31, 2019 and 2018, respectively. This agreement will expire upon the expiration of both research programs and all evaluation and testing periods.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.19.1
Convertible Promissory Notes
3 Months Ended
Mar. 31, 2019
Debt Disclosure [Abstract]  
Convertible Promissory Notes

8.

CONVERTIBLE PROMISSORY NOTES  

 

As of March 31, 2019, the Company did not have any convertible promissory notes outstanding. See “Repayment of Convertible Promissory Notes” below.

 

June 2016 Note

In June 2016, the Company issued a $1.5 million convertible promissory note to a related party. The June 2016 Note accrued interest at a compounded annual rate of 8% and had a maturity date three years from issuance, if not converted before then. Upon the occurrence of a default event, such as payment or performance defaults, bankruptcy, change in control (if elected to be treated as such by the lenders), or other violation, the interest rate would increase to a compounded annual rate of 12% until such time the default is cured. Upon maturity, the holder of these convertible promissory notes was to be repaid the outstanding principal plus all accrued interest. The Company also had the ability to prepay the convertible promissory notes, plus accrued interest, without penalty. The debt issuance costs for these convertible promissory notes were not material. The June 2016 Note was paid in full on August 17, 2018. See “Repayment of Convertible Promissory Notes” below.

January 2017 Notes

In January 2017, the Company entered into a convertible promissory note agreement whereby it agreed to issue, in the aggregate, $10.0 million of convertible promissory notes to a related party (the “January 2017 Notes”). The $4.0 million of the January 2017 Notes issued in January 2017 did not accrue interest, but the other $6.0 million of the January 2017 Notes issued in April, August and October 2017 accrued interest at an annual rate of 2%. The January 2017 Notes had a maturity date three years from issuance. Upon maturity, the holder of these convertible promissory notes was to be repaid the outstanding principal plus all accrued interest. The Company was also authorized to prepay the January 2017 Notes, plus accrued interest, without penalty. The debt issuance costs for these convertible promissory notes were not material. Of the January 2017 Notes, $6.0 million were paid in 2017 and the balance was paid in full on March 8, 2018. See “Repayment of Convertible Promissory Notes” below.

Derivative Liabilities

From the proceeds of the convertible promissory notes, the portion equal to the fair value of the embedded derivative liabilities and the option derivative at the time of each respective issuance was recognized as a debt discount to be amortized to interest expense over the term of the related convertible promissory notes. The Company recognized interest expense of $235,000 for the amortization of the debt discounts during the three months ended March 31, 2018.

Repayment of Convertible Promissory Notes

Of the January 2017 Notes, $2.0 million issued in April 2017 was repaid along with accrued interest in May 2017, $4.0 million issued in August and October 2017 was repaid along with accrued interest in November 2017 and $4.0 million issued in January 2017 was repaid in March 2018. The option arrangement associated with the January 2017 Notes was also waived upon the repayment of the January 2017 Notes. As a result of this repayment, the related $0.3 million derivative liabilities associated with the conversion feature and the option arrangement were written off and the $2.2 million unamortized debt discount was recognized as a loss on extinguishment of related party convertible promissory note in the condensed consolidated statement of operations for the three months ended March 31, 2018.

The June 2016 Note was repaid along with accrued interest in August 2018. As a result of this repayment, the related $31,000 derivative liability associated with the conversion feature and the option arrangement were written off and the $199,000 unamortized debt discount was recognized as a loss on extinguishment of related party convertible promissory note in the condensed consolidated statements of operations in the three months ended September 30, 2018.

 

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.19.1
Commitment and Contingencies
3 Months Ended
Mar. 31, 2019
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

9.

COMMITMENTS AND CONTINGENCIES

Sublicense Termination Payments

In 2006, the Company licensed certain technology to EUSA Pharma SAS (“EUSA”) and in 2008, this technology was sublicensed by EUSA to Glaxo Group Limited (“GSK”) for development. GSK terminated its sub-license with EUSA in March 2010 and ownership of the technology reverted back to the Company. The Company may be required to pay EUSA up to $25.5 million plus ongoing royalty payments of 1% of net sales upon the occurrence of certain events involving the previously licensed technology, including a Phase 3 clinical trial, FDA acceptance and approval and product sales. The Company is not planning any further commercialization efforts related to the previously licensed technology, and therefore does not anticipate any of the above described amounts will be paid.

Operating Lease

The Company leases its facilities from 1895 Management, Ltd., a New York corporation controlled by an entity affiliated with a director of the Company, under non-cancellable operating leases. Following entry into a lease extension agreement in July 2018, the lease agreement requires monthly rental payments of $14,000 through October 31, 2020. The Company is responsible for all maintenance, utilities, insurance and taxes related to the facility.

As of March 31, 2019, the future minimum payments for the operating lease are $266,000.

Rent expense incurred under the operating lease was $42,000 for each of the three months ended March 31, 2019 and 2018.

Contingencies

The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount.

In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. As of March 31, 2019 and December 31, 2018, the Company was not involved in any material legal proceedings.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.19.1
Common Stock Reserved For Issuance
3 Months Ended
Mar. 31, 2019
Equity [Abstract]  
Common Stock Reserved For Issuance

10.

COMMON STOCK RESERVED FOR ISSUANCE

Common stock has been reserved for the following potential future issuances:

 

 

 

As of

March 31, 2019

 

 

As of

December 31, 2018

 

Shares underlying outstanding stock options

 

 

538,702

 

 

 

405,683

 

Shares available for future stock option grants

 

 

289,981

 

 

 

423,000

 

Exchange of Vaccinex Products, LP units

 

 

1,202,566

 

 

 

1,202,566

 

Conversion of VX3 units

 

 

1,318,797

 

 

 

1,318,797

 

Total shares of common stock reserved

 

 

3,350,046

 

 

 

3,350,046

 

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock-Based Compensation

11.

STOCK-BASED COMPENSATION

2011 Employee Equity Plan

The Company’s 2011 Employee Equity Plan (the “2011 Plan”) was terminated in connection with the adoption of the Company’s 2018 Omnibus Incentive Plan (the “2018 Plan”) in August 2018, and the Company will not grant any additional stock options under the 2011 Plan. However, the 2011 Plan will continue to govern the terms and conditions of the outstanding stock options previously granted thereunder. Stock options granted under the 2011 Plan expire in five or ten years from the date of grant.

2018 Omnibus Incentive Plan

In August 2018, the Company’s Board of Directors adopted, and its stockholders approved, the 2018 Plan, which allows for the granting of stock, stock option, and stock appreciation rights awards to employees, advisors and consultants. Stock options granted under the 2018 Plan may be either incentive stock options or non-statutory stock options. Incentive stock options may be granted to employees, advisors and consultants at exercise prices of no less than the fair value of the common stock on the grant date. If at the time of grant, the optionee owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price must be at least 110% of the fair value of the common stock on the grant date as determined by the board of directors. Non-statutory stock options may be granted to employees, advisors and consultants at exercise prices of less than the fair market value of a share of common stock on the date the non-statutory stock option is granted but shall under no circumstances be less than adequate consideration as determined by the board of directors for such a share. Vesting period of stock option grants is determined by the board of directors, ranging from zero to eight years. Stock options granted under the 2018 Plan expire in five or ten years from the date of grant.

The Company reserved 425,000 shares of common stock for issuance, subject to certain adjustments, pursuant to awards under the 2018 Plan. Any shares of common stock related to awards outstanding under the 2011 Plan as of the effective date of the 2018 Plan, which thereafter terminate by expiration, forfeiture, cancellation or otherwise without the issuance of such shares, will be added to, and included in, the number of shares of common stock available for grant under the 2018 Plan. In addition, effective January 1, 2020 and continuing until the expiration of the 2018 Plan, the number of shares of common stock available for issuance under the 2018 Plan will automatically increase annually by 2% of the total number of issued and outstanding shares of our common stock as of December 31st of the immediately preceding year or such lesser number as our board of directors may decide, which may be zero.

A summary of the Company’s stock option activity and related information is as follows:

 

 

 

Options Outstanding

 

 

 

Stock Options

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Life (Years)

 

 

Aggregate

Intrinsic

Value (000's)

 

Balance as of December 31, 2018

 

 

405,683

 

 

$

9.69

 

 

 

6.5

 

 

$

-

 

Granted

 

 

135,972

 

 

 

3.97

 

 

 

 

 

 

 

 

 

Exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

Canceled

 

 

(2,953

)

 

 

12.60

 

 

 

 

 

 

 

 

 

Balance as of March 31, 2019

 

 

538,702

 

 

$

8.23

 

 

 

7.2

 

 

$

175

 

Exercisable as of March 31, 2019

 

 

373,777

 

 

$

9.43

 

 

 

6.1

 

 

$

-

 

 

 

The weighted-average grant date fair value of stock options granted to employees for the three months ended March 31, 2019 and 2018 was $2.65 and $15.63 per share, respectively. The aggregate grant date fair value of stock options that vested during the three months ended March 31, 2019 and 2018 was $53,716 and $79,000, respectively.

The intrinsic value of stock options vested and expected to vest and exercisable is calculated based on the difference between the exercise price and the fair value of the Company’s common stock as of March 31, 2019 and December 31, 2018. The intrinsic value of exercised stock options is the difference between the fair value of the underlying common stock and the exercise price as of the exercise date.

As of March 31, 2019 and December 31, 2018, total unrecognized compensation cost related to stock options granted to employees was $710,285 and $435,639, respectively, which is expected to be recognized over a weighted-average period of 3.3 and 2.8 years, respectively.

The grant date fair value of employee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:  

 

 

Three Months Ended

March 31,

 

 

2019

 

 

2018

 

Expected term (in years)

 

6.0

 

 

 

6.0

 

Expected volatility

 

75

%

 

 

75

%

Risk-free interest rate

 

2.5

%

 

 

2.6

%

Expected dividend yield

 

-

%

 

 

-

%

 

Total stock-based compensation expense recognized in the condensed consolidated statements of operations is as follows (in thousands):

 

 

 

Three Months Ended

March 31,

 

 

 

2019

 

 

2018

 

Research and development

 

$

15

 

 

$

21

 

General and administrative

 

 

45

 

 

 

15

 

Total stock-based compensation expense

 

$

60

 

 

$

36

 

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes
3 Months Ended
Mar. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes

12.

INCOME TAXES

No provision for income taxes was recorded in either of the three months ended March 31, 2019 and 2018. The Company remains in a cumulative loss position with a full valuation allowance recorded against its net deferred income tax assets as of March 31, 2019.

 

 

The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of March 31, 2019 and December 31, 2018, the Company had no unrecognized income tax benefits that would affect the Company’s effective tax rate if recognized.

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.19.1
Net Loss Per Share Attributable to Common Stockholders
3 Months Ended
Mar. 31, 2019
Earnings Per Share [Abstract]  
Net Loss Per Share Attributable to Common Stockholders

13.

NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS

 

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

 

 

 

Three Months Ended

March 31,

 

 

 

2019

 

 

2018

 

Preferred stock (if converted)

 

 

-

 

 

 

7,039,155

 

Options to purchase common stock

 

 

432,051

 

 

 

424,843

 

Contingently issuable common stock upon exchange of

   Vaccinex Products, LP units

 

 

1,202,566

 

 

 

1,202,566

 

Contingently issuable common stock upon exchange of

   VX3 units

 

 

1,318,797

 

 

 

800,880

 

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.19.1
Segment and Geographical Information
3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Segment and Geographic Information

14.

SEGMENT AND GEOGRAPHIC INFORMATION

The Company’s chief operating decision maker, its Chief Executive Officer, reviews its operating results on an aggregate basis for purposes of allocating resources and evaluating financial performance. The Company has one business activity, the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, and there are no segment managers who are held accountable for operations or operating results. Accordingly, the Company operates in one segment. As of March 31, 2019 and December 31, 2018, all long-lived assets are located in the United States.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.19.1
Employee Benefit Plan
3 Months Ended
Mar. 31, 2019
Compensation And Retirement Disclosure [Abstract]  
Employee Benefit Plan

15.

EMPLOYEE BENEFIT PLAN

The Company sponsors a 401(k) plan that stipulates that eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100% of eligible compensation on a pre-tax basis. Through March 31, 2019, the Company has not elected to match employee contributions as permitted by the plan. The Company pays the administrative costs for the plan.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.19.1
Related Party Transactions
3 Months Ended
Mar. 31, 2019
Related Party Transactions [Abstract]  
Related Party Transactions

16.

RELATED PARTY TRANSACTIONS

As discussed in Note 9, the Company leases its facility from 1895 Management, Ltd., a New York corporation controlled by an entity affiliated with the Company’s chairman and major stockholder of the Company. Rent expense incurred under this operating lease was $42,000 for each of the three months ended March 31, 2019 and 2018.

As discussed in Note 7, in November 2017, we entered into a research collaboration and license option agreement with Surface to identify and select antibodies against two target antigens, using our proprietary technology as described in the agreement. J. Jeffrey Goater, a member of our board of directors, served as the Chief Business Officer of Surface at that time, and currently serves as the Chief Executive Officer and a director of Surface. The Company received $93,877 and $69,172 service fee payments for work conducted under the agreement for the three months ended March 31, 2019 and 2018, respectively.

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Basis of Presentation and Consolidation

Basis of Presentation and Consolidation

These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. All intercompany transactions and balances have been eliminated.

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and following the requirements of the Securities and Exchange Commission ("SEC"), for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the entire year ending December 31, 2019. The year-end balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. Certain information and note disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted under the rules and regulations of the SEC.

These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 13, 2019.

Use of Estimates

Use of Estimates

These condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, the valuation of derivative instruments, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.

Concentration of Credit Risk, Other Risks and Uncertainties

Concentration of Credit Risk, Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Cash equivalents are deposited in interest-bearing money market accounts and short-term investments consist of highly liquid U.S. government treasury bills and notes. The Company deposits its cash with multiple financial institutions and cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.

The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company’s product candidates and adversely impact its results of operations.

Comprehensive Loss

Comprehensive Loss

The Company did not have any other comprehensive income or loss for any of the periods presented and therefore comprehensive loss did not differ from net loss.

Recent Accounting Pronouncements

Recent Accounting Pronouncements Not Yet Adopted

In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update (“ASU”) No. 2016-02, Leases, which supersedes the Accounting Standards Codification (“ASC”) No. 840, Leases. ASU No. 2016-02 requires lessees to recognize all leases, with exception of short-term leases, as lease liabilities on the balance sheet. Under ASU No. 2016-02, a lease is defined as a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset during the lease term. ASU No. 2016-02 also requires additional disclosure about the amount, timing and uncertainty of cash flow from leases. The new standard is effective for the Company at the earlier of losing the emerging growth company status or the Company’s fiscal year beginning January 1, 2020. Early adoption is permitted. This new standard will require the present value of these leases to be recorded in the condensed consolidated balance sheets as a right-of-use asset and lease liability. The Company will adopt the new standard effective January 1, 2020 and is continuing to evaluate the impact of this guidance on its condensed consolidated financial statements and related disclosures.

Recently Adopted Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which supersedes the revenue recognition requirements in ASC No. 605, Revenue Recognition. ASU No. 2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU No. 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenues and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, the FASB issued ASU No. 2015-14 to defer the effective date by one year with early adoption permitted as of the original effective date. In addition, the FASB issued ASU Nos. 2016-08, 2016-10 and 2016-12 in March 2016, April 2016 and May 2016, respectively, to help provide interpretive clarification on the new guidance in ASC No. 606. ASU Nos. 2016-08, 2016-10 and 2016-12 are all effective beginning the same period as ASU No. 2014-09. The Company adopted the new revenue standards using the modified retrospective method as of January 1, 2019; however, it is not required to reflect the effects of adoption in its consolidated financial statements until it files its annual report for the fiscal year ending December 31, 2019. The Company is in the process of evaluating the effect that the new revenue standards will have on its consolidated financial statements and related disclosures.

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.19.1
Balance Sheet Components (Tables)
3 Months Ended
Mar. 31, 2019
Balance Sheet Related Disclosures [Abstract]  
Property and Equipment

Property and equipment consist of the following (in thousands):

 

 

 

As of

March 31,

2019

 

 

As of

December 31,

2018

 

Leasehold improvements

 

$

3,145

 

 

$

3,145

 

Research equipment

 

 

3,219

 

 

 

3,219

 

Furniture and fixtures

 

 

350

 

 

 

350

 

Computer equipment

 

 

214

 

 

 

214

 

Property and equipment, gross

 

 

6,928

 

 

 

6,928

 

Less: accumulated depreciation and amortization

 

 

(6,384

)

 

 

(6,324

)

Property and equipment, net

 

$

544

 

 

$

604

 

Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

 

As of

March 31,

2019

 

 

As of

December 31,

2018

 

Accrued clinical trial cost

 

$

4,084

 

 

$

3,796

 

Accrued payroll and related benefits

 

 

247

 

 

 

236

 

Accrued consulting and legal

 

 

117

 

 

 

296

 

Accrued other

 

 

72

 

 

 

36

 

Accrued expenses

 

$

4,520

 

 

$

4,364

 

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.19.1
Marketable Securities (Tables)
3 Months Ended
Mar. 31, 2019
Investments Debt And Equity Securities [Abstract]  
Summary of the Fair Value of Available-for-sale Marketable Securities

As of March 31, 2019, the fair value of available-for-sale marketable securities was as follows (in thousands):

 

 

 

As of March 31, 2019

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains

 

 

Gross

Unrealized

Losses

 

 

Fair Value

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

2,348

 

 

$

-

 

 

$

-

 

 

$

2,348

 

 

 

$

2,348

 

 

$

-

 

 

$

-

 

 

$

2,348

 

 

 

 

As of December 31, 2018

 

 

 

Amortized

Cost

 

 

Gross

Unrealized

Gains

 

 

Gross

Unrealized

Losses

 

 

Fair Value

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

14,106

 

 

$

-

 

 

$

-

 

 

$

14,106

 

 

 

$

14,106

 

 

$

-

 

 

$

-

 

 

$

14,106

 

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value of Financial Measurements (Tables)
3 Months Ended
Mar. 31, 2019
Fair Value Disclosures [Abstract]  
Summary of Fair Value of Financial Assets by Level within Fair Value Hierarchy

The following table sets forth the fair value of the Company’s financial assets by level within the fair value hierarchy (in thousands):

 

 

 

As of March 31, 2019

 

 

 

Fair Value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

8,233

 

 

$

8,233

 

 

$

-

 

 

$

-

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U. S. Treasury securities

 

 

2,348

 

 

 

-

 

 

 

2,348

 

 

 

-

 

Total Financial Assets

 

$

10,581

 

 

$

8,233

 

 

$

2,348

 

 

$

-

 

 

 

 

As of December 31, 2018

 

 

 

Fair Value

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

4,881

 

 

$

4,881

 

 

$

-

 

 

$

-

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U. S. Treasury securities

 

 

14,106

 

 

 

-

 

 

 

14,106

 

 

 

-

 

Total Financial Assets

 

$

18,987

 

 

$

4,881

 

 

$

14,106

 

 

$

-

 

 

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.19.1
Common Stock Reserved For Issuance (Tables)
3 Months Ended
Mar. 31, 2019
Equity [Abstract]  
Common Stock Reserved for Potential Future Issuances

Common stock has been reserved for the following potential future issuances:

 

 

 

As of

March 31, 2019

 

 

As of

December 31, 2018

 

Shares underlying outstanding stock options

 

 

538,702

 

 

 

405,683

 

Shares available for future stock option grants

 

 

289,981

 

 

 

423,000

 

Exchange of Vaccinex Products, LP units

 

 

1,202,566

 

 

 

1,202,566

 

Conversion of VX3 units

 

 

1,318,797

 

 

 

1,318,797

 

Total shares of common stock reserved

 

 

3,350,046

 

 

 

3,350,046

 

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Summary of Stock Option Activity and Related Information

A summary of the Company’s stock option activity and related information is as follows:

 

 

 

Options Outstanding

 

 

 

Stock Options

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Life (Years)

 

 

Aggregate

Intrinsic

Value (000's)

 

Balance as of December 31, 2018

 

 

405,683

 

 

$

9.69

 

 

 

6.5

 

 

$

-

 

Granted

 

 

135,972

 

 

 

3.97

 

 

 

 

 

 

 

 

 

Exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

Canceled

 

 

(2,953

)

 

 

12.60

 

 

 

 

 

 

 

 

 

Balance as of March 31, 2019

 

 

538,702

 

 

$

8.23

 

 

 

7.2

 

 

$

175

 

Exercisable as of March 31, 2019

 

 

373,777

 

 

$

9.43

 

 

 

6.1

 

 

$

-

 

 

Grant Date Fair Value of Employee Stock Options Estimated Using Black-Scholes Option-Pricing Model with Weighted-Average Assumptions The grant date fair value of employee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 

 

Three Months Ended

March 31,

 

 

2019

 

 

2018

 

Expected term (in years)

 

6.0

 

 

 

6.0

 

Expected volatility

 

75

%

 

 

75

%

Risk-free interest rate

 

2.5

%

 

 

2.6

%

Expected dividend yield

 

-

%

 

 

-

%

 

Total Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations

Total stock-based compensation expense recognized in the condensed consolidated statements of operations is as follows (in thousands):

 

 

 

Three Months Ended

March 31,

 

 

 

2019

 

 

2018

 

Research and development

 

$

15

 

 

$

21

 

General and administrative

 

 

45

 

 

 

15

 

Total stock-based compensation expense

 

$

60

 

 

$

36

 

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.19.1
Net Loss Per Share Attributable to Common Stockholders (Tables)
3 Months Ended
Mar. 31, 2019
Earnings Per Share [Abstract]  
Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

 

 

 

Three Months Ended

March 31,

 

 

 

2019

 

 

2018

 

Preferred stock (if converted)

 

 

-

 

 

 

7,039,155

 

Options to purchase common stock

 

 

432,051

 

 

 

424,843

 

Contingently issuable common stock upon exchange of

   Vaccinex Products, LP units

 

 

1,202,566

 

 

 

1,202,566

 

Contingently issuable common stock upon exchange of

   VX3 units

 

 

1,318,797

 

 

 

800,880

 

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.19.1
Company and Nature of Business - Additional Information (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Aug. 09, 2018
USD ($)
$ / shares
shares
Mar. 31, 2019
USD ($)
$ / shares
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
$ / shares
Dec. 31, 2017
USD ($)
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Cash flow from operations   $ (8,476) $ (5,165) $ (25,300)  
Accumulated deficit   $ 225,834   216,767  
Proceeds from capital contribution     8,000 $ 12,000 $ 12,000
Common stock, par value | $ / shares   $ 0.0001   $ 0.0001  
Offering expenses     44    
Repayment of convertible promissory note, related party     $ 4,000    
IPO          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Common stock, par value | $ / shares $ 0.0001        
Public offering price, per share | $ / shares $ 12.00        
Net proceeds from initial public offering $ 37,200        
Underwriting discounts and commissions 2,800        
Offering expenses $ 2,700        
Convertible preferred stock converted and reclassified into common stock | shares 7,039,155        
Reverse stock split of common stock description 1-for-10        
Reverse stock split of common stock 10        
IPO | Vaccinex LLC | Convertible Promissory Notes          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Repayment of convertible promissory note, related party $ 1,500        
IPO | Common Stock          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Number of shares issued and sold | shares 3,333,334        
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.19.1
Balance Sheet Components - Property and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 6,928 $ 6,928
Less: accumulated depreciation and amortization (6,384) (6,324)
Property and equipment, net 544 604
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 3,145 3,145
Research Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 3,219 3,219
Furniture and Fixtures    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 350 350
Computer Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 214 $ 214
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.19.1
Balance Sheet Components - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Property Plant And Equipment [Abstract]    
Depreciation and amortization expense $ 60 $ 56
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.19.1
Balance Sheet Components - Schedule of Accrued Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Payables And Accruals [Abstract]    
Accrued clinical trial cost $ 4,084 $ 3,796
Accrued payroll and related benefits 247 236
Accrued consulting and legal 117 296
Accrued other 72 36
Accrued expenses $ 4,520 $ 4,364
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.19.1
Marketable Securities - Summary of the Fair Value of Available-for-sale Marketable Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Marketable Securities [Line Items]    
Securities Available for Sale, Amortized Cost $ 2,348 $ 14,106
Securities Available for Sale, Gross Unrealized Gains 0 0
Securities Available for Sale, Gross Unrealized Losses 0 0
Securities Available for Sale, Fair Value 2,348 14,106
U.S. Treasury Securities    
Marketable Securities [Line Items]    
Securities Available for Sale, Amortized Cost 2,348 14,106
Securities Available for Sale, Gross Unrealized Gains 0 0
Securities Available for Sale, Gross Unrealized Losses 0 0
Securities Available for Sale, Fair Value $ 2,348 $ 14,106
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.19.1
Marketable Securities - Additional Information (Details)
3 Months Ended
Mar. 31, 2019
Maximum  
Marketable Securities [Line Items]  
Available for sale marketable securities maturity period 1 year
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value of Financial Measurements - Summary of Fair Value of Financial Assets by Level within Fair Value Hierarchy (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Financial Assets:    
Securities Available for Sale, Fair Value $ 2,348 $ 14,106
Securities Available for Sale, Fair Value 2,348 14,106
U.S. Treasury Securities    
Financial Assets:    
Securities Available for Sale, Fair Value 2,348 14,106
Securities Available for Sale, Fair Value 2,348 14,106
Fair Value Measurements Recurring    
Financial Assets:    
Total Financial Assets 10,581 18,987
Fair Value Measurements Recurring | Money Market Funds    
Financial Assets:    
Cash equivalents, Fair value disclosure 8,233 4,881
Fair Value Measurements Recurring | U.S. Treasury Securities    
Financial Assets:    
Securities Available for Sale, Fair Value 2,348 14,106
Securities Available for Sale, Fair Value 2,348 14,106
Fair Value Measurements Recurring | Level 1    
Financial Assets:    
Total Financial Assets 8,233 4,881
Fair Value Measurements Recurring | Level 1 | Money Market Funds    
Financial Assets:    
Cash equivalents, Fair value disclosure 8,233 4,881
Fair Value Measurements Recurring | Level 2    
Financial Assets:    
Total Financial Assets 2,348 14,106
Fair Value Measurements Recurring | Level 2 | U.S. Treasury Securities    
Financial Assets:    
Securities Available for Sale, Fair Value 2,348 14,106
Securities Available for Sale, Fair Value $ 2,348 $ 14,106
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value of Financial Measurements - Additional Information (Details) - Fair Value Measurements Recurring - USD ($)
Mar. 31, 2019
Mar. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Financial assets, level 1 to level 2 transfers, amount $ 0 $ 0
Financial assets, level 2 to level 1 transfers, amount $ 0 $ 0
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.19.1
License and Services Agreement - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2018
Nov. 30, 2017
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
License And Services Agreement [Line Items]            
Proceeds from capital contribution       $ 8,000 $ 12,000 $ 12,000
January 2017 Notes            
License And Services Agreement [Line Items]            
Repay an outstanding convertible note $ 4,000          
VX3 License Agreement            
License And Services Agreement [Line Items]            
Research and development, milestone payments to company   $ 32,000        
Terms of license agreement upon termination     the Company will issue to VX3 or its designees the number of shares of the Company’s common stock equal to the lesser of (1) the aggregate of all payments made to VX3 by the Canadian investors divided by $18.20 and (2) the then fair market value of VX3 divided by the then fair market value of one share of the Company’s common stock.      
Base amount to determine issuance of common stock upon termination   $ 18.20        
Services Agreement            
License And Services Agreement [Line Items]            
Services payments received           $ 11,900
VX3            
License And Services Agreement [Line Items]            
Percentage of voting interest     90.00%   90.00%  
Proceeds from capital contribution       $ 8,000    
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.19.1
Collaboration Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2017
USD ($)
TargetAntigen
Milestone
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Merck Sharp & Dohme Corp.        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Service revenue recognized     $ 69,000  
Surface Oncology, Inc.        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Service revenue recognized     63,000  
Number of target antigens against which antibodies are to be identified and selected | TargetAntigen 2      
Upfront fee to be received $ 250,000      
Number of designated milestones | Milestone 4      
Upfront payments fee received   $ 93,877 $ 69,172 $ 250,000
Surface Oncology, Inc. | Minimum        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Term of research program 9 months      
Surface Oncology, Inc. | Maximum        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Term of research program 12 months      
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.19.1
Convertible Promissory Notes - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended
Mar. 31, 2018
Nov. 30, 2017
Oct. 31, 2017
Aug. 31, 2017
Apr. 30, 2017
Jan. 31, 2017
Jun. 30, 2016
Sep. 30, 2018
Mar. 31, 2018
Debt Instrument [Line Items]                  
Annual interest rate     2.00% 2.00% 2.00% 0.00%      
Debt instrument maturity term           3 years      
Debt Instrument Face Amount           $ 10,000,000      
Debt Instrument Carrying Amount     $ 6,000,000 $ 6,000,000 $ 6,000,000 4,000,000      
Debt Instrument Periodic Payment Principal           6,000,000      
Interest expense                 $ 235,000,000
Loss on extinguishment of related party convertible promissory note                 2,180,000
Embedded derivative, Derivative liability             $ 31,000    
June 2016 Note                  
Debt Instrument [Line Items]                  
Annual interest rate             8.00%    
Debt instrument maturity term             3 years    
Increase of interest rate             12.00%    
Debt Instrument Face Amount             $ 1,500,000    
June 2016 Note | Convertible Promissory Notes                  
Debt Instrument [Line Items]                  
Loss on extinguishment of related party convertible promissory note               $ 199,000  
January 2017 Notes                  
Debt Instrument [Line Items]                  
Repayments of convertible debt $ 4,000,000                
January 2017 Notes | Convertible Promissory Notes                  
Debt Instrument [Line Items]                  
Debt Instrument Carrying Amount     $ 4,000,000   2,000,000 $ 4,000,000      
Repayments of convertible debt $ 4,000,000 $ 4,000,000     $ 2,000,000        
Derivative liabilities written off with conversion of repayment                 300,000
Loss on extinguishment of related party convertible promissory note                 $ 2,200,000
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.19.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Commitments And Contingencies [Line Items]    
Royalty payments, percent of net sales 1.00%  
Monthly rental payments $ 14,000  
Future minimum operating leases 266,000  
Rent expense incurred under operating lease 42,000 $ 42,000
Contract Termination    
Commitments And Contingencies [Line Items]    
Termination payment $ 25,500  
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.19.1
Common Stock Reserved For Issuance - Common Stock Reserved For Potential Future Issuances (Details) - shares
Mar. 31, 2019
Dec. 31, 2018
Class Of Stock [Line Items]    
Total shares of common stock reserved 3,350,046 3,350,046
Shares Underlying Outstanding Stock Options    
Class Of Stock [Line Items]    
Total shares of common stock reserved 538,702 405,683
Shares Available For Future Stock Option Grants    
Class Of Stock [Line Items]    
Total shares of common stock reserved 289,981 423,000
Exchange of Vaccinex Products, LP Units    
Class Of Stock [Line Items]    
Total shares of common stock reserved 1,202,566 1,202,566
Conversion of VX3 Units    
Class Of Stock [Line Items]    
Total shares of common stock reserved 1,318,797 1,318,797
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation - Additional Information (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Total shares of common stock reserved 3,350,046   3,350,046
Weighted-average grant date fair value of stock options granted to employees $ 2.65 $ 15.63  
Options granted 135,972    
Aggregate grant date fair value of stock options vested $ 53,716 $ 79,000  
Total unrecognized compensation cost related to stock options granted to employees $ 710,285   $ 435,639
2018 Omnibus Incentive Plan      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Total shares of common stock reserved 425,000    
Percentage of total shares of common stock reserved 2.00%    
2018 Omnibus Incentive Plan | Minimum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Percentage of voting power of all classes of stock to be owned by optionee to determine the exercise price 10.00%    
Exercise price as a percentage of fair value of common stock on grant date if optionee owns stock representing more than 10 percent of voting power of all classes of stock 110.00%    
Employee Stock Options      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Total unrecognized compensation cost related to stock options granted to employees, weighted-average recognition period 3 years 3 months 19 days   2 years 9 months 18 days
Employee Stock Options | 2011 Employee Equity Plan | Minimum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Stock options granted, expiration year 5 years    
Employee Stock Options | 2011 Employee Equity Plan | Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Stock options granted, expiration year 10 years    
Employee Stock Options | 2018 Omnibus Incentive Plan | Minimum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Stock options granted, expiration year 5 years    
Employee Stock Options | 2018 Omnibus Incentive Plan | Maximum      
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]      
Stock options granted, expiration year 10 years    
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2019
Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]    
Options Outstanding, Options, Balance 405,683  
Options Outstanding, Options, Granted 135,972  
Options Outstanding, Options, Cancelled (2,953)  
Options Outstanding, Options, Balance 538,702 405,683
Options Outstanding, Options, Exercisable 373,777  
Options Outstanding, Weighted-Average Exercise Price, Balance $ 9.69  
Options Outstanding, Weighted-Average Exercise Price, Granted 3.97  
Options Outstanding, Weighted-Average Exercise Price, Canceled 12.60  
Options Outstanding, Weighted-Average Exercise Price, Balance 8.23 $ 9.69
Options Outstanding, Weighted-Average Exercise Price, Exercisable $ 9.43  
Options Outstanding Weighted-Average Remaining Contractual Life (Years), Balance 7 years 2 months 12 days 6 years 6 months
Options Outstanding Weighted-Average Remaining Contractual Life (Years), Exercisable 6 years 1 month 6 days  
Options Outstanding, Aggregate Intrinsic Value, Balance $ 175  
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation - Grant Date Fair Value of Employee Stock Options Estimated Using Black-Scholes Option-Pricing Model with Weighted-Average Assumptions (Details) - Employee Stock Options
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Expected term of stock option 6 years 6 years
Expected volatility 75.00% 75.00%
Risk-free interest rate 2.50% 2.60%
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-Based Compensation - Total Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Total stock-based compensation expense $ 60 $ 36
Research and Development    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Total stock-based compensation expense 15 21
General and Administrative    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Total stock-based compensation expense $ 45 $ 15
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes - Additional Information (Details) - USD ($)
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Income Tax Disclosure [Abstract]      
Provision for income taxes $ 0 $ 0  
Unrecognized tax benefits that would impact effective tax rate $ 0   $ 0
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.19.1
Net Loss Per Share Attributable to Common Stockholders - Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect (Details) - shares
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Convertible Preferred Stock    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Weighted-average common stock equivalents excluded from calculation of diluted net loss per share   7,039,155
Employee Stock Options    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Weighted-average common stock equivalents excluded from calculation of diluted net loss per share 432,051 424,843
Vaccinex Products, LP Units    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Weighted-average common stock equivalents excluded from calculation of diluted net loss per share 1,202,566 1,202,566
VX3 Units    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Weighted-average common stock equivalents excluded from calculation of diluted net loss per share 1,318,797 800,880
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.19.1
Segment and Geographic Information - Additional Information (Details)
3 Months Ended 12 Months Ended
Mar. 31, 2019
BusinessActivity
SegmentManager
Segment
Dec. 31, 2018
Segment
Segment Reporting Information [Line Items]    
Number of business activity | BusinessActivity 1  
Number of segment managers held accountable for operations or operating results | SegmentManager 0  
United States    
Segment Reporting Information [Line Items]    
Number of operating segments | Segment 1 1
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.19.1
Employee Benefit Plan - Additional Information (Details)
3 Months Ended 12 Months Ended
Mar. 31, 2019
Dec. 31, 2018
Compensation And Retirement Disclosure [Abstract]    
Maximum employee contribution to plan 100.00% 100.00%
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.19.1
Related Party Transactions - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2017
TargetAntigen
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Related Party Transaction [Line Items]        
Rent expense incurred under operating lease   $ 42,000 $ 42,000  
Surface Oncology, Inc.        
Related Party Transaction [Line Items]        
Number of target antigens against which antibodies are to be identified and selected | TargetAntigen 2      
Upfront payments fee received   $ 93,877 $ 69,172 $ 250,000
EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "XXKTX?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ +CBO3B?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " N.*].[;J8;N\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+/3L,P#(=?!>7>.EU5$%'7"]-.("$Q"<0M2KPMHOFCQ*C=VY.6 MK1."!^ 8^Y?/GR6W*@CE(SY''S"2P70SVMXEH<*:'8F" $CJB%:F,B=<;NY] MM)+R,QX@2/4A#P@KSF_!(DDM2<($+,)"9%VKE5 1)?EXQFNUX,-G[&>85H ] M6G24H"HK8-TT,9S&OH4K8((11IN^"Z@7XES]$SMW@)V38S)+:AB&GQY=YW<*X1-(IS+^2$70*N&:7R:_UPV:W9=V*5_<%;XJJV?$[P;FHF_?) M]8??5=AZ;?;F'QM?!+L6?MU%]P502P,$% @ +CBO3IE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " N.*].\TO[LGH" _"0 & 'AL+W=O<_$J2\94\-;4K=R&I5+=,T+R7+*&RB?>L58_ MN7+14*6GXH9D)QB]6%)3(Q)%:]30J@V+W*X=19'SNZJKEAU%(.]-0\7O/:MY MOPUQ^+[P4MU*9190D7?TQKXQ];T["CU#4Y1+U;!65KP-!+MNPQU^/N#4$"SB M1\5Z.1L'II03YZ]F\OFR#2.3$:O969D05-\>[,#JVD32>?P:@X:3IB'.Q^_1 M/]KB=3$G*MF!US^KBRJW818&%W:E]UJ]\/X3&PM:A<%8_1?V8+6&FTRTQIG7 MTEZ#\UTJWHQ1="H-?1ON56OO_? DB4<:3" C@4P$0OY+B$="/!&P54!#9K;4 M#U31(A>\#\3@5D?-1X&?8_TRSV;1OCO[3%JCB'+T,&%&Q'Y D!D"3PBD M8T\"!!+8$X]._A4X^(@8%HC!"F)+CV?T!*8G(#VQ]&1&7SDOP$>L88$5*+#R MZ*DCX",R6& -"JP]^L81\!$X@A524"'U^=B1 " $ELA B@-* M;'R^:S4 6? :1W [17X$UVX(LV X7FA:[$=P/06POCJY]ZO;6]L%K737= M,MSW_>$NBKK-WM9%=^L.MO'_[%Q;%[UOMH]1=VAML1V#ZBJ".#91791-N%J, MS^[;U<(]]U79V/LVZ)[KNFC_KFWECLM0A&\/OI>/^WYX$*T6A^+1_K#]S\-] MZUO1.>AL:7[3*,!R); MV4T_I"C\Y<7FMJJ&3)[CSY0T//OV7_-!;OBWDH.IN[ZG>Y[??+, V# MK=T5SU7_W1T_VZD@'093]5_MBZV\?"#Q?6Q:YZUT]9?$H=?%ZNI;- M>#U.^=_"^ "8 N <(-2[ 7(*D"@@.I&-I7XL^F*U:-TQ:$]OZU ,DT+<23^8 MF^'A.';C?[[:SC]]62;)^B2!"PE<*W*JD.(LB7S_9PA@(6",EY?Q MP,=+-EZ.\>HR7J(B3A(S2II1DF8*UT%%VHB4)U$LB:(D"I&<)/JB$Y J1214 M))2(#8^B611-431"T:07 YB$T,[,L84$2 M"I(@D(1V HE&'T1.52 4*)XE95E2RH(&?IV27K1";;$3'O13'Q 17/9)AQ,T'J40+;F:"H"E>=%L3 M0&D TP#I1VG ,XY323/SI@5ODH*ZI,(N.6FN)E2FR=@P*I/.F)/@C5)0I\2S M>\UI-&9Y5W--PONDT'36S=7".YR@%J>PLPC&OW I[TFN.7B#$]3A\,*R%HQY MQ2D(@V%8G=!S(\/;G* ^I["_"&IB-X*,S?NB:Q;>Z@3U.NSL:T%M[ 9 IW@1 MSUFA,(E)>";@'0]BRH3]:M)'"]/Q.,._>=<[WU*>-;7]S>'^;.C&PO=V]R M:W-H965T&ULC97;CILP$(9?!?D!8LYD(X+44%6MU$K15MU> M.S $M 93VPG;MZ]M6,1)VW 1G_Y_YAN#G;AC_%64 -)ZJVDCCJB4LCU@++(2 M:B)VK(5&K12,UT2J(;]BT7(@N3'5%+NV'>*:5 U*8C-WYDG,;I)6#9RY)6YU M3?C?$U#6'9&#WB>>JVLI]01.XI9H^15#8VH6&-Q*([HDW-( M(ZTW@I<*.C'I6[J2"V.O>O M/R); P&%3.H(1#5W2(%2'4AA_!EBHC&E-D[[ M[]&_F-I5+1Y@<$>#XW]H\ :#MS#@GLR4^IE( MDL2<=1;O7U9+]#?A'#RUF9F>-'MGUE2U0LW>DR"(\5W'&22G7N).).YU.(<-OO;?H]X_>G_FA11"^)C*0Q$GMGV[:SJ.2_LAF- MOTGCKVGV"YI>$DS2./;P+( >4/P?2/X! M4$L#!!0 ( "XXKTX-M\UT. , $(- 8 >&PO=V]R:W-H965T&ULC5==CYLP$/PKB/<+MODPG))(EU15*[72Z:JVSUSB).@ I^ D MUW]?VQ".>)>H+P&;V9W9#8S6\XMLWMJ#$,I[K\JZ7?@'I8Z/0=!N#J+*VYD\ MBEH_V-ON@/38BW]J@J@P8(4E0Y47M+^=V[[E9SN5)E44MGANO/555 MWOQ=B5)>%C[UKQLOQ?Z@S$:PG!_SO?@AU,_CXW8+?PG M^KAF-L B?A7BTH[N/5/*JY1O9O%UN_")421*L5$F1:XO9[$696DR:1U_^J3^ MP&D"Q_?7[)]M\;J8U[P5:UG^+K;JL/!3W]N*77XJU8N\?!%]0;'O]=5_$V=1 M:KA1HCDVLFSMK[)FQ: M%6Z>%+HG=]V30E\$D_Q'=Q#DW>XPW#D9=,[4=DXZYR,QMXAJ#\1F= M&(H8[ID,>F;JCG8,>B:E$8]Y!"1A2,)B[LZ"P6CRK$2SMT-ZZVWDJ59FR!OM M#@>!)V8F5V=_I0\(W3C_D:8[77S/FWU1M]ZK5'HNMM/K3DHEM$XRTPH/^D S M+$JQ4^:6Z_NFF^J[A9+'_L02#,>FY3]02P,$% @ +CBO3DJDE7D'! MPQ( !@ !X;"]W;W)KK4F=K=Y])G$3K@+A XME_OP,2E.X&?9&+7]]GNH'Q,MR:-BV_9P>SM/V]9GL:EO*0FWA3"Z6) M*SPO<--XMW>FX_K>/?1JG3VJP$+\^_M#_4P=M@ M7N+"S+/DG]VFW$X<[8PVYBW^2,H?V?'1- $I9]1$_[OY-(G%*T^LC=K? MT>M'469IH\6ZDL:_3L?=OCX>&_U?8KR : 1$*P P*" ; =D*R&A0P&\$_%9 MZ$$!U0BHLTMR4"!H!(*SA7!0(&P$PK,%-2B@&P'="JAAEZ)&(#J[-%P'\+XJ MY[4BOA@6:8M]KK:HXW!/JZ1>=HNXC*?C/#N.\M/..<35!H5[*V655W?KA5S_ M:9=>8>]^3K44KY#-->4 HJ GFY+/IJ39 M1,MT?D+490*DIZ-(1;PEG[?D7ZW;W&<"@A T;T?Q=M35B!:*1A1ZPE=H?7RG M'( G981VZ9)R6B+FD='55ZJ #RR@@2$CLX 8P7X\7$=6@TC'TY#W-*2>HJXU M"VG*/ _E?WT%ZKBB>5H;SW=1*VN41V7(][EB&8/NQQ1 M,[;!24"57$2W-#BJS#8XA9K2DJJB#8YS*U* N17'22E"9'--.8AZ&USUJ,". M.0C,($1Q+1KF>J=C0+[5,2#M=9RV MWK+U#":@DPEP@Y@!G4V@I"]P=))F'#]%44W"TZ!(_%05W0>,LCL!01B@+KCB M0-LND+XUYYSLWP@] QCH! 8/<*I\9B'X81!@ER%:BB-U* @^G)<,Q6XF!A%!:^CA3G+8P$!KO)<:[@;W4\U@!]+G" MMDN<*_HTT+>7*$GWDGOQ!EM]WODCSM]W^V+TDI7V=;A^8WW+LM)8A=XWJVIK MXDU[D9BWLCH-[7E^^JQRNBBS0_/)R&V_6TW_!U!+ P04 " N.*].3I([ M?^<# #2$0 & 'AL+W=OE.N]G5=;MRC]UW>4I"-K=255%^T%?5&W^.>BF*CKSV!R#]M*H M8C]TJLH PS )JN)<^^OET/;2K)?ZVI7G6KTT7GNMJJ+YM5&EOJU\\-\;OIV/ MIZYO"-;+2W%4?ZKN^^6E,4_!WO::]1AY3_#TY;BOL.@^.NL;NWL MWNM3>=7Z1__P>;_RPSXB5:I=UYLHS.5-;559]I9,'/],1OV[S[[C_/[=^J9/,:]&JK2[_/N^[T\K/?&^O#L6U[+[IVQ]J2BCVO2G[+^I-E4;>1V)\['39 M#K_>[MIVNIJLF%"JXN=X/=?#]3;9?^\F=\"I ]X[0/R?'6CJ0+\[1$/R8V1# MJA^+KE@O&WWSFO%M78I^4, 3F6+N^L:A=L-_)MO6M+ZM(8R6P5MO:-)L1@W. M-7=%8*S?7:#D8H.L.SXZV')%0K('$I.@H3\])!'+!B+10#08B&8&TLPJPBA) M!DD]2!9YF*16)H(JS1*48XG%6&(AF40VD(@&$I8,A%:7"8ZR00GN95KQIPL(L<;R44G.7.2)Y:/_/_KR27D MJ">$\E0-^2BU9]*D>4B69F5_].- G _D>T'^)N#+'3X$;GP#,A'.KA,R!,? MB+]_ !M?Q&*U-5M!0ZDC%!DAP!E"]BB9- ]5P]P.A8L6B6-2@(P0B%DL$:M* M+%3%QID@HL@UFF0: <=1A'8LG#40)W8L7$2SN?X8BXPD$)@$; IQ*"V '%\\ MD+$$ I> [*P%,&51RO(69#$X1X2,,,B%N1;))E#&#W+\ ,163LCY X8+CEF- M,H"0 PC +@MR BTBQY1%&4"(@A_[2SF)W!E-X7"9.QP99B@L8\ QV5"&$'(( M =B 00$PD6LLR(!!#AA 5A(.CT44.L>"C \45C-HTQLY&C*W(YD-*+ !V4*5 MLX%RU[((93:@P :TV8!\TA.A_1465 M 9SPR&I O;\#VM$&^>HD3L)=S@BIR MK@I(Q@P)F$$;,Y-HOL[.OM]+7N^CWGK/5^,/&,_4[::M_ TW8\7OAM9CSM^%HTQW/= M>J^Z,_OT83=]T+I3)L3P@PGQI(K]_:%4AZZ_3=\?&'-5!XJ[*].#QIO& M6,4]FK9EKK? ZPA2DJ6[W3537&A:YM%WLF5N!B^%AI,E;E"*VQ]'D&8L:$+? M'$^B[7QPL#+O>0M?P'_M3Q8MMK#40H%VPFABH2GH77(X[D-\#/@F8'2K,PF5 MG(UY#L;'NJ"[( @D5#XP<-PN< ]2!B*4\3)STB5E *[/;^P/L7:LY\S*T9B9UZW_/PQ,DAQ=Y4P1E; M$>]0O$/OI4RR)&>70#3''*>8=!VS1#!D7U*D6RF.Z5_P=!N>;2K,(CS[3>$_ M"/:;!/M(L/]OB5LQV1])V*JG"FP;I\F1R@PZ3O+*NPSL71K?Y%?X-.V?N6V% M=N1L/+YL[']CC >4LKO"$>KP@RV&A,:'XPV>[31FD^%-/_\@MGSC\B=02P,$ M% @ +CBO3GN'YI"T 0 T@, !@ !X;"]W;W)K4S,5_APLH# ]*,$=IE(LK*0?GC9Y94(H6+],NN[B/ MTTV:S+!M )\!? '%)DU([%3[WL1GGA_X-B;,CAC*^(=BG?H MO13[),W8)1#-,<>9>!O>/Q3?Z&3]/^(&PC.T?.QN/+ MQO[7QGA *;LK'*$6/]AB**A].'["LYW&;#*\Z>&PO=V]R:W-H965T&UL M?5-A;]L@$/TKB!]0$L==L\BVU'2:5JF5HD[;/A/[;*,"YP&.VW\_P*[GM=:^ M '?<>_?N.+(!S;-M 1QY45+;G+;.=0?&;-F"XO8*.]#^ID:CN/.F:9CM#/ J M@I1DR6;SB2DN-"VRZ#N9(L/>2:'A9(CME>+F]0@2AYQNZ9OC232M"PY69!UO MX#NX']W)>(O-+)50H*U 30S4.;W='HYIB(\!/P4,=G$FH9(SXG,P[JN<;H(@ MD%"ZP,#]=H$[D#(0>1F_)TXZIPS Y?F-_6NLW==RYA;N4/X2E6MSNJ>D@IKW MTCWA\ VF>JXIF8I_@ M('QZ4^!PE2AM74O;6H9I8O!3%7\9=Z+@/XTUZ/<'6 M ]X>.+M(?&]*8,SMB+>>?'6>R_%=G>3 ML4L@FF*.8TRRC)DCF&>?4R1K*8[)!WBR#M^M*MQ%^.X?A?MU@G25((T$Z7]+ M7(OY_"X)6_14@6GB-%E28J_C)"^\\\#>)O%-_H:/T_[(32.T)6=T_F5C_VM$ M!U[*YLJ/4.L_V&Q(J%TXWOBS&<=L-!QVTP]B\S&UL?5-A M;]P@#/TKB!]0^C\38U&"^=-TS#;&Q!5!&G% M>)*\8UK(CA99])U,D>'@E.S@9(@=M!;FUQ$4CCG=T:OC43:M"PY69+UHX!NX M[_W)>(LM+)74T%F)'3%0Y_1^=SBF(3X&_) PVM69A$K.B,_!^%SE- F"0$'I M H/PVP4>0*E Y&7\G#GIDC( U^D=)!;48E'O$ M\1/,]=Q2,A?_!2Z@?'A0XG.4J&Q<23E8AWIF\5*T>)EVV<5]G&YNK[!M )\! M? '<10";$D7E'X03169P)&;J?2_"$^\.W/>F#,[8BGCGQ5OOO12[-,G8)1#- M,<(#KR4Y,:/ M4.L_V&(HJ%TXOO=G,XW99#CLYQ_$EF]<_ 902P,$% @ +CBO3C_< X:T M 0 T@, !D !X;"]W;W)K&UL?5/;;MP@$/T5 MQ >$7>Q]P?&7-F"$N[*]*#QIC96"8^F;9CK+8@J@I1D?+>[84IT MFA99])ULD9G!RT[#R1(W*"7LKR-(,^9T3S\7;G-Y14D$M!ND?S?@%YGJN M*9F+_P87D!@>E&".TD@75U(.SALULZ 4)=ZFO=-Q'Z>;Y':&;0/X#. +X"[F M85.BJ/R3\*+(K!F)G7K?B_#$^P/'WI3!&5L1[U"\0^^EV*=)QBZ!:(XY3C%\ M';-$,&1?4O"M%$?^#YQOPY--A4F$)W\H3+<)TDV"-!*D_RUQ*^;ZKR1LU5,% MMHG3Y$AI!ATG>>5=!O:>QS?Y'3Y-^W=AFTX[7S;VOS;& TK97>$(M?C! M%D-"[U,8J[M&T#7.=!5Y%D)(LV6SV3'&A:9%% MW]D6F>F]%!K.EKA>*6[_G$":(:=;^N9X$$WK@X,56<<;> 3_LSM;M-C,4@D% MV@FCB84ZIW?;XRD-\3'@EX#!+7YC_Q)KQUHNW,&]D4^B\FU.#Y144/->^@]X>.+M,<'>E,$96Q'O4+Q#[[78ION,70/1%',:8Y)ES!S! MD'U.D:RE."7_P)-U^&Y5X2["=^\4WJX3I*L$:21(_UOB6LSA0Q*VZ*D"V\1I M---/XC-W[AX!5!+ P04 " N.*].\1SX@+4! #2 P M&0 'AL+W=O&?$3S8CL 1UZ5 MU+:@G7/]D3%;=:"XO<$>M+]IT"CNO&E:9GL#O(XD)5F:)+=,<:%IF4??V90Y M#DX*#6=#[* 4-[]/('$LZ(Z^.9Y$V[G@8&7>\Q:^@_O1GXVWV*)2"P7:"M3$ M0%/0^]WQE 5\!#P+&.WJ3$(E%\278'RI"YJ$A$!"Y8("]]L5'D#*(.33^#5K MTB5D(*[/;^J?8NV^E@NW\(#RIZA=5] [2FIH^"#=$XZ?8:[G0,E<_%>X@O3P MD(F/4:&T<2758!VJ6<6GHOCKM L=]W&ZV=_.M&U".A/2A7 7X[ I4,S\D3M> MY@9'8J;>]SP\\>Z8^MY4P1E;$>]\\M9[K^4N^YBS:Q":,:<)DZXQ"X)Y]25$ MNA7BE/Y'3[?I^\T,]Y&^7T<_)-L"V:9 %@6R=TOJK M'&:+*EP MT'&25]YE8._3^"9_X=.T?^.F%=J2"SK_LK'_#:(#GTIRXT>H\Q]L,20T+AP_ M^+.9QFPR'/;S#V++-R[_ %!+ P04 " N.*]. 0/L<[0! #2 P &0 M 'AL+W=O[5JXQ=@AGEOW@Q#/J)]=AV )R]:&5?0 MSOO^R)BK.M#"W6 /)MPT:+7PP;0M<[T%42>05HSO=F^8%M+0,D^^LRUS'+R2 M!LZ6N$%K87^>0.%8T#U]=3S*MO/1P!)PNA69Q(KN2 ^1^-37=!=% 0**A\91-BN\ !*1:(@X\?,29>4 M$;@^O[)_2+6'6B["P0.J[[+V74'O**FA$8/RCSA^A+F>6TKFXC_#%50(CTI" MC@J52RNI!N=1SRQ!BA8OTRY-VL?IAK^;8=L /@/X KA+>=B4*"E_+[PHQ&?>'_DH3=5=*96I+L@W@7OM=S?\IQ=(]$<_P:=J_"-M*X\@%?7C9U/\&T4.0LKL)(]2%#[88"AH?CV_#V4YC M-AD>^_D'L>4;E[\ 4$L#!!0 ( "XXKT[LB2K]MP$ -(# 9 >&PO M=V]R:W-H965T;,]XSIDSXW':&_OB&@!/WI34+J.-]^V! M,5F\U)H.%GB M.J6X_7<$:?J,KNF[XTG4C0\.EJ@O&CS.@J" ()A0\,'+<+W(&4@0AEO(Z<=$H9@//S M._M#K!UK.7,'=T8^B](W&=U34D+%.^F?3/\(8ST[2L;B?\(%)(8')9BC,-+% ME12=\T:-+"A%\;=A%SKN_7"S2T;8,B 9 QZ1OG_P%02P,$% @ +CBO3ET0;!"T 0 T@, !D !X;"]W M;W)K&UL?5/;;IPP$/T5RQ\0L^PEZ0J0LJFJ5DJD M5:JFSUX8P(HOU#9+\O<=&T)1B_IB>\;GG+EXG W&OKH6P),W);7+:>M]=V3, ME2TH[FY,!QIO:F,5]VC:AKG. J\B24F6)LF!*2XT+;+H.]LB,[V70L/9$MW[":09+%IM5*J% .V$TL5#G]'YS/.T" M/@)>! QN<2:ADHLQK\'X5N4T"0F!A-('!8[;%1Y RB"$:?R:-.D<,A"7YP_U M+[%VK.7"'3P8^5-4OLWI'245U+R7_MD,7V&J9T_)5/PC7$$B/&2",4HC75Q) MV3MOU*2"J2C^-NY"QWT8;[;[B;9.2"=".A/N8APV!HJ9?^:>%YDU [%C[SL> MGGAS3+$W97#&5L0[3-ZA]UIL]I\R=@U"$^8T8M(E9D8P5)]#I&LA3ND_]'2= MOEW- MI_%-_L#':7_BMA':D8OQ^+*Q_[4Q'C"5Y 9'J,4/-AL2:A^.MWBVXYB-AC?= M](/8_(V+WU!+ P04 " N.*].OX!4YK,! #2 P &0 'AL+W=O3+AIT&KA@VE;YGH+HDX@K1C?[6Z9%M+0,D^^LRUS'+R2!LZ6N$%K87^> M0.%8T#U]"[ MA-&MSB16=Y3,Q7^&*Z@0'I6$'!4JEU92#IUV:M(_3S1V?8=L /@/X KA/>=B4*"E_+[PHQ&?>'_D MH3=5=*96I+L@W@7OM=S?\IQ=(]$<_P M:=J_"-M*X\@%?7C9U/\&T4.0LKL)(]2%#[88"AH?CW?A;*&UL?5/;;MP@$/T5Q >$7;S91"O;4C91E$JMM$K4]IFUQQ<% M& ?P.OW[ '9R5;#R1#;*R7,KR-('#*Z MI9^.Y[9N7'"P/.U$#2_@OG&X"_$QX$<+@UV< M2:CDC/@:C"]E1C=!$$@H7& 0?KO /4@9B+R,MXF3SBD#<'G^9'^,M?M:SL+" M/F:C-Y24D(E>NF><7B"J9YK2J;BO\(%I \/2GR. J6-*REZZU!-+%Z* M$N_CWNJX#^--DDRP=0"? 'P&W,8\;$P4E3\()_+4X$#,V/M.A"?>'KCO31&< ML17QSHNWWGO)M_OKE%T"T11S'&/X,F:.8)Y]3L'74ASY/W"^#D]6%281GORA M<+].L%LEV$6"W7]+7(NY^2L)6_14@:GC-%E28*_C)"^\\\#>\?@FO\/':?\F M3-UJ2\[H_,O&_E>(#KR4S94?H<9_L-F04+EPO/%G,X[9:#CLIA_$YF^&UL?5/;;MLP#/T501]0.4[29H%MH.DP;, &!!W6/2LV;0O5Q9/D MN/O[4;+K>:O1%TFD> X/*2H;C'UV+8 G+TIJE]/6^^[(F"M;4-S=F XTWM3& M*N[1M USG05>19"2+$V26Z:XT+3(HN]LB\ST7@H-9TM8Y&%^JG"9!$$@H?6#@N%WA :0,1"CCU\1)YY0!N#R_LG^*M6,M%^[@P>:,F%I2B^,NX M"QWW8;S9[R?8.B"= .D,.,0\;$P4E7_DGA>9-0.Q8^\['IYX'C%T#T11S&F/29[=$E=B[I+_DK!%3Q78)DZ3(Z7I=9SDA7<>V/LTOLG?\'':OW'; M".W(Q7A\V=C_VA@/*"6YP1%J\8/-AH3:A^,=GNTX9J/A33?](#9_X^(/4$L# M!!0 ( "XXKTXM#X^2M@$ -(# 9 >&PO=V]R:W-H965TOG M8'RK"[P+@D! Y0(#\]L%[D&(0.1EO,R<>$D9@.OS._N76+NOYN M*_ M1C4T;!#N48]?8:[G&J.Y^.]P >'#@Q*?H]+"QA55@W5:SBQ>BF2OT\Y5 MW,?I)MW/L&T G0%T =S&/&1*%)4_,,?*W.@1F:GW/0M/G!RH[TT5G+$5\BK!M'&:+*KTH.(DK[S+P-[1^"9_PZ=I_\%,RY5% M9^W\R\;^-UH[\%)V5WZ$.O_!%D- X\)Q[\]F&K/)<+J??Q!9OG'Y!E!+ P04 M " N.*].ZQ6U-;0! #2 P &0 'AL+W=O9NQ%$BF>PT.*2GICWUP-X,F'DMJEM/:^/3#F\AJ4<#>F!8TWI;%*>#1M MQ5QK0101I"3CJ]4M4Z+1-$NB[V2SQ'1>-AI.EKA.*6%_'4&:/J5K>G6\-%7M M@X-E22LJ> 7_O3U9M-C$4C0*M&N,)A;*E-ZO#\=MB(\!/QKHW>Q,0B5G8]Z" M\:5(Z2H( @FY#PP"MPL\@)2!"&6\CYQT2AF \_.5_2G6CK6D=) :7HI'\Q_3.,]>PH&8O_"A>0&!Z48([<2!=7DG?.&S6RH!0E/H:]T7'O MAYO=%;8,X". 3X"["&!#HJC\47B1)=;TQ Z];T5XXO6!8V_RX(RMB'&PO=V]R:W-H965T!!MYX*#E7G/ M6_@.[D=_-MYB"TLM%&@K4!,#34'O=L?3(<3'@$U7+B%>Y0_1>VZ@F:4U-#P M0;H''#_#7,\[2N;BO\(5I \/2GR."J6-*ZD&ZU#-+%Z*XL_3+G3YP9&8J?<]#T^\.Z:^-U5PQE;$.R_>>N^UW-UF M.;L&HCGF-,6DZY@E@GGV)46ZE>*4OH*GV_#]IL)]A.__4?AAF^"P27"(!(.M/YMIS";#83__(+9\X_(/4$L#!!0 ( "XX MKT[=H/I2[0$ &8% 9 >&PO=V]R:W-H965T5D)QJ8\J:J%X"+5T0 M9R0,@IAPVG9^GCK?1>:IK.[A(3PV<4_G[#$R,F;_S[XZ7MFZT=9 \[6D- MWT!_[R_26&1A*5L.G6I%YTFH,O]I=SHG%N\ /UH8U6KOV4JN0KQ:XW.9^8%- M"!@4VC)0L]S@&1BS1":-7S.GOTC:P/7^SO[1U6YJN5(%SX+];$O=9'[B>R54 M=&#Z18R?8*[GX'MS\5_@!LS ;29&HQ!,N:]7#$H+/K.85#A]F]:V<^LXG<3W M,#P@G /")2!Q 602[[ZE]XMTI-'=36*>["G=FDE?&>\MW MR2XE-TLT8\X3)EQC%@0Q[(M$B$FH1E&+CQ:JT<'G&"/$NP=P?Z? M$L--B1@FPD4.J,@!(=AO1##,?RJ)49$8(8@W(ACFB(L<49$C0I!L1##,(RZ2 MH"+)>X+'8"."8;8_'EG]YQQD[3I<>848.C==5MYEB#R%KD_^PJ<)])7*NNV4 M=Q7:=)OKB4H(#2:5X,$\76.&WF(PJ+3='LU>3JT_&5KT\U0CRVC-_P!02P,$ M% @ +CBO3G&% R7$ 0 -P0 !D !X;"]W;W)K&UL;51ACYP@$/TKA!]P[*)>MQLUN;U+TR9MLKFF[6=61R4'8@'7Z[\O MH&?M'E^$&=Z\-\,PYI/2+Z8#L.A5BMX4N+-V.!)BJ@XD,W=J@-Z=-$I+9IVI M6V(&#:P.05(0NMO=$\EXC\L\^,ZZS-5H!>_AK)$9I63ZSPF$F@J\QV^.9]YV MUCM(F0^LA>]@?PQG[2RRLM1<0F^XZI&&IL /^^,I\_@ ^,EA,IL]\I5ZP#N?$ BHK&=@;KG"(PCAB5P:OQ=.O$KZP.W^C?U3J-W5QU7GD? MUFD^2;,E+!Y EP"Z!AR"#IF%0N9/S+(RUVI">K[[@?D6[X_4W4WEG>$JPIE+ MWCCOM=Q_I#FY>J(%H(NR[OF$)C=*67"I[.Y<+IV;XM40T%B__>#V>G[+LV'5 ML(PI6?\5Y5]02P,$% @ +CBO3CR@(ONV 0 T@, !D !X;"]W;W)K M&UL=5/;CM,P$/T5RQ^P;MU NU42:;L(@012M8CE MV4TF%ZTOP7::Y>\9.VD(2WBQ/>-SSEP\3@=C7UP#X,FKDMIEM/&^.S+FB@:4 M<'>F XTWE;%*>#1MS5QG0921I"3CF\U[ID2K:9Y&W]GFJ>F];#6<+7&]4L+^ M.H$T0T:W].9X:NO&!P?+TT[4\ W\]^YLT6*S2MDJT*XUFEBH,OJP/9Z2@(^ MYQ8&MSB34,G%F)=@?"XSN@D)@83"!P6!VQ4>0;^L=8 M.]9R$0X>C?S1EK[)Z(&2$BK12_]DAD\PU?..DJGX+W %B?"0"<8HC'1Q)47O MO%&3"J:BQ.NXMSKNPWBSO]'6"7PB\)EPB 0V!HJ9?Q!>Y*DU [%C[SL1GGA[ MY-B;(CAC*^(=)N_0>\VW]_N478/0A#F-&+[$S B&ZG,(OA;BQ/^A\W7Z;C7# M7:3OEM&3_\1/5@62*)#\5>+A38EKF/LW0=BBIPIL':?)D<+T.D[RPCL/[ ./ M;_('/D[[5V'K5CMR,1Y?-O:_,L8#IK*YPQ%J\(/-AH3*A^,>SW8&PO=V]R:W-H M965T<^;,>)R/QKZX#L"35R6U*VCG?7]@S%4=*.ZN M3 \:;QIC%?=HVI:YW@*O(TA)ENYVUTQQH6F91]_)EKD9O!0:3I:X02EN_QQ! MFK&@"7US/(JV\\'!RKSG+?P$_ZL_6;38PE(+!=H)HXF%IJ!WR>&8A?@8\"1@ M=*LS"96ZH+L@""14/C!PW"YP#U(&(I3Q>^:D2\H 7)_?V!]B[5C+ MF3NX-_)9U+XKZ"TE-31\D/[1C%]AKN<3)7/QW^$"$L.#$LQ1&>GB2JK!>:-F M%I2B^.NT"QWW<;JY^3S#M@'I#$@7P&W,PZ9$4?D7[GF96S,2._6^Y^&)DT.* MO:F",[8BWJ%XA]Y+B0^:LTL@FF..4TRZBDF6"(;L2XIT*\4Q_0^>;L/WFPKW M$;Y?9\^R;8)LDR"+!-D_)28?2MR*^:B2K7JJP+9QFARIS*#C)*^\R\#>I?%- MWL.G:?_!;2NT(V?C\65C_QMC/*"4W16.4(Q MY1N7?P%02P,$% @ +CBO3OP<0.*W 0 T@, !D !X;"]W;W)K&UL;5/;;IPP$/T5RQ\0LX9-HQ4@95-%B=1(JU1MG[TP M@!5?B&V6Y.]K&T)HRHOM&9]SYN)Q/FKS8CL A]ZD4+; G7/]@1!;=2"9O=(] M*'_3:".9\Z9IB>T-L#J2I" T2:Z)9%SA,H^^DRES/3C!%9P,LH.4S+P?0>BQ MP#O\X7CF;>>"@Y1YSUKX">Y7?S+>(HM*S24HR[5"!IH"W^X.QRS@(^ WA]&N MSBA4OQ >9Z]AC-Q?^ "P@/#YGX&)46-JZH&JS3F M"L[8BGCGD[?>>REIDN;D$H1FS''"T!5FMR"(5U]"T*T01_H?G6[3T\T,TTA/ MU]&ODVV!;%,@BP+9/R5F7TK7P)W?E[N"$A""J=\GX'+, M<(QOB=>V;HQ+D#SM60W?P?SHS\I&9%$I6P&=;F6'%%09?HR/I\3A/>"MA5&O M]LAU97C9YC[.6 T-_\5KL MW%5B/0K)M?]%Q:"-%+.* M+46PCVEM.[^.L_Z-%B;0F4 W!#(9^0B;'((FAX# IXU) !-'89,D:)($!.*-20BS/6^R MNAT"5.WG0J-"#IV?R55V&;U'ZF_77_@TM]^8JMM.HXLT]H[ZFU1):<"6$MW9 MAAO[5"P!A\JX[;W=JVE@IL#(?GX+R/(@Y7\ 4$L#!!0 ( "XXKTYEF-9B MLP$ -(# 9 >&PO=V]R:W-H965T[!Z:% M[&B1Q=C)%!D.3LD.3H;806MA?A]!X9C3A%X#S[)I70BP(NM% ]_!_>A/QGML M4:FDALY*[(B!.J>/R>&8!GP$O$@8[ M0*D@Y,OX-6O2)64@KNVK^J?8N^_E+"P\H?HI*]?F]#TE%=1B4.X9Q\\P]W-/ MR=S\5[B \O!0B<]1HK+Q2\K!.M2SBB]%B[?IE%T\QUG_2MLF\)G ;PAL2A0K M_RB<*#*#(S'3['L1KC@Y<#^;,@3C*.(_7[SUT4O!DWW&+D%HQAPG#%]AD@7! MO/J2@F^E./+_Z'R;OM^L^Z'SY697D3] MU!PXE]YS653-S#](>;P-@F9SX&76W(@CK]0O.U&7F53+>A\TQYIG6VU4%@&$ M81R465[Y\ZG>NZ_G4W&215[Q^]IK3F69U7\7O!"7F4_\EXV'?'^0[48PGQZS M/?_!Y<_C?:U60>]EFY>\:G)1>37?S?S/Y'8-46N@$;]R?FFNWKTVE4,$WLG61J<>9+WE1M)Y4''^,4[_G; VOWU^\KW7R*IG'K.%+4?S. MM_(P\U/?V_)==BKD@[A\X28AYGLF^V_\S L%;R-1'!M1-/J_MSDU4I3&BPJE MS)Z[9U[IY\7X?S'##< 80&] DU<-J#&@_PW(JP:1,8AZ WC=@!D#]EZ&V!C$ M%D/0%4M7?Y7);#ZMQ<6KNP-TS-IS2FYCU=]-NZG;J7]3#6C4[GD.))X&Y]:1 MP2PZ# PPR1"SQ##I$+/",),AY@[!0#C$K#$,Z3&!RK=/&M"D03N@ P> .Z"H M ZH=1 ,'U*I(AXDUIM*83VF46+5=(2A&8F95!4$!HV&(QQRA,4=.S,PJ[#)R M: !82B,KF@[&KF$D3N($CX:AT3 G&G+5PZXVS.%)P]"*^8XY,1-P4.NW4(.( M8S3B&.FY59EEATFN:,(;16,E=OI4]EHM+ 3E&6"9!+C#DB(#['P_8(F(W.0O-W>A0&]MW$$GSX$$*K$I@+D MQ([0X#.*8$,JM6GI]7C?=Q?[;B'%T7RT!/V7T_P?4$L#!!0 ( "XXKTXU=!V% M< ( "X) 9 >&PO=V]R:W-H965T6;GUB+/^%&QLJ9KX*--PHT2OL>5,VE]O>Y2*5QV+EE*1M[8M:]N> M._Y+F#L =0&H#X#ANP&X"\"C - JLZE^(8KDF>!G3[3_5D/,IH!SK,WHFP$X" M; G" <%LE$:+B2VFMIAXAM)1)G= RFA4THXE1(&(RDM)KI:Y5.,TW"DQ8E" MH5M,Y!033<3@4<;+:+)*%(Z53#%Q<$-'[-01.TRYL4,2)T'R^ Y)G03I SLD MG:2)81B-O+@#&DB9.:7,'&8@-P$,W%4;/&X'O%'X\ %#.M @601GX^J_@QK* M<9\ $#E,P3'R!U0*P9<75SF)?&3B$-92V_#E;X#[4VUYUQ1 M31@\:8,*_7CI!XSNE>DFNB_:&[P=*-YTKQ/0/Y'R_U!+ P04 " N.*]. MCENKH]D! !@! &0 'AL+W=O :T\B3,2 M1]&&<-H)7&3>=U!%)D^&=0(."ND3YU3]W0&30XY7^.)X[9K6. 02 @:E M<0K4'F?8 V-.R*;Q9]3$4TA'G-\OZL^^=EO+D6K82_;65:;-\1>,*JCIB9E7 M.;S 6,\:H['X[W &9N$N$QNCE$S[7U2>M)%\5+&I/K /M[Q"99CI L%I%X?G)5 MQ&99(%T42+U >B7P>-.%@-EXC A)1C=UW$/6MVF0V<-P4(V?88U*>1+&M6#F MG=;D*78/>^/?V?4)T_XI$W;O!U5-)S0Z2F/'QC]N+:4!FV'T8 >ZM>L^&0QJ MXZZ/]J["T ?#R'[<9S+]J13_ %!+ P04 " N.*].2514C@H" #U!0 M&0 'AL+W=O@[D;)):BJ(@2%%+FLXO=/#MO/,##0043E([$-7=*#9N_,G*I6J-%;$<6;'-VT MT:39CYIHJ?FH*-<*',X2I !FBLA)$9E\_('BV6V G0;8&,1+@R2PRA@UJ=%T M1A,'F]BJ9"W"V7/J1HF=*+$#);101DVR6"6*,XO$H<$/0!(G2.( L7[SNR]1%)(NL%(UU>H-G@,*E=3=3/7Y^!*- M@63]],BB^:4O_@%02P,$% @ +CBO3A>E@>XZ @ &@@ !D !X;"]W M;W)K&ULC9;;CILP$(9?!?$ :\XYB" UJ5:MU$K1 M5FVOG602T!K,VD[8OGUMXZ 7I:;8)M_?G]C#W;2AK)7G@,(Y[TD%=^XN1#U M&B%^S*'$_(G64,DW9\I*+&2771"O&>"3#BH)"CPO024N*C=+]=B>92F]"E)4 ML&<.OY8E9O^V0&BS<7WW/O!27'*A!E"6UO@"OT#\KO=,]E#G>-^\=<[/U !6O&G@(8_M!V5RH'25]7Y?MJXGB(" D>A++!\W& 'A"@GR?%F M3-UN3A7XV+Z[/^OD93('S&%'R=_B)/*-NW2=$YSQE8@7VGP#DU#L.B;['W # M(N6*1,YQI(3K7^=XY8*6QD6BE/B]?1:5?C;&_QYF#PA,0- %^-%D0&@"PD$ M:LETJE^QP%G*:..P=K=JK(K"7X=R,8]J4*^=?B>SY7+TE@5QE**;,C*:;:L) M'C5]Q6ZL"/U.@B1 1Q%8*0(='_8H8KM!:#4(M4'4,T@&:;2:1&NJ5A-&RT$F M8Y$?^5YB9XFL+)&%93%@:37QPS3> &1*T8.(K1"Q!6*0ZS;^%&)*T8-(K!") M!6(U@$A&4UAV92R:V)6%E64Q9DD^2&9I-5C.K]&5U6 UHT97C"HUHJD*F93T03XX@/P9E6I$DR!3DCZ(_0SR@QG5:D2?'"(6E6V'T,,A MK6[-GYA=BHH[!RKD>:]/Y3.E J2E]R03R^5%W74(G(5J+F2;M;=5VQ&T-C&PO=V]R:W-H M965T):E6@)1-5;52*ZU2M7GV MP@!6?*&V6=*_KVT(H:G[@CWC.6?.C#T4DS;/M@=PZ$4*94O<.S<<";%U#Y+9 M&SV \B>M-I(Y;YJ.V,$ :R)("D)WNULB&5>X*J+O;*I"CTYP!6>#["@E,[]/ M(/14X@R_.AYYU[O@(%4QL Z^@_LQG(VWR,K2< G*Q0JN6C]'(PO38EW01 (J%U@8'ZYP@,($8B\C%\+)UY3!N!V_\K^*=;N M:[DP"P]://'&]27^@%$#+1N%>]339UCJR3%:BO\*5Q ^/"CQ.6HM;/RB>K1. MRX7%2Y'L95ZYBNLTG^1W"RP-H N KH L-H?,B:+RC\RQJC!Z0F;N_<#"%6=' MZGM3!V=L13SSXJWW7BMZFQ7D&HB6F-,<0SRN[&:^G]A*Z&@-:%[9W? MF_F=SH;3PS*"9/T/5'\ 4$L#!!0 ( "XXKT[C*O(W[0( + . 9 M>&PO=V]R:W-H965T<\LJB=1- M5;52*ZVV:OO;FS@)6L 4.\GV[6L;@K(P(.=/N.3,R9F!C^#E131O\LBY\M[+ MHI(K_ZA4_1@$^ZY62_%215YQ9\;3Y[*DC7_GG@A+BN?^-<3+_GAJ,R)8+VLV8'_Y.I7_=SH MHZ!WV>4EKV0N*J_A^Y7_B3QNJ"VPBM\YO\B;?<^T\BK$FSGXMEOYH4G$"[Y5 MQH+IS9EO>%$8)YWC;V?J][]I"F_WK^Y?;/.ZF5W/4DERLY%1RG9>[O-*[N]=/[7 M,KP N@+H"T@T6T"[ CHH"-IDMM7/3+'ULA$7KVFO5LW,34$>J1[FUIRTL[/? MZ6ZE/GM>0Q(O@[,QZC1/K09N-1\5F[&"DEX2Z !]"D!3@*VG'U(DN %%#:@U MB&X-XL6@C5:36$W5:FB4#3H9BTA$PHDL$9HEXO1J.U9A>8*; MI8-9R_U@S2&OI/Z!$ MW:T/@WZ1NOX/4$L#!!0 ( "XXKTXEAFJZO@$ %$$ 9 >&PO=V]R M:W-H965T?X'&Q3#$J_F0[ HG?!I2EQ9VV_)L34 M'0AJ[E0/TKUIE1;4NE+OB>DUT":0!"=IDBR)H$SBJ@B]K:X*=;"<2=AJ9 Y" M4/WO";@:2KS I\8KVW?6-TA5]'0//\'^ZK?:5612:9@ :9B22$-;XL?%>I-[ M? #\9C"8LSGR279*O?GB6U/BQ!L"#K7U"M0-1]@ YU[(V?@;-?&TI">>ST_J M+R&[R[*C!C:*_V&-[4K\@%$#+3UP^ZJ&KQ#SW&,4PW^'(W ']T[<&K7B)CQ1 M?3!6B:CBK CZ/HY,AG&(^B?:/"&-A'0B+/*;A"P2LBL"&9V%J,_4TJK0:D!Z MW*R>^C.Q6&?N8]:^&;Y=>.?2&M<]5NEJ69"C%XJ8IQ&3GF,N$9N/B&4V08@S M,+E(9UVD@9]=N%C-"V2S ED0R"\$'JYBC)AEP,B 2:YBW$)0S)KY< MF<@_-7$+,9H@9YOK+]L/JO=,&K13UIV3L)NM4A:<6G+G3G#G[O=4<&BMGZ[< M7(^G?"RLZN,%)M-?I/H/4$L#!!0 ( "XXKT[\U6HSX ( &<+ 9 M>&PO=V]R:W-H965TP[T=>0;+27 MJ[++"EK6&2L=3O=S]QY-'U&J"!KQ.Z.7NK-V5"K/C+VHS=?=W/551#2G6Z$D MB'R)O-,:KIB^9]L)XYS-W&='=V34RY^ ML,L7:A*:N([)_AL]TUS"5232QY;EM?YUMJ=:L,*HR% *\MH\LU(_+T;_C083 ML"'@EB!]7R,$AA"\$\*KA- 0PEM#FAC"Y%8/D2%$[X3H*B$VA-CRX#5O5Y=K M3019S#B[.+PY<151!QM-8WD@MLJHZZ__DQ6KI?6\P(D_\\Y*R&"6#0;W,*B/ M60\Q%F(#J> 6X\DHVU Q%.H2#P2BH.]C-83@Q,*L 4P?\?"QH\T0$ECY/D*Q MA'"^ 5B:0 L$/8$)+!"" J$6"+LUP5:4#PTFTIA28Q+?MP[ 9@A">(!Z_ C5 MBW@"1CP91(R3"!:(0('H]G<6@P(Q$$%L]4,\2#0Z&6L5SS9O1K-H)59JSUVMEZ\1]02P,$ M% @ +CBO3I;#E!^N @ *0H !D !X;"]W;W)K&ULE5;M;ILP%'T5Q ,4KOD(1$FD-NFT29M4=>KVVTV_O9 MAC)B+E7[!VQS[KGWV!S;BPL7+_+(F/)>J[*62_^H5#,/ KD]LHK*&]ZP6G_9 M0F0"+ M^%6PBQRT/2/EF?,7T_FV6_JAJ8B5;*L,!=6O,UNSLC1,NHX_':G?YS2!P_8; M^Q?F[V*GCTL]\;\?V]%2J1W[YRCI!B>]UZK^S,RLUW%2BW3VYZDXE7'HDNIZ&O[+FK[OG3\;V%X .D"2!\01^\&1%U U <0>#<@[@+B MCP8D74#B! 2M=CN9&ZKH:B'XQ1/M_]!0\]O!/-'+M36#=G7L-SV?4H^>5R3/ M%L'9$'68NQ9#AI@,KC'K,<9!W&,LI,<$NLJ^5(*5>D?&!'GNE#'&1&%XC=D@ M/.#PW",8 GBQ$3JOD26(KPJ9((A1@M@21%<$$].5H 0)4D'D3$6+22VFMI@T M#P<3=I4F1=.D2)H8)YBA!+./"\U0@NP#0EM,,A0:30K-T30YDB9QG)*/TDPH M@1!W8X@D25T[AJ-5(TDXJ08FC ](JIF;"D:")M864,_> D&R9.[>04:"\BB; M.<5L$%B:PXRX^\P8]N[TX/X%S,#Y! 7N8/B$A0'W," FAM!=) PTL=< ;F) M7 Q3I>(VAD_X&' C ^+DL5H,%#EY@L'Q5S%QL'<1Z6WYJ59F6Q^,]O>=6V*. M3V=\#?-->ZS^IVDO43^H.!2U])ZYTH>S/4+WG"NF:PQO](H<];VM[Y1LKTQS MIMNBO;RT'<6;[F(6]+?#U3]02P,$% @ +CBO3F2GS$"L P EA$ !D M !X;"]W;W)K&ULE5CM;J,Z$'T5Q ,L>,QGE$1J MVDW2:%>J]NK>^YLF3H(6<"XXS>[;KP$W#?8XE_9' 7-FSHP]9QP\O?#Z9W-D M3#B_RJ)J9NY1B-/$\YKMD959\X6?6"7?['E=9D(^U@>O.=4LVW5&9>&![T=> MF>65.Y]V8R_U?,K/HL@K]E([S;DLL_KW@A7\,G.)^S[P(S\<13O@S:>G[,#^ M8N+OTTLMG[RKEUU>LJK)>>74;#]S'\AD VEKT"'^R=FEN;EWVE1>.?_9/CSO M9J[?1L0*MA6MBTQ>WM@C*XK6DXSC/^74O7*VAK?W[]Z77?(RF=>L88^\^#?? MB>/,35QGQ_;9N1 _^&7-5$*AZZCLO[$W5DAX&XGDV/*BZ?X[VW,C>*F\R%#* M[%=_S:ON>NG?Q($RPPU &<#50'+?,Z#*@'X8W&<(E$$PUB!4!N%8@T@91&,- M8F40CS5(E$$RUB!5!NG8:27^^\KY&H?7+WE70T^9R.;3FE^@<2S ML(_HD.+1A$"B89Y,#"7A$/,5PT1#S!+#Q$/,"L,D0\P:PZ3:U"$8\(>8S=WI M&9=@[H@,2R0@'N(>@\! ,/H$T_AM&6Z.L(S'($9H5A CRC$,\H1#QH MQ;+",!'.$N$L$>)!+Z4>$W68JE>/W__A5#%.%2-46D4^Q095I#'URS02MQR) M6_6X\ 87W,LPP3-,D PU/:T2@TF/:,"4XDRIP11K%;A)C=2!AO>HVFZ--F'? M)-.:\$9A;M,"DMSALC5\8DXAU19KK4"WJ5%BI\)[^@,!A,K2=(BE;Y%/-"YB MZ5QD1.M:8R *%B)+0R$C.LH:!5E:"K'T%((T%4IU(@QDZ9#$TE$(UE)BGNU'T4*!HK$]'"QZ!$QJL<6'16H0?B)IBXH VYKU_1+,O5E/ M6OUDC,P&C>Z$(SP.P[=H$Q!MFFMF:A,-_W$L<(D ]3R'X5O4#IC:M=G?@+F9 MTWM <7DW'U#Q$>H/TXT\87 M9+(FR/@SF6SZ(X(/]_V)Q?>L/N15X[QR(3\*N^^V/>>"R?C]+W*2CBS;71\* MMA?M;2SOZ_ZDH'\0_*1.0;SK4,QV?.F6/C(>\9?Q$5 M@/1>&]J*K5])V6T0$F4%#1$/K(-6K9P9;XA44WY!HN- 3B:IH0@'08H:4K=^ MD9O8@1%_=D!9O_5#_RWP5%\JJ0.HR#MR@1\@?W8'KF9H M9#G5#;2B9JW'X;SU'\/-/@QT@D$\U]"+R;NGK1P9>]&3KZ>M'^B*@$(I-051 MPPWV0*EF4G7\'DC]45,G3M_?V#\;\\K,D0C8,_JK/LEJZZ]\[P1G,5)LO"*)M>W 7XQG4YX);NV4E^4273LIH]87_]9?*>[ MK&D+[S2V17\G_%*WPCLRJ9J+:0%GQB2H*H,'=6*5^BN,$PIGJ5]5$_.X;8UV M(EDWM'TT_GN*OU!+ P04 " N.*].]PD3H4P" Q" &0 'AL+W=O M$-K?>7$14647HIS(!M!R=$652Q ,1!1KG1+&3-,6L?O MGM0?[FD*Q_,;^R=K7IO9$TFWG/TJCZK8^*GO'>F)7)AZX>UGVAN*?*]W_Y5> M*=-PHT3?X\"9M+_>X2(5KWH6+:4B;]U8UG9L>_Y;F;L ]05H*(#A/PMP7X G M!4&GS%K]2!3)UX*WGNB>5D/,GP*NL [S8#9M=O::=BOU[C7'8;H.KH:HQSQW M"H'O$=H[ <( $6L"@ CE5(%N/[U1D;@+L),"6(!P31&!BH\-$%E-W& T" M83PQ\S[N3E#H%!0Z!#V()'(21,LCB9T$\8)(XIG5"*<)F#[>.2P$49QBMYS$ M*2=QR$%N@M1)D"X/)',29 L"R69.49IE*9P$,H>%" , W'(@<+<>< AZD"E\ MT+UP>2C0W7H0+8BE!XT-0P10%$][9P'P7I2[G:&KG\,'%.X&A.%_1.-N01@M MB2::.\8P3;)D&LW[P$Y4,'IWF\/T&Q'GLI;>GBM]#-B7]8ES134I>-)TA3Z_ MAP6C)V6FB9Z+[A#K%HHW_0$=#%\)^5]02P,$% @ +CBO3G+'%P= P M:PX !D !X;"]W;W)K&ULE5?MCMHP$'R5* ] M8CM?($ Z0%4KM=+IJK:_L>.YU=1 MO=1'SJ7S6N1EO7"/4IYFGE=OC[Q(ZXDX\5+]LQ=5D4HUK Y>?:IXNM-&1>Y1 MWX^\(LU*=SG7N#?N?QQ>JS4R.N][+*"EW4F2J?B^X7[0&8;I@TTXF?&K_7@W6E2>1;BI1E\ MV2U)?.(B!DLQA!&, D&:\&T/;NI180=!-!!H!T$-PY\ MHY@M)M28LL4HD!]$1C+_Q]T0"B&A$!"*#4(M)AD$HI/(:('U&$3"R6 !;KA$ MD$L$N"0&EVB4-&'A-+:T4@SCQ"#.U(C38J)!G)#%Q%B"]1@53WW?QV022"89 MDXG,CDC&88A/$V,)-F-8H-J333&=*:0S!70L$B$^WB_\CXN$6+8<\@&9=*!A M*P0TM%:?P&WE@5"0,#5# 1"UM#;!.P=A(([-!=X[2'!'8;':"9![%)C9(E!H MB8.53("4H\B,@T"Q)0Y6,@%2CA*+"ZP_DMQ15:P9@D1C;B@(%!L]O8$@B_PH MEA_U@0O;28OE1\G'2T*QK"A03&R-L$<@6!\N* L7$%L50K!@:WY$M5@P%1]8X6P2RK2V6%45BL(B;83&P.\XB MAL7 P%DTRA:"S#C>X(N[X-5!WV9J9RO.I6P^2@>S_8WI@39?[,;\BLS6[;WG MGYOV&O8MK0Y963O/0JK[@/YJWPLAN>+H3U3_'=7-KQ_D?"^;UUB]5^WUIQU( M<>JN=EY_OUS^!5!+ P04 " N.*].35>X(*\" "A"0 &0 'AL+W=O MGZ$@.>W9G9X(753:HG?1;"1,]UU>AU?#:F MO4L2O3^+FNN%;$5CWQREJKFQ4W5*=*L$/_B@NDIPFN9)S^MJ.1M':/X9>%K>3H;MY!L5BT_B6_"?&\?E)TE0Y9#68M& ME[*)E#BNXWMTMT.Y"_"('Z6XZ=$XI7QRDT^'=9PZ1:(2>^-2QT4<'<217RKS5=X^BMY0 M%D>]^\_B*BH+=THLQUY6VO]&^XLVLNZS6"DU?^Z>9>.?MS[_2Q@<@/L / 3@ M[-4 T@>0(0!1;[Y3YJV^YX9O5DK>(M7]6RUWFP+=$5O,O5OTM?/OK%MM5Z\; M0MDJN;I$/6;;8? (@_Y%[*8(7. !DU@%@PP,R=CB:8* 8HH@"&8@H%'BX\G8 M1$[@!$LPP=(G6(X%%&E0J0Z3>4SC,H-[;;,*#2,;H3,ES MD"<'>(*B;_,)SSO,LAD[%*2A;R@;G=!DI*!IN 6FL->J6X!R"D .">04$QY" M":44YF$@#P-XE@%/ARE&/&R1,Y@%I?#GFP(\6?C]=B V-K1@,W;03)] %$> M$J$)$<*+?(8([ 3W"+^A M$-1?BI ( K'0-@!BZ8P8N A( FQ,+/L0?EXUU%LX G M&1UXM5 G?S?0T5Y>&G\Q&:T.]X][[ _,O_#N\O*%JU/9Z.A1&GOL^L/Q**41 M5DNZL)[/]KXT3"IQ-&Y([5AUEX9N8F3;7XB2X5:V^0-02P,$% @ +CBO M3M?;B)C[ 0 = 4 !D !X;"]W;W)K&UL?53; MCILP$/T5BP]8$VZ[&P'2)E752JT4;=7MLP/#16MC:CMA^_>U#6$)L?*"[>&< M,V?,,.G Q;ML !3Z8+23F=6*,B'\[H'S(O(UW";RV=:-, .=I3VKX M!>IW?Q#ZA&>5LF70R99W2$"5>2^;[3XQ> MX:V&0BSTRE1PY?S>'[V7F^<80 M4"B442!Z.<,>*#5"VL;?2=.;4QKB #$N/'ZHGIB'4++DRR*N0^YLI([#02.P0>5T95D?N8*R.) MTTCB$'A>&;G%1+Z_,N+"K+L'+YJ5@:CM?RU1P4^=,FVQB,ZCXR4PS;Z*[_1( M&2? I\PXCWX24;>=1$>N]*]D&[[B7(&VZ#_HRVKT")P/%"IEMH]Z+\9!,!X4 M[Z<9A^=!F_\'4$L#!!0 ( "XXKTX7EA+,(P( '<& 9 >&PO=V]R M:W-H965TU#6$I\59Y 7LXY\R< 0_IP/BKJ &D\T9)*S*WEK+;(22* M&B@6#ZR#5CTI&:=8JBVOD.@XX+,A48("STL0Q4WKYJF)'7F>LEZ2IH4C=T1/ M*>9_]D#8D+F^>PT\-U4M=0#E:88^^;N# M[VF"0;PT,(C%VM%63HR]ZLW7<^9ZNB(@4$@M@=7M @<@1"NI.GY/HNZ<4Q.7 MZZOZ9V->F3EA 0=&?C5G66?NUG7.4.*>R&-6(6TCPP2>S MM9:QM901VP4>K0*/]S="#2'KP?#N:,4$6K[Q:-T+"\9?>T&+XTJ!5V:R":=@ M?2OUP5A$Y^GY%.CCOHKO]50U8^!=9AS)WS&OFE8X)R;5,#%'OF1,@BK1>U!O MJE9_@7E#H)1ZN5%K/H["<2-9-XUY-/]K\K]02P,$% @ +CBO3I*@2IKY M 0 -@4 !D !X;"]W;W)K&ULA53;CILP$/T5 MQ >LN:>*"-(FT6HKM5*T5;O/#@P7K8VI;<+V[^L+RQ)"TQ=LC\\Y/C.,G0Z, MOXD:0#KOE+1BY]92=EN$1%X#Q>*!=="JG9)QBJ5:\@J)C@,N#(D2%'A>@BAN M6C=+3>S$LY3UDC0MG+@C>DHQ_[,'PH:=Z[L?@9>FJJ4.H"SM< 4_0/[L3ERM MT*12-!1:T;#6X5#NW$=_>XPUW@!^-3"(V=S1F9P9>].+K\7.];0A()!+K8#5 M<($#$**%E(W?HZ8[':F)\_F'^I/)7>5RQ@(.C+PVA:QW[A?7*:#$/9$O;'B& M,9_8=<;DO\$%B()K)^J,G!%AOD[>"\GHJ**L4/QNQZ8UXV!WDG"DK1."D1!, M!#^^2PA'0OA)B.X2HI$0+0C(IF)J<\029REG@\/MW^VP;B)_&ZGJYSIHBFWV M5'F$BEZRR$M2=-%"(V9O,<$,XT\(I-2G(X*U(_;!#3VX/N!PBTC":\CQ%A+^ MPT2XFF=H^.$\AR19%XA6!2(C$,T$-IM%G2PD,9#60+Q%HO<05Q[B50_QC8?( M6YJ(_V?B> ]A3:!9]U#@E;F9PLE9WTK]$V;1Z?(_!KK[%O&]OSW8._PI8U^4 M[YA732N<,Y.JMTT'EHQ)4 :]!^6P5H_8M"!02CW=J#FW5]DN).O&5PI-3V7V M%U!+ P04 " N.*].^4=7$F " #'!P &0 'AL+W=O9C>W$*N-GQE%_R&F(X_55 M_:,UK\WLB:1;SGZ6!U4L_=3W#O1(SDR]\/83[0U%OM>[_T(OE&FXJ43GR#F3 M]M?+SU+QJE?1I53DK7N6M7VVO?Z5YB:@GH &@L[]-P+N"?B=8+L9=)59JQ^( M(JM,\-83W==JB/E3P&>LFYF;H.V=?:?=2AV]K$*09L'%"/6838=!(PP<$(%6 M'U(@5XH-FM'1;8+M'!%C=P;L-($M/QSQT]C-#YW\T/+Q31,6;H'(*1#-"@@A MF)CL,)'%U!:3 +R 4>1.%#L3Q;-$.$[= HE3('G<:NH42/]M=9/.K(88@0A. M.N* H3 -[WSZA;.$GCG$,$'FM*#QG8A BB*XTE;'@#> M%N4\=FN('$6A.Q+NF *0IF-04C*Z_ MBHJ3G132R_FY5N:B&46':;1&YOJ V_ML5$F@*JB M)T?X#NI'OQ7ZA&:6?^(,9TF3>+D_L[_:VG4M.R)AP^FO=J^:,LS# M8 \',E#UQL?/,-63A<%4_%) M_YSF3\!3 IX3LOAA0C(E)',"=L4[9[;4%Z)(50@^!L)]K)Z8?R)>);J9M0G: MWMEWNEJIHZ(S3T"YWC&(.U@MH%]-M;XCB"-TQL1 M'R;SBR3>6A-+D%P1+/P$J9<@M03I%<'RIED.DUE,=].L*XG,*Y%Y)/(;B>Q. M(O)+++P2"X_$)S_!TDNP_/\^YEZ"_-X!CFZ*S!_TT?T/CQ#.!+JX!0S$T0X, M&=1\Z.RPNHC.,^D9VUOT#^X&VCH?.! MPD&9[5+OA9LD[J!X/PU)-$_JZB]02P,$% @ +SBO3OEQ;-_2 0 ;@0 M !D !X;"]W;W)K&UL?531;ILP%/T5RQ]0!T.3 M*@*D)E6U29L4==KV[, %K-J8V29T?S_;4,H2U!?L>WWN\3FV+^F@]*MI "QZ MDZ(U&6ZL[?:$F*(!RAMQ) MYZGJK> MG#0RO91,_SV 4$.&(_R>>.%U8WV"Y&G':O@!]F=WTBXB,TO));2& MJQ9IJ#+\&.V/B<<'P"\.@UG,D7=R5NK5!U_+#&^\(!!06,_ W'"!(PCAB9R, M/Q,GGK?TA6F;##]@5$+%>F%?U/ %)C_W&$WFO\$% MA(-[)6Z/0@D3OJCHC55R8G%2)'L;1]Z&<1A7[G=3V7H!G0KH7.#V_JP@G@KB MCX)M,#\J"U:?F&5YJM6 ]'A9'?-O(MK'[C +GPQG%]:<6^.RESRA44HNGFC" M'$8,76"N$,=;!'V@,X8X!;,,NB;C0&\)KK:X1<31^@[QJM$XU,=+$[OM.D&R M2I $@N2_D[H2>5C#Q%=&/L>,0LCB^B3H.KQT@PK5MZ'+%MFYF1YIN/X/^-B) MWYFN>6O065GWB,)55TI9<%(V=^YY-Z[YYT! 9?UTY^9Z;($QL*J;NIO,OYC\ M'U!+ P04 " O.*].B%_+\$," #T!@ &0 'AL+W=OV.FS 0?!7$ YS!?"8B2)?DJE9JI>BJMK\=L@GH %/; M2:YO7]LX' 'W>G]B>YD9SZZ==7:E[(67 ,)Y;>J6K]Q2B&Z)$"]*: A_H!VT M\LN1LH8(N60GQ#L&Y*!)38VPY\6H(57KYIF.[5B>T;.HJQ9VS.'GIB'LSQIJ M>EVYOGL+/%>G4J@ RK..G. [B!_=CLD5&E0.50,MKVCK,#BNW$=_^90JO ;\ MK.#*1W-'9;*G]$4MOAQ6KJ<,00V%4 I$#A?80%TK(6GCM]%TART5<3R_J7_2 MNKQ:O1O-#L!&P(>"#AYEQ 80O!&\-\EA(80?I00&4(T M(: ^=UW,+1$DSQB].JR_#AU1M\Y?1O*X"A74IZ._R7IR&;WD(0XS=%%"!K/N M,7B$P:E_C]G,,1/$DTT%#Q@D70Y6L?=8[9S#/87$[,6 M#/;M9@-K70,M$-R9C>T"H54@U +A.)-PFFV/B36F-9MXLWS_A[HS$UG-1',S M7F@7B*T"\S6BZ"-$DF%9^C MXH6?X,D=FZ-PY,T/!HW^R@VPD^ZKW"GHN17JBHZB0^M^Q*H53.(;?[GM6\2; M3/\>?"/L5+7)+>3Z.P R00! !0 !X;"]S:&%R9613 M=')I;F=S+GAM;.U]:W/;R)7HY^6OZ)KK9*4JB$-2[W$V5;1$>91(HB)*3N9N MW0\0"4F(08 !0,E,Y?03:$"D[,GNWKC*#XEL-+I/GS[OQ^^*HA1?YDE: M_,O+><_A_=%F8?3\O\U/GF[6D35+_N]G3]5/QO"Z!D] M<9:$C]5O'\*DJ$VCWW$=Y7&&"YR)T["LC5/;[_S;O[5N\BPNIF$B?HG"7)S! MAS4HK_.T7(OW^3_UJY_PDWT&"/HX<57 MX;RVY4_A=!JGT9< CFO:;9CC!):=PY+/ 6>^B#]&J^JX7J_7'_3VCP>#ZC>\SRV@JNLG0'MA+!&!@QX]$-,TWF M89*(#\L"-E[48%_FR]K*Y(.C>90_XBE\S+.7\DF<9/-%F-;6HD9_$7!J:1'3 M#>#C;@)P-I_#F$F933\'8D(W5XR795&&*1Y[#:H9G$1:P#[AIR)+XAEM^D.8 MA.DT@@F D!1BZRX-E[,8OMD&>G W.15;[[;%.Q&GXO8I6Q8P=VWWI]%44X"C MIL,,BP+F_ZGV=5@\"9A43/&'Z&_+^#E,8'SM)7#//D=E>)]$HHBFRQP@5*=4 MP^D4R5XA\F@:P4PP.A!I5%;'7>?1(HQG(OJR0) 4M(*L? )DF3KKK5VIK 2, M;!]SG0.USN&$<%+GJ_BW"% MF_5\#YAI]NE__\7Y\,/YQ?GM^:B^"$"RN,3U,XRFP @ MZ)T"LL16U=9&8GC M[U&=FS#W*4MF45[\]O\<#?J'[PE/Z N@!8,DR$MF#>-?K(B41 ')F7^^!X?2"'O^5'$V$R_(IR^._ RS" M A\#=)H^:;9%>P,TCN;W,(U"99BI'^P='@0',+^<*"Z*Y5LFV0\.]X[5))FY MI1O,5#ON,( J+9;Y2 Q+.,BB?"^.]@=Z30_P MF8'RUZQK"DQKF1!UF44/\32NXSU=(Y>/\'LK^-#P/%!NQ,0\2Q*$89R6$>S! MWXY,__CR^.!W=3-3$HS_=G=_^\NI]$,.KTPV>WYS&;EV'>,N?HC(& M7HH+'XN=(7&1% ^MKDW9KF ]H MG,TC\^*6$[F)GJ/4=P*%I+2*9'MH(6@)L*'6#7^':;W]7AR_=<+<&[ D"3Z LRJ65^U\;3('<#<:$87 J@9$>JZ6D; )WF?+H9GC+7&5J[H6>,Z MXZM[66?>=<97WU\SNKRRWMKXM<0/TG//DNSE;2KVR7#RLSB[&/]Y(LYNQI=B M?#VZ&=Z>7WT4PY/;\T\DJ]:UP]E?EX54WH"F@4X,V!?#!= $$)D$_$RZMZ*3 MDGFC:C(%ANQ7/$\CD)Y ^B2YDT2(>0:WZ^]>9!I:WS&SOR^!9A:DN_K815AY M -XUCY?S0A+;0BJ]\.5\':L "QU%97.DN].,:VG8QJ)0AX6D)@T2V=4Z$'[M MP,^O/HTFKQWX)$RD+6,>EA(8"+^UH'2]!*D1" ,#W&?":-P823LSV-P]<":Y MRVWX^PRD;;-MGIU?#:].7MGF=;C2]PKDUA*5H,7R/@%NG#W 6> K25RML[@% M/\K:;J,0&+CRHD=DFT;13 J[TS5(I1=2#ZS!M<+G:G0+1W]R,QI.1L#T1_S3 M-GPF"'2HGM(/J(]^&EZ,KCR&I*:!I,OVWW^('N,TQ77@R7M-CJ]-@=;9QHGYY.1B/+F[ =UZ?":NQE\):UL( H*EGQ6'!F3KHY M5N.-#%^QH^DK[N*7[U&FAJ_8W9KF R*3(&&:,6HMWFJFE$9F&G^%I(#VWV2] M'N>/8:K(K>%A^!NZ9J[1A)>6_(%C>;!87*.FZS<&]KN=D_'E]?#J%SKPJ^$M M8 0BQ(>[R?G5:#(!5EY,\WBA6(!:>U4RWRJSQX@@\A*73R*&I13+^R*>Q6$. M]RD0\)U +!WTWDNHT&_]]]OB)2Q(X*_H$8 /P\7>9P R^_U M"9!Q(9ZBX>*3,_/A0**8@[*%Y M9Z5R2&X<@H?80O:59<,[$Y(%"KJB*/T"C#'':-9"0F M= @7$="=*3'T$D3@$N@\7,5E@=. 1!QIZRV+V05#:YG.@3#-HQDN#B0!H&D! M0B19DFERBF)0CKKN,L]FT2-9#$A'5[,&C.W+,HOG\V5*7V0Y2L @#\0([3A*B[?!L] "WF^07.)497N'9?1D"65U)T@GO,_)8!E<#) K 3@L8.-\" ME@CT(#"G $P1_K7F"\1# EM:\CX=>0B.=9E(J>Q!DQGXFKS"))0C(!%3Z73N M<481&N7Q89GR&2PR7 <]+2&HI+P561,7\"L"A>[!(UZT% \#QN?1(RI_>$N" M"I!)LI*WA3 %I@().X.C T## F>$CX FZJ(^LM./& Z0>N3S$9$Q+97AMD$8 ML"Y&5YP_.!=EE@%^(4(9!$I6#LK X>;J\ 0^TH(]<0F;A@MV'\&A*'N'O-N1 M=<%(EL5YP^E3'#W35P\@Z3 0N^)CADL'=@$'BYH+W$B1LCXA :4O+.%?D=X4D0VG6N8L.-Q+YN-2D2=F'TMBY$7\F,:@ M\J//'%4K27'3Z)%O%DE_#Z3_54RD\"@12D4DM8UURFH;O<+&<3D]"!W G0 E MGD09H\WP"ECI2>C_NUC:%W[JB[+^9P,&IC[P;[ MW5W]"4INN)+R*8\B,>5A?4/[(_6=G^Y;W8 )9U%@ I\:? X-8*&10W%8S(VD =%S!B'\3B> M8J QN>31FZ(7@P*G(:J)$+?II=9!X%U(/.$?%A?U!%UYMRWA(0^!_]L\&TC4 M$G1Z8"3 ^LHW X"!]SK!F&5$#IGE1D3P0LO60E/ C@KA\>'K-]&.;H3LS4#IGW7'W1[&NN-"]E1 M9R52-?D3 %=)^(J 4_#F(KJK1=-EI2V@>;(KAH477^H42*!07I1(XR69)JE, MD%16L%E)RU2!@YQ>?%<\$&\%Z^,V?/P 9?TK99S-&QQM6F0%$0FQ)_/36F#$ M#XBY01O1_8CB N!-CM^BO(J(8$E+@!!Y9*(S<&#T)6:CR[0ILD8:B#PF(>"N MP.:3,.5["CP6E PBHUZ*@8%*(0N%];T";FMM!3XC^OD "P1I2&I0)/JALD!$ M:5DXQ,'&XDLC4L&MD9HO''V$[D,&Q2Q&11I'D!J2KJ"5$I@($K9F2$7%E MC<3.FF4>KA2E8=$>$;$JWM=%4&D\7-PH3S*"HUT^$]H,OW&10->F64SXD\L?'N MFHUW8V4, ;(U7#X"/9<,UEZZ0LN95"W]YK\M2^T_OQYKE1]P00J0I0[E@=L M_&8F=H/=7?R[9X7$X#NF3NR"CC=201043A/65@ W8LH!2DAA>\;7Z(I2FA C M9U\HPR(^MGO8'1AQY*$D'0,I!,X..!;E+WAK"?F515RIDK U+8$-C%3#^"M= MU&8RO69M9^+G#M5S%49"SE30(/GJDP:%X 8X_]0A2!^\[Z *;\#H(_'P6;IC M1T*Y!EEE(>-HI!?$;;0S8&SP-&3]AX;+$Y26,V#+9$(!%#P,>KO'07]_?[/C M?&^V(/H[ *F=?H]$YYS( BZF -VC;-J6$T2%%B;6^Z+9>URGGMQEQF3E"P%5 M+&FYQ3ZM4!<.X@]H=8%;]$]Z8HM.:L>='%Q8N:4]PD)Y5]!2D5[P4LJ3T6)"\Q@3W.DY4NZ&/\7%$4X MTSSP A%-CO&,&/D)*)\/8O0%*!1)NF,D,Z3E(L3FD;+9V@C0E$ "/T4 MZ6RW'G6XG,_1;@&C)I9R)/T\B(?7('Q.FX-+[2$M 3Z#;F=R=WDYO/D%S9J3 M\X]7YV?G)\.K6S$\.1G?79&Q^WI\<7Z"868?4+G%-3G&5@Y4LNVQ1A1?5[F& MBY20H0NEV*E%)UQ%S<9'_+9\RECWK5I4#0FM"JJAL*5#LQ@E)X*PE\C?E,W3 M$B%X4??L>[5M A'RV10WR)03-T%/2YKQ-68&:;_/9\86%)I3!A(.DRS0I\8* M-=DFIZBG&SOM71IK;R]!<@AR'N"4V/KAKCL!$6XXO/YAFRU: )KLA40G(X]H M3Q9^-M&B&#TP^B+->B>:IL.TD]')#W#OM-LPKSR$K+8R8/,%B!,L#YG;'B!OC_( MT"PE,Z#9I^ U'",TXB$-(F6<(^'THIKXBO=P^$8H MJRD\:5UJ95M1.,+..=0SB,(@A9:"K%I0G*"D.R/%]CE2"U&S TN%XV7#E#(D MP!5&V@#X@"M7C#3:/M.4&85+5!H]Y$SAD)S(D0%!F$^K$(;%1BA!4 MCC'+ROC*":/ H^VGVF 9XE"4Y*!B!P5?H3NBA-Y5>S;0%879,'V\_IFR!

YCYDE6R%,*$R(:>;^XA0_2&B!U2@S. N^CW=OZH\:W=1/@0HR2BUPZ0 MP5G8R-??5=AXQXQO!'=[3D3]FQ O!B B$HI([N'R#>"AVJCDG;AM%H7&A>V# M0%TL_ P74>^&!">0'^<+1A.F2R2DRON.X(UFQ@3VT! L(P4%^R[(P K.$2D; MG]/(B3!4/V\"8/7FRF)9DY9*C+1*F6'$TXD*=L4$55T+3@8^BDA(KFG9$FVH MJ5@>G%V:(?C86/#/I"D?G9;2">V,LN*=XQ0DR*5D*K@O,S!$>8'EH? QQ(%H MQ&:]R$0*2R@#ZT>G6J()]I0N,%M&E!$2MZ2WVF7O35H:I#N!J4&WN8D+T(TX M]OF&7**XL#MMK\1#/+,8DMX!8Y-VOB4KXVAUK6M3^\V[MP#[<"3!O4M6LGY7)$9:&)>[J#Q0EIR M>,]JM;#&I_CQ"5:;Q/#&&5]-XUPDUSQ%I\)-2 K-2RK>%;FZ@K557#_=\SD< M*@JCCB0 1UDNC?A,H[4,C9:K; J?D34'EG5/80W1EZGT0-J6;9AKF1M#Z%DT MH_2 4UZ,.$^E-0F6R?$2)'Y8IKE[M%,_2Y^<62.=)V!HAM&"%O4M(K-05!Y! M^)I+%RLJ$\BN\2:#R@%#9B1J2,='R9;R&M" [!/RF \91\Z?:0LLOB8Z\ZNG!A\D+&=GA:@1&Q:"&G8^ 7)ZZ1,+19H MOGB"(5UQ&A>+)9(="RZ\ >';098S$H8RGO$QR]B\AG$U,<)27G0# GI?C ]+ M@@ 4;54!@S1"KFN)IY01LHB@S /CIVSL\PJB75^NC7-T,5T#9IKDO.8()^Y@IQ2XJJ1/N6B/;,L,(F=;ESL7S:#>:M-'Y5WK@HPQC2I6@3Q+LZ6T:A=H M5Q&_P/#A+"-M\!RDD>@^7Z)8CX87IOF&1EHS3=#@A7Q!?"![A6VX.1M./AAC M)5MY/(^*NP5Q3F69&4[N]%-769=6L-,;!.*"@W_D?[PK.#.UZN;]G:-<1%O9 MDUN!E>D53>[4:_9V>L>!N+%=RR=H!0C1>TTX?2(C) H]"I:1/:9Q6TPY9

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end XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 142 190 1 false 43 0 false 9 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.vaccinex.com/20190331/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.vaccinex.com/20190331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.vaccinex.com/20190331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.vaccinex.com/20190331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) Sheet http://www.vaccinex.com/20190331/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitUnaudited Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.vaccinex.com/20190331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 100060 - Disclosure - Company and Nature of Business Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureCompanyAndNatureOfBusiness Company and Nature of Business Notes 7 false false R8.htm 100070 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 100080 - Disclosure - Balance Sheet Components Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureBalanceSheetComponents Balance Sheet Components Notes 9 false false R10.htm 100090 - Disclosure - Marketable Securities Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureMarketableSecurities Marketable Securities Notes 10 false false R11.htm 100100 - Disclosure - Fair Value of Financial Measurements Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureFairValueOfFinancialMeasurements Fair Value of Financial Measurements Notes 11 false false R12.htm 100110 - Disclosure - License and Services Agreement Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureLicenseAndServicesAgreement License and Services Agreement Notes 12 false false R13.htm 100120 - Disclosure - Collaboration Agreements Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureCollaborationAgreements Collaboration Agreements Notes 13 false false R14.htm 100130 - Disclosure - Convertible Promissory Notes Notes http://www.vaccinex.com/20190331/taxonomy/role/DisclosureConvertiblePromissoryNotes Convertible Promissory Notes Notes 14 false false R15.htm 100140 - Disclosure - Commitment and Contingencies Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureCommitmentAndContingencies Commitment and Contingencies Notes 15 false false R16.htm 100150 - Disclosure - Common Stock Reserved For Issuance Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureCommonStockReservedForIssuance Common Stock Reserved For Issuance Notes 16 false false R17.htm 100160 - Disclosure - Stock-Based Compensation Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 17 false false R18.htm 100170 - Disclosure - Income Taxes Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 100180 - Disclosure - Net Loss Per Share Attributable to Common Stockholders Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders Net Loss Per Share Attributable to Common Stockholders Notes 19 false false R20.htm 100190 - Disclosure - Segment and Geographical Information Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureSegmentAndGeographicalInformation Segment and Geographical Information Notes 20 false false R21.htm 100200 - Disclosure - Employee Benefit Plan Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureEmployeeBenefitPlan Employee Benefit Plan Notes 21 false false R22.htm 100210 - Disclosure - Related Party Transactions Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 22 false false R23.htm 100220 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.vaccinex.com/20190331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 23 false false R24.htm 100230 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureBalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.vaccinex.com/20190331/taxonomy/role/DisclosureBalanceSheetComponents 24 false false R25.htm 100240 - Disclosure - Marketable Securities (Tables) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureMarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.vaccinex.com/20190331/taxonomy/role/DisclosureMarketableSecurities 25 false false R26.htm 100250 - Disclosure - Fair Value of Financial Measurements (Tables) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureFairValueOfFinancialMeasurementsTables Fair Value of Financial Measurements (Tables) Tables http://www.vaccinex.com/20190331/taxonomy/role/DisclosureFairValueOfFinancialMeasurements 26 false false R27.htm 100260 - Disclosure - Common Stock Reserved For Issuance (Tables) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureCommonStockReservedForIssuanceTables Common Stock Reserved For Issuance (Tables) Tables http://www.vaccinex.com/20190331/taxonomy/role/DisclosureCommonStockReservedForIssuance 27 false false R28.htm 100270 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.vaccinex.com/20190331/taxonomy/role/DisclosureStockBasedCompensation 28 false false R29.htm 100280 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables Net Loss Per Share Attributable to Common Stockholders (Tables) Tables http://www.vaccinex.com/20190331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders 29 false false R30.htm 100290 - Disclosure - Company and Nature of Business - Additional Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails Company and Nature of Business - Additional Information (Details) Details 30 false false R31.htm 100300 - Disclosure - Balance Sheet Components - Property and Equipment (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails Balance Sheet Components - Property and Equipment (Details) Details 31 false false R32.htm 100310 - Disclosure - Balance Sheet Components - Additional Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails Balance Sheet Components - Additional Information (Details) Details 32 false false R33.htm 100320 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesDetails Balance Sheet Components - Schedule of Accrued Expenses (Details) Details 33 false false R34.htm 100330 - Disclosure - Marketable Securities - Summary of the Fair Value of Available-for-sale Marketable Securities (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueOfAvailableForSaleMarketableSecuritiesDetails Marketable Securities - Summary of the Fair Value of Available-for-sale Marketable Securities (Details) Details 34 false false R35.htm 100340 - Disclosure - Marketable Securities - Additional Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails Marketable Securities - Additional Information (Details) Details 35 false false R36.htm 100350 - Disclosure - Fair Value of Financial Measurements - Summary of Fair Value of Financial Assets by Level within Fair Value Hierarchy (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureFairValueOfFinancialMeasurementsSummaryOfFairValueOfFinancialAssetsByLevelWithinFairValueHierarchyDetails Fair Value of Financial Measurements - Summary of Fair Value of Financial Assets by Level within Fair Value Hierarchy (Details) Details 36 false false R37.htm 100360 - Disclosure - Fair Value of Financial Measurements - Additional Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureFairValueOfFinancialMeasurementsAdditionalInformationDetails Fair Value of Financial Measurements - Additional Information (Details) Details 37 false false R38.htm 100370 - Disclosure - License and Services Agreement - Additional Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureLicenseAndServicesAgreementAdditionalInformationDetails License and Services Agreement - Additional Information (Details) Details 38 false false R39.htm 100380 - Disclosure - Collaboration Agreements - Additional Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails Collaboration Agreements - Additional Information (Details) Details 39 false false R40.htm 100390 - Disclosure - Convertible Promissory Notes - Additional Information (Details) Notes http://www.vaccinex.com/20190331/taxonomy/role/DisclosureConvertiblePromissoryNotesAdditionalInformationDetails Convertible Promissory Notes - Additional Information (Details) Details 40 false false R41.htm 100400 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 41 false false R42.htm 100410 - Disclosure - Common Stock Reserved For Issuance - Common Stock Reserved For Potential Future Issuances (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureCommonStockReservedForIssuanceCommonStockReservedForPotentialFutureIssuancesDetails Common Stock Reserved For Issuance - Common Stock Reserved For Potential Future Issuances (Details) Details 42 false false R43.htm 100420 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 43 false false R44.htm 100430 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityAndRelatedInformationDetails Stock-Based Compensation - Summary of Stock Option Activity and Related Information (Details) Details 44 false false R45.htm 100440 - Disclosure - Stock-Based Compensation - Grant Date Fair Value of Employee Stock Options Estimated Using Black-Scholes Option-Pricing Model with Weighted-Average Assumptions (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureStockBasedCompensationGrantDateFairValueOfEmployeeStockOptionsEstimatedUsingBlackScholesOptionPricingModelWithWeightedAverageAssumptionsDetails Stock-Based Compensation - Grant Date Fair Value of Employee Stock Options Estimated Using Black-Scholes Option-Pricing Model with Weighted-Average Assumptions (Details) Details 45 false false R46.htm 100450 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationExpenseRecognizedInCondensedConsolidatedStatementsOfOperationsDetails Stock-Based Compensation - Total Stock-Based Compensation Expense Recognized in Condensed Consolidated Statements of Operations (Details) Details 46 false false R47.htm 100460 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 47 false false R48.htm 100470 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersWeightedAverageCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareAsTheyHadAntiDilutiveEffectDetails Net Loss Per Share Attributable to Common Stockholders - Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect (Details) Details 48 false false R49.htm 100480 - Disclosure - Segment and Geographic Information - Additional Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureSegmentAndGeographicInformationAdditionalInformationDetails Segment and Geographic Information - Additional Information (Details) Details 49 false false R50.htm 100490 - Disclosure - Employee Benefit Plan - Additional Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails Employee Benefit Plan - Additional Information (Details) Details 50 false false R51.htm 100500 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.vaccinex.com/20190331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 51 false false All Reports Book All Reports vcnx-20190331.xml vcnx-20190331.xsd vcnx-20190331_cal.xml vcnx-20190331_def.xml vcnx-20190331_lab.xml vcnx-20190331_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 67 0001564590-19-019256-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-19-019256-xbrl.zip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

F!*[=N. M\E,@GN$R%?P2:@TM0"6>YL+#X.L7=E.["E4FKA6@GJ ^B>\O-"3\ 65@LB[$ M-*NT5+.E7K@K2AZJN!R:QY[#CJ9+VW)]U3QA7LAI7OA$=BY_@G6M2Y&+[_PG M<"3'IF]DLR\ZA83T;#5E:^,+8]/S+]6"48D^,'H?Q$RU=NO\_RW4*=(C9KY2 M(^%MB_UX?#,N@(>G*.>\W0V5+>Z%%W2FDY'8+YS=CJ^%,9RJ_.G2T1Z4Y&BC M][._*%=P*80Z.]3KW2WQ/?@Y"!PE#9NR_NJCBU;,:Q^<]I3(A/,8?ZL'.EX]2G)Y,K%@#B0 M%X1.%"U6K%?G' '(K7@= SDAYA?OEC,RK#,!/6+Z4K/<)$BC@4%5&)Y M*4-I&0PE1 ^65;C-@ WI5+GG\ &=3U3$$5[$V]RK +OWE:G$)%]L*H4K^^JS MPEZ9PC)P*]S31E&(\R?A8X#23\6\Y^'SDI$1X4-Y0D)BMRF^]<*B34XT6C'& MB9"P&*UMB5\TE95^AO-DCK++PO42!G.N":-H\X5+S9.YY7!T*H$AYRI-_E3H M-^S-$QLBH;%^L(R2R$\O0B537".Z&!C@R^.)9@;=, M>7]@)NS_A;E>WZU3)$T8\D4\7#;8B],;5"78Y1X"F/E&LF4"6?+ M@8J-+63181L)LUBD[+^#X6;B(Z;<<0FV 1,O5@^0Q"DE+E;@%XXN5YM_RS// M9Q C!MH*QKHP]AXMV2 =$UT8=-QCHT4^?J(HL9JCY$2MA_5B%ACTM$^"74_416WI.%7.P9Y"%?Z#$9B^J&O)S0"[-XB[!0N M[C5!K>@$L?@D6WF6?$+TJW'GT!$4!V^NS[VE+X,U^;A-1YVR+/FDH@@L+A>! MZ3O/=<1+0^T#MBA,I]6JC<+<,S [VE)26E)4D '7_A 87YJNC.&?CCY]=(2/ M\N0%$%(66%ZH_=;2*8W)Y$&PH0E[,NV=S(#_ )^,:*'3^OG#Y<.[Q3_;/_\H MBZ((8:UYA/9E)G>O/\2^?OGP)?'MSVY3CNB\U6FL3VF_TJ+E4?I/\NQ*0JD: M85I-T!^0E!FZ6&LG>.4*[99Q;,B<) 9YM3K(Y8\.>ZV&EG&H:P8H-J$/7Y)/ M#.>_C$[(\Y_*>?.8X3X[8MVHVP+R>0WE-8!K.EMLJI?>=O0AG8=G7^*!A3!+ MD@B?-\6V"X+$FP8&AR/4DRR(L MW51V"T,.!)IP&]\FVGL/<4!A94=]=G"00 M"U0>WU Q>O5N0YM*;U_E<71UM220IEKF M1_U)[:L\%II[OCQ3FQRJ?!B,,H !@+>G,J_R\X&,UL'4X7""6"?1#8UXU$3- M#*2> FOH)H;8PD%/7^XQXD$A_1)9^Y^;\$P=O64:@GYAX!MPAU?Y7>)S"]"Q%(X/1G593NQ:_+P9C MAM$@*Y:>A!F)?R>F]$UL!2-1*F97$,N(4!0FXRPZU*:24:!"7BRJOB&*EE ) MKM;WZ^6F(G4)M9HG=P5RC')&\M<2XU_BL4DD\OD6#T.$01A7"Z]MJ3F'7K>< MK/CDL]@\RX&#_-0&.U>0,$I!Q%)5)66"4/"]6%X1GV]D_I,B^AM=N>M468ZNVNR M1KQ*.\!'N"7$#IZ;D-E_ O-Y:9889.IWY!64Q0%B(43W209Q MX'1"8(^E+5\,HJD)_;H,GL7@0,7ZV52L?][NJ04R#C/Q2QJ0_O'37%XFE:2I M/+LD*RY/["S30JZ@)@O02#Y+CC#":M/P^"LG9=A03GB[%1W+%*\[($65%U9[ MADNA"K9\+3\5&IJ+Y '.!DQUPNP9A(]>Q-I5,6-!U.K.CRUP7CC=H8H!1RYH M;+WJ7S3S#AYBU^ S+P6T=$@6!X549 #DNDD/5D)^(95$HXZL 5]L*H*%%S65 MVPL&#"N\RDA"PM$5NAA!N=X-:(]^UB;N-_%L>5D<; W$(A8'4.2^8'D@4F-0I4^E0P N5GGM2K?0("E+J&RR]J<]]<7-J'I.'YP=');U@,4+T4B?V*WRV!"[H4>R MQNP6CQ+44P)P\0*'<26"H^:YR I:RS,24.8#$IL>5)Y(IN1RJ#9[[J'#BXB3$D>-"Y$=@27^0*:L>,M28+NX.=(Z>QB4= MJIX.$<]@08)T!"LRQ#/$,ZA!H1PK:G@^!)YCR;HWLM*P]1U>4XZU DI#431" MAER";2Y!OV@_=-*@^FH0L0P6)$A'L")#+$,L@Q@2U-G.LJ[4GAAF4!T@@ 8@ M6%*@>.X=88*I E'1;%>-R##B1*^3^;(8N1\PVTZ[A\-09K>2I'H(X")>PPD/ M\=IIHD>\1KQ65]4[V11ON]L5*@H=75S* M@>=%8]0I6H^#0OGU5;)-3'7J^E(!:(BZ*@L=41=15[5!H2QT]3#[Q#A_ PUK M@VD0%HF'?E'0=U7VE79DPVS/M_Y/7S0/.7J$BD+Y50L&4RB_RNA1*#\?I#]< M-+I#BN97 :H?<:!$C%8UFTB,5F7TB-'R,UJ'&*T*4*4PVM'2TFF;;],-H+%4 MIUDVS54Z5^VPHL?!R\5LK6>R-\CP:U<% LD9@LAI>-;:=:E\2<[RD#UUEZ;? M*^K/E&QALYO76JHD&HM+A(@:'B)$(D0BQ%URZBTBQ!PX*2PB* [72#IOEOTG MV;AY\:FPI?.RY_?VKMW)+M\/QH29@&X07,_&3I3Y9M^1;CC_!3B^_% MNWUWZM7M.Q2-QK[/F,,9IS[?!O7YSFQMJN[2G5YR+"YE]$W\J!-J%9"L<2?4 M&^KSC<.R4AO4XV- [$;L=GHVKL;L1GV^J<\W=B-ZL@4*\(=9H]"085N.9>BV MX'=+_+?A\F.?^*#:!">1RZ(\%2K$Z%YG#AA[C5;ABQ-TK[.^9I$("@L21%!$ M4"=,4-W&8'2!%DHBJ/)VO'L/']9NQSO3YYYKV_*J@\=4M8$GYK"QY1<6.R[-T"+$VD05F2(9; @03J"%1EBF1C+=(MN0DF#JK0) MI;1KZ6E7U^&![]B'VNQ9M]'&<\@MP(($&36LR)!;L(2KW2ZZ^20-JJ\& M$DKC]A'H[C\@CN(F%"J )!42I# M6V7TJ QM/D@''1QVDDK05D/SB-90PT.T=IKH$:WE/%1\[&0NT5KE,[Q48GW; M/CNJQ7;DV!65D:UH")C*R-;X]A.5D&PL=4H)$LVER@1-3Q$B42) M1(D[46+WXMA5+2I%B:=26SU[K?1DC?4;W?O*Y+,?F!%XZO-L35GU;LW*JD-5 M0>TF*A^KPOCB>$Q,KK;T^)MN.<.[T43F-8]='/[TYRF+:ZH;<(%-$&M6A:0(S10U) MRU "0TR%!0EBJHHBE^UX#3%5)< DIL(*##$5%B2(J2J*W#!;MI.HJA)H$E5A M!8:H"@L21%4516Z0+>U(5%4)-(FJRLLI(KN$EPNQ2A1!_-)\:&J/'M-YX,UC MZ48<.7P$U_ P@87FA%,6'R3M< P5=L($6B+[N#MLIUZUJ=/H]H8X["/",TZ8 MD$)C+XG.4,-#='9*=#8D.LN#XSD.VTA45@U;252&&AZBLM.BLMX6-2,N(RZK M&DIHC"5Q&6IXB,M.BJ+%!TPZ&&H52+^DBTZ=>TA6P,L@Z@1%%5) B MJ)=T8:"II69MZ9%Z25?!Q"+C1P(%%>]1+VDB/B*^G/.G7M+5P(D8LKJ@(&%( MZB5='&GJ)5T=K%!7/]BHG=1+&N-Y0FHF@P8):B934>2HE_0)@4F]9+ "0TR% M!0EBJHHB1[VD3PA,8BJLP!!384&"F*JBR%$OZ5-"DZ@**S!$55B0(*JJ*'+4 M2_J4T"2J*B^GB.P27B[$J)?T*5S#PP06FA-.67R0M,,Q5!$($VC42SH7CNU> MH]VZP&$@$1YRP@05&H-)?(8:'N*S4^(S:B9]D&JN1&6UM)5$9:CA(2H[+2JC M9M+$9:>F;FB,)7$9:GB(RTZ)RZB9-,493U3G4-^GI&[2Z,\24(<4U/#L=.2* M.J14KT,*-<]$X\C4LD,*F5QB1-3P$"/6BA&IG32.,#6182VM+9$A:GB(#&M& MAM1.FMBP=OJ(QMP2&Z*&A]BP5FQ([:0I6DK]I#-E?=?WD_[EIX"?/^OZ[,W- MHN[KP^(>YJ,8T3O;-;Z^_>M?-.V7Z*-0;%G66K[DG/G\TC$_6?J39[A.9[ 5GS@L^MXT3_?Z=SBC_!+B^=KEOGKV8<_A5 [K=Z99HA9B[?N MV?C7LROX:[O3ZH\ZG3\[K?:HU6ZUU8MNMWWV=BW&@&B[,UNGGG%,U_:_/C". MCQ.FC5W;=K\)T6A1X5V?BS]Z_D3SX6TH;OT" H?NK_"7*W]1/ M/*V?^ W00-1,?(1#X:C+&MIFXC@)JU(H$G6AQ@9)0Z!VJ]D>4D>@8E#CZPA$ MA'9L#!*FL) ZD:TD6WEZMO*3#!.U<2@I&& \B(K4X*3F*K$C.+ M>\_Z[S6SB F>*YU/-/;?P!*2%@,LG%O<_SD,RBWBP('L&%)DE,- _D UT"(] M0HL,[5ZQ($$Z@A09XIHJH45ZA!89XAHL2)".($6&N*9*:)$>H46&N 8+$J0C M2)$AKJD26J1')>;4JG);K]UM#M C="/>GFM36219&P>.R='FIH46&N 8+$J0C2)$AKJD26J1':)$AKL&"!.D(4F2( M:ZJ$%ND16F2(:[ @03J"%!GBFBJA17I48FJMK$1H(H]VJ([LE;B)]J6I/32U M1X_I//#FL;3;D5/7ZSJB[ANPTU"RHY\LR-+JE$PD2O221:5W!_#4W9%.H]L; MXK"4"-O78D(*C>X1L:&&AXCM)-$C8JO6R54BM4KI'9$::GB(U$X2/2(UVJV1 M[A&QU1<>(K:31(^(C79K]=2[HUT^3,N0FFX 5_(ZS;*9KC-H=OOH<7MT?=W6 M/EB.[AB6>'7).?.+YD?+Q6NM8[(WN$Y#Q8Y^/&1KS]8T/&OMN10M>G"@(UH' M!/;4/9IVJ]$?MG'8V.P&MI9*B<;F$B6BAH)Q\KG$B+4TN<2(J.$A1B1&)$8\?"*XEFRHD(B 2,/LN'G@GV1% MU,6G3.NE@(02 OG'ZE+<."[Y*_%?5-59%;J_GK7.-(/9-N G5L+BW^'*D/\. MUYPA?IAYBQ46+@^!BJW/.'L3O?A9"Y=0JQ4O"[$^%;[O=;S[?>&8O5$"*,/@ MD+. [6Q>7,I/KFUNM#;#+-9F_]B(X0F!"'#:O;-C\G]OT.QM 2^2X:&4"PV4 MEUQSQ]I[9K#I$_.T;KNA=5IM--O=@Q$W&D#*.;Y54\ZJ%(K$7JBQ6;!7YZCD MU6X5VKT2N\% M!=[[M?R]]B'-@DV.G.\TL8H+G2N<3C?TWL(2DQ0 +YQ;W M?PZ#);1(C] B0[M7+$B0CB!%AKBF2FB1'J%%AK@&"Q*D M(TB1(:ZI$EJD1VB1(:[!@@3I"%)DB&NJA!;I48DYM:K: M&/97YFOCP#&+MN>DLSI8K!F=$-@3,D6KP1_H! XY S#;7F-8N/TE:4Y];1JQ M"Q8D:JHCQ"X5 (G8!2$H%;!IQ"Y8D*BICA"[5 "DHDVH2&OJ:\^(6; @45,= M(6:I $C$+,@ H=MFJ.&YD0DQV;&1,R/P+-]B];QRA@D52O03,N0-U $MTB.T MR!#78$&"= 0I,L0U54*+] @M,L0U6) @'4&*#'%-E= B/4*+#'$-%B1(1Y B M0UQ3);1(CTI,K965"$WDT0[5D;T2-]&^-+6'IO;H,9T'WCR6=CMRZGI=1]1] M W8:2G;TDP596IV2B42)7K*H].X GKH[TNXUVJT+'*828?]:3%"A43YB-M3P M$+.=)'K$;-4ZNDJD5BF](U)##0^1VDFB1Z1&VS52/F*V&L-#S':2Z!&ST7:M MGGJ7S)%&@IBH<;3[S0L0]]DZ=/=T+3$M=VJZ 5S6ZS3+9L#.H-GMH\?ST?5U M6_M@.;IC6.+5)>?,+YHY+1>OM0[+WN Z#=4[^L&1K=UHD2B1*+$XDCO4AZ5&+&6)I<8 M$34\Q(C$B,2(1TKT$B76TN82):*&ARB1*)$H\? 9XEJRH4(B B(-L^,FB'^2 MQ5(7GS*MEP(22@CD'W$!=+9(8..8?_DIX.?/NCY[\T&WO-]U.V J-WKIF)\L M_N\^"+O]XSSKP79GYPO0^!+Q[ZD?- =PR6_+)FF;^>??A3 M -UI]<\T0TQ.O'7/QK^>7<%?V^+/HT[GSTZK/6JU6VWUHMMMG[U=*U60H133 M:RG'Q=IK]GO_6*ODAUM;2EAB_""&B;$+TV MM5KP\R?I+Z_LVFA?M MYL7%L4\?DA^:W";L!DC,VU KL@QW(R[V)]'$+'\- MH2$[CQ[)&MOY]\Q@TR?F1:9^B,/,D*E'5D-LHUT)MV>G'RQ^F A6XUH@AN?9 M$[]4Q,OSML#%H=M&!2 5.LR!!YH86&R*NRT!%YY3EKWNHW+H9=M& 2 M>96W<]Y[1*YN.V?]1;=LF;B&;'N858_OF[5G\<2CWR G!P1M#H(,7_604?X% MN0\PV\YPU!@=_;(::5'UM(BH!RTTI#18D2'JB>U<.]V&& 5:K$B+*.>+#Y[K M[\9$=YZ9YHZUWW7#L!SV7;OS7#,P?-[0/MUI@6,5WK%2R!PM.5&HKK[(D-L0 MNTK>Z+0ZC?[%LN*ZU81N108 GC4<*2ZZ/4S7PXCUT2Y)MWVL#$882W%39U' M4"H@T5VU\"*Z.TWTB.Z([NJM@$=+*J=MS_=6:;3=;0[0PZ;Z:7%U6%KLT8UX MR;*H4MF10V&;'9@\V)$#@R%T275C3QC>C->ZJ()L5LR[C6Z_U6CUCIV,J%0E M6=)0(LQJX46$65-XB3"),(]/F-4NO?[+3P4+DZNJYE'5] =CPLS 9K=C>7/X MG>M:#T6HZ8ZI>5@:G:J?'S;6 MN;[S/%4_/VKZ;DV3I*/G[^)R1U_&,EX6M]T[:EWOBAARKW2X+ M7>+00"H/6S2K4PN^JA1FQ%P50PM+0?=6H29QQ&PP5[F%U&YW*M=,G';:]K&0 M1I$!)0-:!ZC_)?HSJ^?DK[\SS[!X36=_YUD&PT%7Y#(< M'X-L+D/M^(%<@=I 3:Y ?5V!>S;5+2<1%Z[3]*_$.YYN^(%NUU, GZPQTW[X M@^D>_Q$''R.\&X(&+?*=3@DF\IVJ#_7E\[/'GG6_IN[#1T&?EL,MHY[3_UVW M T&?XD?_1Y^Y_&?B4/R8[2L-O_<3SF%F_O0/F[_3;3AA"F<6W;%65H/C ]1+ M!&^(+G^@Q(8:W%45NE$V[Y3N;,!LJ;\=2ECP:QF1%V)LB+S60_=WK(@19^5 M<=2\&&$%D@@++3)$6'BQ(<*J*G3$7#G@O&CVL>)(Q(46&2(NO-@0<=%.ZW3Y MZAPKBL16Y>8B]WYFI*1<9"7*NOXF/N@7+MQZ@-;BY$^@Q8;L&E)DE-] ;@', MMMWM-T:##E:H2(G0(D/4@Q<;TAJDR!#U+-'J-H_>DH0TJ'(:1+R#&!O2&J3( M$.]4"2W2([3($/O@Q8:T!BDRQ#Y50HOTJ-R$7%4N!U8B(1>5+SMV+T7R$*IY MQ((P0I;:XV0F4:*7O*&_.X"G[I+\T&F,^D4K>)Y^'7%,4"&I]DX45Q4C26I5 M0;BV$UA^Q$Z=Q-J=YD4+!7JD;)52-B*SJ@%&^E4EN(C,*@\A:5RUX")&JQA@ MI%]5@HL8K?(0DL95^U9B6B[4=(,GFVF=9MFY4/RP)?L8WNB>,8F:&!Z[X4F* M:Y(',')-,)P/R=NY.8$P94]1PYNQOGEY")^ZZ]/O#AN#5M%BIR7;W^S&E]03 M 5Q$EQ4#C/0+=5>/E W\CD"=.HL-FYUC-_DE%:NB120*JQA@I%]5@HNX+#^$ M@R;MQJJ $S)5(RJK&F"D7[0;.TD&:P^.W0>8-.S4[Y36.(\:UGO58?XEYE(/ M<,R+W!&,ATZRYE+79M$HEUI9>%_G4O>,\*G[/=U!MS$8'+N!%_D^E5)/HLMJ M D;ZM9?=^P$.0]/N/16Y4;.'M=P"J1AFBT@45C' 2+^J!!=Q67X(+YIM%-B1 MJE5*U8C*J@88Z1?MQDZ2P8HV(:FE?BDD(B#2,-N_-2Q]OCG68:'L[D\^9!07 MGS*M%WC]RT\!/W_6]=F;!V/"S,!FM^.'B8#ZG>5.9\SANF^YSH/O&E]O M9_"27QJ^]6+Y\T=XY*.8R3M;O/GVKW_1M%_2GG>GSZ=BPI??=,^,/^]WW0[D MCUQR'DS5WY+/UBSSU[,/?XJET&D-SC1#"$2\=<_&OYY=P5_;G59_U.G\"0G2 M5KO55B^ZW?;9V\<)TYX%U+YFZC[3QKKE@6(%#%*K;#JSW3EC DCX%5?]MO9- MYQKCOC45WS"U@ NMT73MG:T;7\_%Q%Q;P*,^>S[S+ />GKHFL[5OEC_1?/&+ M8]>VW6_PAEJ+S#S77YBG/T-2=S')-SF746+5_"/SNI"_$B*N;(O,+BN5__6L M)03*;!N46@QX\>_07,A_AX9(>3L+LQ/:#*&JMC[C[$WTXFNQ0C-391TVG)8'(G!XC\=S"]" T$UCI>AL/Z5PBS. M YVC\D"[UVQWDD=8LI0#(*: N>(Y*HBPW!$:E+ %VIH7O1T5[ABATZK!2?:U M^E +^SK$H;-D7P_OI.Z]$E+HMYY^[N+Z^XP9$&43!F*J_6 YVISI'B_:;(0Z MU&%-">X?F:ZD,THLJ:,111M2D ;55X.D^T\''E!B0UJ#%1GB'>(=Q)!@#]33 M'FBQ!WIQ;=VW;,N?'SFT0$J$-5!+-)2IRE;1$B6D0'M"Y!]H :%-#UZ;5E-E MJ0 RQ#;$-G@126$;2O<<$YA[BW\]'\,A1@LHE7%?\W2?4

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end